var title_f36_60_37824="Tracheal wall perforation";
var content_f36_60_37824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior tracheal perforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 202px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADKAbIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1n4ZeAfB158NvCd1eeE/D89zPpNpJLLLp0LvI7QoSzErkkkkkmum/4Vx4H/6E3w3/AOCuD/4mj4T/APJLPBv/AGBbL/0QldVQByv/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNdVRQByv/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNdVRQByv/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNdVRQByv/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNdVVfUb2306ylu72QRW8Q3O5BOB9BzQBzv/CuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTXVUUAcr/wrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE11VFAHK/8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNdVRQByv/CuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTXVUUAcr/wrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE11VFAHK/8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNdVRQByv/CuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTXVUUAcr/wrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE11VFAHK/Cf8A5JZ4N/7Atl/6ISuqrlfhP/ySzwb/ANgWy/8ARCV1VAHH/Fa2gvPCUVrdwxT20+raVHLFKgZJEOoW4KsDwQQSCDU3/CuPA/8A0Jvhv/wVwf8AxNHxL/5Fyz/7DWk/+nG3rqqAOV/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJrqqKAOV/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJrqqKAOV/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJrqqKAOV/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJrqqq6pf2+l6fcX17J5dtboZJHwTgD2FAHP/8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E11VFAHK/8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E11VFAHK/8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E11VFAHK/8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E11VFAHK/8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E11VFAHK/8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E11VFAHK/8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E11VFAHK/8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E11VFAH5o/E22gs/iT4stbOGKC2g1a7jiiiQKkaLM4CqBwAAAABRUvxY/5Kn4y/7DV7/wCj3ooA+/8A4T/8ks8G/wDYFsv/AEQldVXK/Cf/AJJZ4N/7Atl/6ISuqoAKKKKACiiigAooooAK4v4xx30/w81O10lgl/dtBawsWK4aSZE6jnPNdpXP+OF3aTZjP/MUsD/5NxUAbGnXSX2n2t3GMR3ESyqPZgCP51YrE8Eknwho2cZFpGOPZRW3QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr8J/+SWeDf8AsC2X/ohK6quV+E//ACSzwb/2BbL/ANEJXVUAcr8S/wDkXLP/ALDWk/8Apxt66quV+Jf/ACLln/2GtJ/9ONvXVUAFFFFABRRRQAUUUUAFch8XLWa++HWtWVqxW5uo0tojz995FRenPVhXX1i+Lxu0eMHp9tsyfp9pioA0dLvE1HTLS9iDLHcwpMoYcgMoIz+dWawfATFvBWhljk/Y4v8A0EVvUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH5rfFj/kqfjL/ALDV7/6Peij4sf8AJU/GX/Yavf8A0e9FAH3/APCf/klng3/sC2X/AKISuqrlfhP/AMks8G/9gWy/9EJXVUAFFFFABRRRQAUUUUAFcX8WNe0vw/4ctbvWb63tIF1GyfMrcsEuY2bao5YhQTgA8Cu0rgptK0/Vvi/qI1Sxtb1bfQrQwi4iWQRl7i53Fd2cZ2LnHXaPSgDZ+HGoWmpeCNGudPuIri3a2QB4myBx0PofY8iukrj9E0zT9H+IGowaRYWlhDPp0M8yW0KxCR/NkAZgoAJwMZ612FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvwn/5JZ4N/7Atl/wCiErqq5X4T/wDJLPBv/YFsv/RCV1VAHK/Ev/kXLP8A7DWk/wDpxt66quV+Jf8AyLln/wBhrSf/AE429dVQAUUUUAFFFFABRRRQAVieMQTofyjJF1an8riM1t1h+NbuCw8OXF5eSJFa28kMssjnCqiyoSSfQAGgCP4fIYvBOiRkk7LVF59hiugrn/AN3DfeENNubaSOWCRGMbxnKsu4gEH0IFdBQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfmt8WP+Sp+Mv+w1e/+j3oo+LH/JU/GX/Yavf/AEe9FAH3/wDCf/klng3/ALAtl/6ISuqrlfhP/wAks8G/9gWy/wDRCV1VABRRRQAUUUUAFFFFABXH2X/JXtZ/7AVj/wClF3XYVx1nn/hcGsen9hWX/pRd0AWoCf8AhZl6Ow0iD/0dNXT1zEH/ACU69/7A9v8A+jpq6egAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4T/8AJLPBv/YFsv8A0QldVXK/Cf8A5JZ4N/7Atl/6ISuqoA5X4l/8i5Z/9hrSf/Tjb11Vcr8S/wDkXLP/ALDWk/8Apxt66qgAooooAKKKKACiiigArn/H0cUvhS9juI0lhdolkjdcqymRQQR3GK6CuN8YeGtP8Xa7aaZr6XFxpkdq8/2aO5khR5N6AM+wgtjsCcDnigC98O4FtfCVrbxokccE1xEiIu1VVZ5FUAdgAAK6SuD8HaJaeEvF91oWiy3g0uSwW8+zXF1JOsMhlZSULkld3JIzyRnjv3lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB+a3xY/5Kn4y/7DV7/6Peij4sf8lT8Zf9hq9/8AR70UAff/AMJ/+SWeDf8AsC2X/ohK6quV+E//ACSzwb/2BbL/ANEJXVUAFeMfEPW9XHxaudIt/FVx4f0y18LNqyMiwlDcLcMgL+YjZXb1AI6detez1jav4W8Pa1fRXusaFpWoXkShI57qzjlkRQSQAzAkAEk49SaAPBNW+I2v6l4RvryU3Wm6pJ4Lj1PfBO6Kshumj3rH0BYAMG64YDpXU6/8WtR0fxbZaZaW9jf6el1ZWN42JFliedV5LkhS3zZ2qrcDkg8D1m90HR7+SV77SdPuXmtxaSNNbI5eENuERJHKZ52njPNV7rwp4dvNRTULvQNJnv02bbmWzjaUbMbMMRn5cDHpjigDx/w18TPFkehv/ar6NdaheeI30W1mkYpHa4aTPmhVXKgIAnRm5yeK1tP+KXiDWD4YstH0jSX1PVpdSt3e4upEtg9oVG9HVGLI2SentnvXpcnhbw9KuoLLoWlOuouJL0NZxkXLAkhpOPnIJJyc9TVmHRNKgeweDTLGN7BWS0ZLdAbZWADCPA+QEAAgYzigCC516K3uJIWsdUco20tHZSMp+hAwRXH2evRD4q6vN9g1Xa2i2S4+xSbgRPdHkY4BzwfY+lej1x9l/wAle1n/ALAVj/6UXdAFm3BPxMvmHT+x7f8A9HTV09c7b4/4WHf8HP8AZdvzjj/XT10VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvwn/AOSWeDf+wLZf+iErqq5X4T/8ks8G/wDYFsv/AEQldVQByvxL/wCRcs/+w1pP/pxt66quV+Jf/IuWf/Ya0n/0429dVQAUUUUAFFFFABRRRQAViyEf8JnAO/8AZ8n/AKMStqsaYj/hMbQYO77BNg/9tIqAKIz/AMLMbgbf7IHPr++P+fxrp65rDf8ACyc7hs/snhe+fO610tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB+a3xY/5Kn4y/wCw1e/+j3oo+LH/ACVPxl/2Gr3/ANHvRQB9/wDwn/5JZ4N/7Atl/wCiErqq5X4T/wDJLPBv/YFsv/RCV1VABRRRQAUUUUAFFFFABXH2X/JXtZ4P/ICsf/Si7rsK46ycj4wawnY6FZH8ri7/AMaANS3X/iub5sjP9nW4/wDIs1btYkBH/Ca3wxz/AGfbnP8A20mrboAKKKKACiiigAooooAKKKKACiiigAooqlrWrWGiabNqGrXcVpZwjLyytgD0A9SegA5J4FAFi4mWFVLBiWYIqqMkkn/JPsCe1S1y3hW+uNcvri/1CFrUx4+y2Lg74YmHyvMOizMBnZ1VWAPJNdTQByvwn/5JZ4N/7Atl/wCiErqq5X4T/wDJLPBv/YFsv/RCV1VAHK/Ev/kXLP8A7DWk/wDpxt66quV+Jf8AyLln/wBhrSf/AE429dVQAUUUUAFFFFABRRRQAVjTNjxlaLzzYTHr/wBNIv8AGtmsKd8eObFMjnTrg4+ksP8AjQBXfb/wsiL+/wD2S/5ectdLXNsg/wCFjRvg5/sphnt/rlrpKACiiigAooooAKKKKACiiigAooooAKKKQkKCWIAHJJ7UALRWLo18muyLqVpIJNLXi0kQnFxxgyDnleqjI5wWGQQa2qAPzW+LH/JU/GX/AGGr3/0e9FHxY/5Kn4y/7DV7/wCj3ooA+/8A4T/8ks8G/wDYFsv/AEQldVXK/Cf/AJJZ4N/7Atl/6ISuqoAKKK5vVdP1rErWI0+7d8j99LLanBAHzNHu3H5VGcDjP0oA2NS1Ow0uIS6nfWtnGej3Eyxj8yRXOS/ETw/wLF9Q1Nz90adp1xchvoyIV/HNYFp4OuIbSzv1S2tbkOBMNGtYpJ9u7DA3E7MxAx1Xa3oM9MrWtJ0O9jvLJ4tUmvZLXLNruvyxrbqxxuaJpSwA5wypglSM9TQB1Enj+7EPnDwfrdvb85kv5rS0xz6STBsfhVZfijaxl/tekyoqjIaHU7CXP4CcH9K5jR7jw1ovhy91bRdO0bW7y4t1kklt7ZkSXYAu1Y9rtkkEkcDPpSmXw9eavLqWpT+GJwIzCljFpTXKxIGLea4O0pISTlcdgOSM0AdMvxc0BsD7LqZY/wAKRJIf/HXIqr4L8Qw+I/ivq95a2l/awDQ7WNReQGJnxcXB3KD1X5sZ9c1QnTwpp9+LW78P2dstyu6e/wBIsfMt32gbdw8sgZB7biMEE46v+HOsaBrPxX8QSeF5bJ7WHTIIZEtrFrby3EsmVfON59wAB0oA6HXfFej+G/Hky61cyW4n0yFkZbeSRflllzuKKQv3h1xntmtnTPGvhjVGCWHiHSZ5D/yzW7Tf+K5yPyrx34332naT8YNA1LU7i4H2bSnaK0gMkbXbGRgV81GXy8ZyC3GePesuy8VeD7yeefUZ722vAip9i1S/u5yygf65ZIg2DltpDKQSgxjkkA+lI5EkUNGyup7qcinV8r6Ovgidvtepa5fWi28xISGzaSJkzwPNeIFjhc5KqRuwQeKdF4g8C4FlHfXl/OE3NcTytaxYJOA3lW5UNtxxgj3zQB9PXF7aW2ftN1BDjr5kgXH51Tm8RaJBnztY02PHPz3SD+tfO3hXUfCkMFxbXdpBrlxFI8iGxkud7IWysfFuil1B28kZ68ZpuheKPCGta6k1pa6joCWkPlT2Oopc3C3Ejkcp5b5TZtI3dG3H5eM0AfQ0nirw/HEZH13SljH8Ru48fzqqPG/hx9vkatBclugtQ05/8cBrxzVPEvgUahaQyz6j/aKStJGtvpN7JGqgEMJUlz5qHI5UcHB96rDx38OX8Yi31b+yobC2j86SR9CuLaQTAk7XLEkAjaQNvPQ9aAPXtU+Imi6fkPDq0jDqP7PliHt80iqv61g6j8WLaOB5ra3s7eFYzIZdQv0AUDqdsAlJAwfSuK1DxHoui+H7zV/C9tLLDIc2+onw7GRGXfgh/k3qpIwME9Bk9r+j/EC5uJVtNU8J63a3k26JPtt/JIJx3Ji4GCM8EBfUgZNAHRW+qeLvEMi/Y7u9ht3QOstlpa2sTqRkYluS7Hg9RF/MVRkl1ez+0T/234tk+y5VzBcWdwJHHBVB9n2sQeDu24PashfEnhDT/EFlZedeFr6JnFhPMby1RgeQiWruiFjnK7dpx2PXR8Q+O08D+GtQmj0PXxpEGFRbbTGt4Yg2B8skrZVcnrsAyRgd6AJLfXNe1Aomman4k1hJSf8AkG/2cPKBUHEsjRqEOMcYDc9K57WI76N7Zf7KuJfGMkXmW9pLenUbywUnH2h5pCbe2GAcFVySQB0OLGq+KBqcempoa3mnyXO2OSbSHuZzIPK2hSUXyNw+UbjIzYXAIPNdP4C8Dajpfh9bF5roRXWZL2S9Kia7durTBWZz8uAB5o44I60AdR4P0O28PTJC+oSXmo3URlcBF2DLbmcYGRuY8sxJYgZJI462qOkaZaaXaiGztreAYG/yU2hj6+v5k4q9QByvwn/5JZ4N/wCwLZf+iErqq5X4T/8AJLPBv/YFsv8A0QldVQByvxL/AORcs/8AsNaT/wCnG3rqq5X4l/8AIuWf/Ya0n/0429dVQAVHcTLBHvcOVyB8iFjycdB29T2qSqGsx2D2m7U5FhiQgiYymIocjGHBBXnHfmgDMvfGOlW0xgQX93chA4htLCaZiD7quAfqRXN678UIdLYo+lC1cKW/4mmp2lmMDjoZWfr/ALP68VS1hPCWjXzQeJvEep3tpfKI4Yb6+ee3U8/LtQ+g6yAj0bOazIb/AErQLNk0az0CSOMBd9nokqsrgqC2GYIeMHBkH1PcAiuPi3qVzsazn8HWMZkWFhJf3F8/mN91QIYguW7Ddmr194+8SaPKx1WbQ/KjIVlbStStyScAAN5bg5J44OapS+LLWDxJc39xPqd2ZUQi4CotpA6MdkZgVwxOGLZdiSfoAK0niLUtV1a4bWYPEt5Y28/nab/Z9n5cW9cDMjxhmUqwcbSWyG5HGKALY+Odus8MB060mmkUlVhup1LkDnaJLdCw4zx2rT8C+PIvGXxHWEae1lNZ6VMxBuo5tweaEDhD8v3O/rVHU/G8iWbxqJtRvxIkkmm6lCIJYQG2l0fahwRyuEJB6lQeJPAviGy1b4tm00/7fEtrokha1udhEG6aH5QRljk7jlifbAoA3fF3i7TvC/xE01NRh1CVrzTpFj+yWzT7dsqZLKgLfxDoDW3Z+PvDFzL5R1iC1nHWG+DWsn/fMoU15r8boLe4+I/hkTaRf6zLHYXEsVlbW3nRyMssRBmwQyoDg5H8QHB6Hl4vEmknUBb63oGreH9QW3YQWNz9uvIJ1ZsudqAOhQ4UOBjDkY4GAD6Stby2u4xJaXEM6HgNE4YfmKnr5MstP8Hz3t5c6pqWtaQI3/0dU0+SSEJnoGuYy5Jxkg429iRT4NU8AQ/6MfEevXVzmV0kFyYUVN/7tXKxEA4OO4+Un2oA+sKQEMMggj1FfKen6n4S/ti6fVNUgudPkCtDDDfRzMuF+ZZC1uF5PIO4E5x2zUMmt/D3V9UtLbw9cPp09vM0t2mqxRQQtCpwVEixOQ7EqylcjAOfSgD6zJwMnpUE95a2yb7i5hiT+87hR+tfOd9cfD5YW+1eI9FtVdkREW9WdpTvGY5FWBWjRhkb8/Lnd2qbQbX4e6h4rXS7G/02ziWEXMlzZa95iSAEgxANGB2BOCDtIIoA9zuPFfh23bFxr2kxNjOHvIwcfTNUn8caMwP9nm+1NgM40+ylnB/4Eq7fzNeR6jqvhrwtpt7Lc6hpWo3auUgjh1yWMOWJKBgqqowMgktjAOcZpljqXw18WafPELxb7zUeIwR2VxAAeMlXJYAjIOdxPpngUAd9L8Rb+a6khsNEs4So5W/1aNZVPHDRQLMy8nnOMd6cPHuqoiu2m+HrlCSpe119cbvQGSJAT64PFZnhY3o0e60y11mwRbdVijvPDllHIu1kG1pMs+1+MnIAxgg88N1bUPCg0zTbTUL+3067lniZGOqlpCwcbzFsldt/ykbieCc5OMEA0Z/ig0YQHTNOjkJ2t5+v2aKp9Mhyf0rkvE3iu+8QJaR3dzbXmnX0/k22maQzGG7OB/rJ32NOgJ5jhUKcgM+M1Jrt0mlTs2k6PbeMr5YX8ufUYJy8JBHy+Y6sh3eilMkE8AcTeA7O+vdRh1bUbCwj8TZVDdfZ2uINNjCgfZbdEYrEoB+Zt4J3Oe4wAeoeDF1FdFUavam0uA2BESp4wOcKxVR1wo+6MDnGTu1T060lthI9zcvc3EpBdjlUGBjCJk7R+Z9SauUAfmt8WP8AkqfjL/sNXv8A6Peij4sf8lT8Zf8AYavf/R70UAff/wAJ/wDklng3/sC2X/ohK6quV+E//JLPBv8A2BbL/wBEJXVUAMnk8qJ32O+0Z2oMk/SuGv7nWl1iJP7SubZrlTHBb7IIklfGcgMZZOACThQO5wBUPxC8aanoOoCy0eGymuCgci4STgY9sA9+M9uteXW3xBsLbULzUvE3jfToNQBDDT7LRIhIsh4AWRvMY9B16etAHaajpGlWt/8AbtX1uKC6n3LchJ5WVowcOzEukK4JyWMf5nFZ11rvgW08yLSrfVL+MrvN3aYtreQDkr5gKBxyM7Q3X615949+J9tp9jFJe2+u3q3zvJAl9N5YIQ43iNs7QTgD5ADg4IrzO08b+MvEzyxeHtHvZUUKZP7MhkeUgEZ3yKC2CBgYxjPFAHr2qeKo728aG20nSYr1mV4I4rMy3RCFSq+W5J2kg5ZkQEEAE9a07h/iteQwuPBmm6fZoCIEitbVnVj03IWfj1xsxnn20vA8ltbeOtOtte0XTbC+kiElpDbgqkSMUIDEJl5BICGL4+dQf7mPW47RpNaluBdTvFZuyNAJGIdn2uC2SF+XJwB0B/CgD5r8NT/Eu48T3+iWuneH9I1obp4o9QsYLUyIy7S8QRGL7SM7lc84zkZFdt+z5put6P4417TvE2hadpGoQ6fExeywftm+aQmV2DNubPHbHTA6V0XxETwpceFLG71nX7aG3jUm2jtSBGZ3GP3ZUeYuTnHzcHnjbxU+Dh83xbLc/ZNMjaXSEV7yybc2oMk7KbiQ4HJORnLZIbkjFAFjx/qE1h8WbNrXR9U1W4fRSI0025jhlU+cck7mUlfoSBjkHgjD8KeItU1bSHm1jwXrN7qdtcPBLqlvqIch0PC7oTvVehKRqUzk4646vxIzRfGm0uP7Zt9Kih0FjK0sKuZFNwBgMxwvO31z0x3FW/1fT9Q8SX+laxrFtYDTY47x/wCwLl1mndgw/ehBvyu1XCDdnjcSOCAY+kx6pqianF4i8FXl3byHIl/tC93LGV5UecA5yR0QAYPTPV6eIdYs4jqOrTXNv4djkJ3S3D2kckT7fLYS/Z1YMvIId1DFuvSp7LxVZapcR28Wta3rsJj3PBe262RgIOQwcJGrSAgEK4IyM5GObb6yPEOg/wDE51zUIrGUqJ7OPTfLlQBtzCaRlAZMYDFFUdcEjmgDJ8Q+I7a9igh8MRtLNeuWljl1t4oJyEAYtszI/wAuPuYycFs98jxRrHiW78PS2vh/wZbW2v3G2KOXSmvI2SEdNzCGIeoG5wOv0rttV8SX2p65p9xYadr11olsm+Q20K/vJQflkXKEOME8Bx24rP1jW/DGvarrGm6j4dvpb+5s1domWQXzoGO1cD54UDZGR8vzZ9cgHnviPUNZuL6w8OzaRpumeIJkSVFtLGOW4EYIOHJuMjcVGV2ncM9RmusupfHXhLw9PcXmqeFrc3CmZLC604ecz9MBYMLyccndgty3auB0bwr4f8Palb6lpmh+KdJ8QwM0tvLq93DvTtuWEAu6gHALJjpnPSu8+G3i2wiS/wBa8aaZqltqhmLxGVDd7YgBtYMuSz9c/KoUcKqjqAVLLQfEut6Daafp6eI2jhB8sXVvb6bZwrjiMD5pnTHy5U8jJya3dA+DLnTwPGWrwTp5eyS3sYFhhjQc7VOANowBkpuIHXk10GofFmxa1aTQNG1bUPlz9ourdtPtI/eSe4CgD6BiewNcf4hh17xFZJqPjC6gTRPtEMawiORLItJIiR7YSVkuTuYEvKUTusbdaAO50/VfCnhTTJIPCOlG5C/LjToPkc9t07YT834riNW8S2up+NLbTfibdPp1tcCO40O206V3t2kDdZXChnmBxhWGwA9CSCewn8BiXToTZT2Gq2zYkVLiIWxYHkGKe3CsnbBIeq+geFLDVL9zJNO/2IhJ9O1SNZprd+oVj0kjYchjuJxkP1AAOri1W5027it9Ri36ZcNHHaXoVgxL4URyoF+Vs/xHCnIBweD0lc5p/httGubiXSb65eGXkWl9PLPFEeOI8t8g4zjBx2wOK6GPcUHmBQ+OQpyM0AOooooA5X4T/wDJLPBv/YFsv/RCV1Vcr8J/+SWeDf8AsC2X/ohK6qgDlfiX/wAi5Z/9hrSf/Tjb11Vcr8S/+Rcs/wDsNaT/AOnG3rqicDJ6UAFcd4/sba5ij/tJLW4gmPkrC9tG7Hgk5MrhMdeo7jrWT8VPG2nabo15YRXE/wBvMfmKbaF5iqA8t8hyOjDPYqfrXz7fWOp2U0WoTeCp9Yhba4j8RTkb8sB8izSb2PIGdpxkUAe0S3ujabo/l3UNrHqEkJJ0wassDIQSNm23UL0HUcZPFYcnxDW1s2h0PwZbrfKQDNfKo3Y6kKrO7dOrMo5yTwc8h8RU8a+GvB9xrN1Y+GdBVvLNnpNiBJMm4jdlWwCVB52BhxnAAzXimmx+NvHGsR2v2qeN5o97SzN9lh8vJO4kAAjk9Af0oA9x8Q+NfFFzPcXVpLdQ2mnsxnGgKxQOf70aOVyS3G+QEkZ2k1PZeEfiFreni/tfGVvoOlXMjSx2VxqErmdiWJdnGCAzZ4U4OMjOcmlpfw28X/D7wRdX2p3Y1CKynFzHZWA8+CRHAV5HXYHZlyGyQRsVxxur2jS/E3h3xLZacbvU7aOCK1ju5opLmJNro6lWbAHAZWwQQpweDg4APEdW8M/Efw/r8El/42v10Vv9Gubyyvbi+Gns6hkMkeUZV5X5uQBgn0r0b4W2eoaZ8SLe0vvEFj4hR9GurpNQthCGmMlzASzBPm9MFmYHtjkVY1/4keAdQ0W4XVr+fWJGf93aW8citOCFOIQoG9O4yTgk5OaxPgjqVrf/ABJmTT5BDaxadeONPmgWOe1aS5hdgxHLKcg+gbfjIoA6j4lJfy/EfRotM0G312Q6XO5tpb37K0YWeAeaj4PzDdjscMcHkg8f4TvPEF7barZ6l4Lg8QGyv2Vr6LWzJPCV+ZAPMxIdm7blduccDqa7vx/f6bp3xD0mfWdZn0i2XSLoiSGUIZm86D5OhJx1AHPXtmsrWNZ0LXNXmg1XWLzVdF0uJblWsreVWMzbgFeWIANtGGGNu04Jz2AMnR9O126OqL4h8DC9spf+Wkl/cRyRoV2sF8x3Y5H8Kbe/XNK2r+KbWP7UJL7T9CjJeNJmaJHgwpUNIbQuhAV9xcj72cjGabY+KLLVL2GC0m8S6pBsIez1h1iWMj+JJEHzSDsHJXvuUjnVg8SXOp6EJrzxFrkME6eU9pBpKrcwZB3b5JIwrAAgbkUc8gmgDM1Tx1pc2mtdeHbm+bU5UWLdFrFqv2gKWZY2lkJB+8wynz4PFc/qfiGGDRrm+t/BJPiDyjBaXNjq0t7NK5OTl/LJY5Aba2c47YrtdV8RPeR6Lp/hiz1i90Cz+S7extEKPGgGwxkxvkgjOAVJ/kat4r8Lazr5t9QXWbS9msniWV5HguoA2MiKFTvRiQCXKgcDBOMAA8s1rW76XRNMh1nwldad4gZD9lur+W+eTeVxI6w7doI9S23B6emvqFhc6f4bvtV8V/CvwtMk+ZUuJLoW0zbvUSF5CR2AIPYKMVzn/CM6Tbawvij7Z4+vdV0yfzrQavagx/um3JEZWbEg3dkYbhnG3Oa9N8Ca/wCGNV04a/491Hyb95WVbbWx5Qg2sQM7lVCTgNhRtXI4zliAclcC+1LwpY6LoUOjapFaIirDoen3MxbYw2s1wxSISjCncQTuycCui0T4d+Ndaa31HWpodC1AKFRxObma2T+LaSX+ducsrJjtzzXoFx8VPCMZW00G8OvXoXMdlokf2lsDuSvyIB6swArjb3X/ABd41u4ILWT+x9Nmk8uNLK6RRI+Cdkl4VYMcKxMdujYwQZKANX/hDfhz4KYS61Cusa9MmXe83317eMF5Ii+YngdlwOM1h6N4TsfiDqul+K9O0zStN0eweaOCxsWNnfK4OC00kYG1/l/1XQBs7sni5d+HbvRGgjkddETKr5rQpPYSn5cK0saxyRHcB80gIzjljgUeFfhxqdl4u1PxDHEthq9wzF/NxPbvMOQzKCNyHAIdSr5JBHUUAdHoXhTwDrmord2mni51Cy+SWO8eWZ4SeqSLKWG7Oc98g89a9Fghit4ligjSKJRhURQoA9ABXI6cuoPd2t/4usI4tQsywim00O8TKy4IYZLEZ5GRxwetdgDkAjOD6jFAC0UUUAfmt8WP+Sp+Mv8AsNXv/o96KPix/wAlT8Zf9hq9/wDR70UAff8A8J/+SWeDf+wLZf8AohK6S8t0u7WW3kLBJFKsVxnB+tc38J/+SWeDf+wLZf8AohK6iRBJGyHowIPAP86APO5vhh4ShaJtcuLy+jX7seo37GMnsduQpIwe3c1kSaToXhO/svEdla6VptnGriWW8S0Hlxc48gRlQCT1bd06hu1+bQNA8JX0sc+o3s17qdw9zDFHZRTXLPtAKRlYuFVV4AAxyc8muJ+IUOreHVMvh74Z2eoPfsfnvpTcTSseHDQxnaCRg7VY5UEkDBFAFz4g6dZeKSus+MNEu59LsI2uYUlvAp2EbsIihSAcDO4OWwuMVl+GvHOmadMdN8EWlhokEEYneS/up7mBt2PlCwkqX65U4K47dK6D4QsnxA8NPLqVvb6Dd2reRPplhp62zxA8oS8gZyrKBgrt6Ec4rkdC8I+MPDfxEkv9Z1mXWPDNpetbXcIuWjlt4GA8qdlXAx86sdueFbI44ALHirxPr3iQia48K2d/DbKfI1q0S4tCpPZPN2sV5IOcqc9CM1k2Okrqnhu+e91jx29zKVubiy8+O309ZSeFMrbUdPlHzKQMDoDwPTPiX8HPCms6ct01hNGYJPNuWglYyyRZBfaWJ+YAZHryP4qh8O/Cjw54F8QWep6NbJfaNfN5M8V8q3BtmcgwyQsVyq5+Vuud6kn5aAPFb0eHNKEEZ1zTbmUApdxQakFmkPAxDMxZYRnk9yOM85rvv2e73Qo/ibqtnoTw7JtJVsR3T3OWSYlsysBvP70dOmPpXo3xD+F3hTxZrNrea7pSSmWH7E00TNE8R6xuCvXHzLzkfMvpXDaR4Kl+H/xX8MGxeeXR4t9kCzKBHFNGQuQACSZVRSef4c9RQAfHGC7n+KOmPZ+EpPEqRaUEmC+di13zMVc+UC2T5bcY9a4TUfGOiaEtloetXq297pt0k11A9ndRLLg7vLlhHyMhDDtngHmvf7PTkHju48VxvKrTTto8qlso0KgBDjPBE6uAR2kPtWL49+Enh7xh44F/rf2kLdWvl4gYLukQgHJIPJTaP+AUAZV9aeK/Eul28506caUyiZYorW1ikK4DKY95LD6EKT04rzfVfiL4R1izghGuQWksVzFcCHUtE8pt8bhwkhiRwU3AZGRX0f8ADy1l0zwzDotxcPcy6QxsPOcYLogHlk+/llM++aoWHhPQrmXVdN1LSLC6ihvHuoRLbocLON7Y4/vtKPoKAOOh+J2t6rYxS6OmmSJMSsU8Frd3KS44JQKgPXjoelVNT8HeMPGd7ZavqF3Lb3lmkq2o3Np0cYdQGGIyZ33YAOXiwOg9fR/A+iWvhdtS0LTUMWmxzfa7SHdkRJLksi+iiRZCB2DCupoA+SfDfgf4ga7qklk1vbeGreNjGZ9NtEAkAOH3XDbpWcEEEOxJ/n2Nt8IPHNpDDey+OdU1B7SQy/2VPcSpFdBTxHvSQbNwzz2JHFe2XELaXqkl/ArNaXWPtaLklXAAWUD6AK3sFP8ACc7NAHNaH4Y8PI1tqlpp6yTsokinuneeSPPPDSFip+hryj9pfVrifUvDmj2UrLHZXtpqN2F775xFED+IkP5V7pZ26WqvFBEI4d7OMNnJYlm47ck189+OdON58WPEy3mTDdT6HHbbuxW6jDAfmx/4FQB7v4bjkgsJoZI9ix3U6xjOf3fmMV/DBAx7UzXNOleaLU9NVf7UtgQoLbRPGesTn0PUHswB6ZB1LeSOWLzINpRieR3OeTUlAFXS7+HUrNLm23BWyGR12ujA4ZWHZgcgirVUBpqx6q1/bSvE8oCzx9UlwMBsdmHA3DqODnAxfoAKKKKAOV+E/wDySzwb/wBgWy/9EJXVVyvwn/5JZ4N/7Atl/wCiErqqAOV+Jf8AyLln/wBhrSf/AE429dVXK/Ev/kXLP/sNaT/6cbeuqoA5fxT41sPDus6bpVxBPNfagsjW6o8SKQgyxZndQox3PXoOeK53VvFf9oTfZfsOryrd27xGPSPIuhgg/fkGfLJGQOcehzXfaxDPNp06WcVpLdbSYVuwTFvHQtgZxn0rhLvw/rvi/wAISy3viS/s9QlRjHBpv+iRwSqSGjYgl3GQyklsHrgHGADldIsdVk08GWHWdFtLJngFs9vGqrbqx2bp2eMsCPmODwGKnjiuE1L4neMXuVsJ9a062tJLsW4a3vLSBvIyeQ28ukmBgcFQTyx6V1nwe8E6j4Z1iKbxHPb+I9E1XJs7u6zJNY3A5KOr5ClvnUlc/MgHG6tz4zfCjw14r1fStQ1NJbISBrB7m02pskdsxO4x8w3bl+si0AeZ6vqGr6bFLJYeKdc0SMHMlze6zPqny+0KQ4Qk4GS3sBzmud8LahoviPxBqTXsGgeJr+5jBjnu7S7MqFA2QIYoyzhiVO7IIwR0xX1d4Xs5bnwfHo/iAreXFvEdPu3IIFxtG3ee43rtfrxu61zFr4O06001LjS9NtrbxB4duD5VxawrHJcqAXKMQPmEscp3D++xPUUAfO/i+PS/BdlaxajZazp0127Mk0WnfZY2xglF3gOYgSBtJ34PLc12v7OXiKHxF8XNQnhuIrgpojh3jtDAoYzQ8AszO2MdWNe/+JLOz1XS7W+lhhuobci4Cyxq6vER84IIOQUJOPULWB4f8GaT4T8c2zeH9PtrKynsLgFI8go/mQkgZ/hPB9ivHWgDnfjBp2sap468PW+g21rczjTrxpUntoZyI/Mt+VWVkX720EhsjIrwvXfFtn4SuLLw1r51KTVtEvo7mWW8s0kZnXLLuPnsGUhwcAD+E9RX1VrrJbeOvD92ytu8i4tS4GcLI0XH4usf5fnzXjP4UeEvFnjeW+8RWTzz3looTbcNHhojhjgEZJVo+ufuUAYGsaV461/RlutRjuJNNiVbs2SzWqTTbcOoRfJkAbjGN6g9DXkuveP/AAr4m0U2jeIrjTYHYnyrzR0SQ8FdjSRI4ZPm5GBX1P4BgksfCtnps873Eum7rEzOMNIsTFFY+5UKT9aytK8H+H7yzuNN1TRNOu006+m8gTwI/lrIfNGMjjiQD8KAOD0f4razfaXC+mQ6BPb7CkU9tHclJCvGEiKqxHGMDOPXioNT0Px545v9P1OeQ6fPp8jtaNawnTwm5SrbpZQ8zBhxtEYHueDXpngjQLHwnqGr6No8S2+myOl/BbhiViMmVdVHZcxg47FjXW0AfHGn6f8AEDWvE8traaFbaXfKWi+3XkUt9NIP+WmZ5t6nGPmA29cAdq7TS/BnxI02exvvFWo2N74d3hL2G0tLeK4jRjt8zDQkFUyGYHsDgd696aFtM1lrmIE2V8wE6jny5sALJ9GACn3CnuxrWniSeGSKZQ8cilGU9CCMEUAcra+AdHRk+3G61BEIKw3EgWEY6ZhjCxt+KmvL/irrEmrfG3wN4Qsxs021ldrgR8YlaBto9tsZ3D/fr3XT4/Js4oczMIh5YaYgswXjcSPXGa+dfAkV1q3xTtb+/LfaU8Xaw/zc/uVso1jAPXABXAz0oA+gNHkOqeHLGS/jSQ3dojTI6fK25BuBU9jk8Vm6HG+gXqaJIztpzgnTZGJYooGTbknklQCVJ6rkfwEnoo0EcaIudqgAZ9BVbU7CDUrRre5Dbch1ZG2sjA5VlI6EHkGgC3RWbpDamu+HVkgZl+5cW5O2QdPmU8qx64GR78VpUAFFFFAH5rfFj/kqfjL/ALDV7/6Peij4sf8AJU/GX/Yavf8A0e9FAH3/APCf/klng3/sC2X/AKISuqrlfhP/AMks8G/9gWy/9EJXVUAUtWsvt9oI1cRzI6yxPjO11IIP6YPsTUXiCykvdNcWpAvIWE9ux7SKcj8D90+zGtKigDCvEji1PTNYiiCNMBazttwxjflM/R9oGem9vWm6ppyHxHaXX7zyr2CSwuY1xtkGC6Fu/wAuJQMY/wBYfart9Z3V3ps0LyRef5vmRNggALIGTPuMDmrN3BJNNaPHL5Yhl8xxtzvGxl2+3LA59qAKvhueS60Gze45m8vy5M/3l+Vv1BpLXTf+JCdNmJ2KjQKwHIQZCEe4GPxFWtOs1sYJIkdnDzSzZbsXdnI+gLYqwqkFiWZsnIBx8vA4H8+fWgDNiZ9U8PxPuInZFc7eCJFIJHPT5hiuW+KZ+029jY2crw6lcSJGjxybHjywKbT2YyIuD6K55wa3tW1a08PWv2eHY1wxaRYzkKm5idzkA4BY4HBLHhQTxWRZ6DcSiLUtTIbUZLqF1EgClQHBY4zwSoIC5O1RjkliwA3TNMn0fwFd6XBNNfXWmSuyyyndJOwcTAsf7x3D866PXNsc+l3BBLR3aqOf76sh/wDQs/hUd/FLY6RqklqGe5uHZk8s/NvbCLz7cflVzUrR7qWwK42Q3AlfPoFbGP8AgRWgCDTN41bWARiPzYyOOp8pc/yFKgRPE0pCv5ktmmW3fLhHbAxjr855zUmmW00NxqUs4UfaLnzEwc/KI0Uf+gk496n+yp9vN3lvM8rygM8AZz/n6UATeWglMoRfMI2l8ckemfTk06iigAooooAK8c1uBrj46Q6ZPbyBGih1hJRjayQ8FcnoRIE/BhXsdZ2q6dBdFpMiK8eF7ZJk2iTY2CyqSD/dB/CgC3Ysz2Vu0n3zGpbnPOPXvU1U9N1Gzv4mNnMrGNvLeM8PGw6qynkH2NXKACiiigAooooA5X4T/wDJLPBv/YFsv/RCV1Vcr8J/+SWeDf8AsC2X/ohK6qgDlfiX/wAi5Z/9hrSf/Tjb11Vcr8S/+Rcs/wDsNaT/AOnG3rqqACq9sI0luI4oWjAfcxK4VywySPX396sU1Y0WR3VQHfG4+uOlAGJqdp/xT+owxeWJYpHuUEfZw/nLnnqWwTUviSKDUvCt7u2PC9uZkLAEZA3qefcA1r4HPA56+9NeKN4midFaJl2lCMgjpjHpQBk6VKTr+qx7jh47e5C7s7dysv8A7Tq/DbJHqNzOrjdMkYZO427vm/EHH/AasLGisWVFDFQuQOcDOB9Bk/nQEUSFwq72AUtjkgZwP1P50AZ+l2bR6U9lcptjDSxqA2cxFjtx6fKRVSdDF4k0JGIJW1uEyAcE/uv8K3axtfxDe6PeEE+XdiJiOyyKyD/x4pQBT8TW011q9iltnzlj81enIS4t2PX2B/OtHUwo1jRnwN5lkTOf4TExI/NV/Ks6W1/tXxNqBEjxrZx28Acf3t4mkUfVREPxrfltopbiCdwTJDuKcnAJGCcd+P50AUNCbdLqrKRsN6wUAYxhEB/UE/jS6eI11zVQiBXPks7bs7jtIHHbgAVftraK1R1gQIru0jDPVmJJP4kmpcc570AZ7WzHXo7oIAi2zRs2OpLqQM+2D+daFFFABRRRQAV4V8PLe1vvHOrulubiTR5rizvY5E6zTtBCT6EbIGP0PvXutc9Lo+n6VfXF9EIbZb++jubx2XiSQII05z8vKx/jnuaAOhooooAKKKKACiiigD81vix/yVPxl/2Gr3/0e9FHxY/5Kn4y/wCw1e/+j3ooA+//AIT/APJLPBv/AGBbL/0QlReOde1Wx1HQtE8PJZrqmsSyqlzeqzQ28cSb3YqpBdsYAXI7knANS/Cf/klng3/sC2X/AKISpPHXhUeK9PgtzevYT2863FteQJ+/t5Fz8yNnAJBIOQQQSCDmgCXwzb+Kba5uE8SajpGoWu0GGSztJLeQNnkMpkcEYxjBFdDXnyfDSSVmfUvG/jO7d+oXUhbr+CxKuKkPwn8MSHN4davBnO251m7kGfXBkoA7xmCjLEAe5qrNqdhBL5c97axyYzteVQcfQmuJuPgz8P7lNtx4bt5ec7nmlLH/AIFuzXjWk6R4G1u41K40L4fTsLd44o2spZ5WKNkAsiSoRnaTuBwB1yesuai0nuzanh6lWE6kFdQs35Xdl+LPoufxVo0ZYJfJcMq7mFsDLgepK5AHuSK5qTx3Fq8pttDu7FSX2F/tcRb3+bJRfw8w/wCyK8xtvB0cAtl0/wCGtqtzNxctcpcyIi8nCuz5bnHYVZsPh/NDqDtZ/DTSIwCWjnkVBg4/i3TE8nsoXjvVGJ6xo1vpGnv9qv8AVbGe6B8zJnXZGxGN3JyzY43sSccDaOK1P+Ep0AyGNdb0x5ANxRLpGIHrgGvH9S8DaxcPbmfwforBGzIw0+0k3LnOwGWYlOg5+Y8dqrz+FfEdtbPHY6FBY7gwSYS2NusQ5xtRQyNj/aGc85oA9nHirQCzKNYsCy8MomUlfqO1RyeMNAQkf2nAxHUR5f8AkDXhX/CMeJ1uLU29tpcbR5M0txrMUT3XHBdoUyMZP3QPw7ieDfG4luX/ALSsJWmP7h4vEtxm2UrwFjwI5Np5+cHOec4oA91Hi3RWPy3UjHrgW0p/9lp0finTZP8AVpqTDIGRplyRk+/l14hqPwn8R61dTXckFj+9iZMjXbpsuQMSDgqGXHAA288g9lX4Pa2l3b3KaJo7mO2a3kgudVmmicn/AJaAOhxJ79PYUAe3f8JPYBHcw6mEXqf7OuPzxsz+lYkvxT8IxXLW7ahdNOpw0aabdOyH0YCM4Psa8usvg3qlqumrF4a8KE2SlQ81wGabIwDIfsvzEevrzXUeD/C/xE8KWDWWlP4bFgZZJUtpZnYRl2LHDLCpIyTwckDvQB0Q+Lvg4y+Wt7qBb/sE3Yx/5CoX4seG5VZrWLXrlQcFodEu2Gfr5dVn1L4pWwbzNA8N3mOn2a7dM/8AfeKhbxL8TIkP/FBWdw/YLqsUY/Ekn+VAF+X4reH44PNkj1CFAwVjdwCz259fPKVz114xvPEGu6LqmjNKmnWnnTLBFLI8d6uNjsWjgkVwmcfK3BPXtVqbxT8QruF7XUPhbE1vMCkhOsW8ybTkEGMgbvpnmuY8LWHjnQrTUrRdAvb+2ubhpoIJo4YDZIylWjikF0xHy4AbrwTzmgDqtV1XTtbuY4td0y80G+Zl2ahGwUxkEFd+4K5XIHJUgA9V5NaWteL28M6tJp+o6pYm4K+fb2t2G824iyRmNo1JJBGNvlk+5HNc7e6f498UzRDXdHsNPit1cQtNPH5SlkKF3CNI7/KzDaGjDZwxIrufAvhGz8NWskovZ9V1W5VFutTumDSzbBhV44VB2UcDOeSSSAVLL4gW8lrHNqXh/wATaZuAO2fSpZMZ9fKDY/HB9QK1bTxl4dum2R6vaJLnHlTN5T/98vg/pW/RQAUUUUAcr8J/+SWeDf8AsC2X/ohK6quV+E//ACSzwb/2BbL/ANEJXVUAcr8S/wDkXLP/ALDWk/8Apxt66quV+Jf/ACLln/2GtJ/9ONvXVUAFFFV72ytr6NUu4UlRTkKwyM4I/kTQB5h4i+JrReMdU0Sw1PR9O/s7bG32u1nu5riUoG+WOIjag3BSSSSc8DHPSJ8SvDIRQ97ctJgbtmnXJwfp5fH411lnaW1lD5Nnbw28W4tsiQIuSck4HcmsPxnp95d2azWWszaW8AYqUjZ0ZiON6qwZgOuAR060AU/+FjeGecXl22ODt065OPyjpX+I3hhIw7386oQTlrKccev3OleXtZXctpKlz471ubzpN8kseiX6yKMglYzklV4+7+tJLp0T3am18WeJYVKbG2+HbyQEc9GYEq3csCGOBknAoA7W7+OPw9tiobX/ADGbosVnO+fyTr7VynjH42aRrOiahpvhGw1W91ry1khMtuII4ZBIoR3MhBwHKHABz046jKu/Den3bW7X2satcJbzGZBeeGtRkG/dnccyfPz03bvauY8axWOgWVvo+nXMcttcyNNcIumz2bKpJ+UiSTcVJLHClQCoxjtlWqxow55HdluX1cxxCw9Ld3/BXPXvBnjq1sbK4h1kXlxrUspuLx4rPyomdgABGGc5VVVV4J6c46V0UPxB0yZd0dnqRGcf6lf/AIqvCL/w9pv+iPP49t7W0tozHCF8JTv+7JBxmUvk/KMMcnrzyaTR/B3h+2W3ltvHOh3cNufNW4udB8u5Y7s/vps73HOCG4IODmtTias7M9uX4o6C0ixiO980nGwxqGH1G6rcnxB0mPy90N4PMGVG1P8A4uvCZfh14VuZppoPGXgOSWdklSA2lvEgZfugYbIX1XGG/iBq1p/wkuyl8bHVfArw3/EyxwIwwV24Q7Ds47LjB560CPcrXxzplwNyw320DJKw+YR6ZVCx57cc1mr8WvB7tIqX1+5jYo/l6VduFYdQSsRGR9a8/svg7qMa2jfYPBd2LaE26CS0QqV+X5m/cHc/yj5jk8n1Nbnhvwz8T/CmjW+maPqPhu6srZRHBDeF8RoDwu5IlJGPXn60Ab83xi8DwMFuNWuYCRkedpt1GMfVohTf+Fz+AgELa6yq5wrNZXCg/QmPFVV1r4q26t9q8KaFdHdtH2O/I/H94Rx+tRHx549t2K3fwtvnAA/eW+qwOGP07fnQB0B+JXhlrR7m2uri4hXGXS1kVeuPvMAvX3rj9L8fRvruu3GuKLvSL4JHaWifZXMUSghlYiYl9xJbbtOM1gfEC9ufF+kXNtdfDDU9P1dBm11Ge0+0eS3qDCjsf93oc+1amjeMdf0+y09rnwlrd3fhIzfTw2VyiXcgTYzsjwAgkAEEdTweOaAOp0O6ubG1u9S0bVXvtFijjT7BexOJrTb1U4G5RtIOdp+UA4P3jsXHjzRtMltIfEc8WjS3YzbvczIYZxjOUkUkEfXH0rzzwn4Z8X6nI8kbz+GrS+WU6hOYwkzCRgwjtoyzmPaQ+JHOR5rbUGBj03wz4J8N+GbVINE0aytgsflGQRBpHX0Zz8x/E0Aaunarp2phjpt/aXgXqbeZZMfkTV2sC+8GeGb9993oGlyS84l+yoHGeuGAyOvY1oaRpNrpMbx2ZudjkfLNcyTBcdAu9jtHsMCgC/RRRQB+a3xY/wCSp+Mv+w1e/wDo96KPix/yVPxl/wBhq9/9HvRQB9//AAn/AOSWeDf+wLZf+iErqq5X4T/8ks8G/wDYFsv/AEQldVQAUUUUAcR8YfEq+G/BF48b7b28U2tuAcEFhyw+i5OfXHrXiXwBuEHjc2E0s8cd7bSRgRTNESyjcOVIPQNXqfxl8AXHipU1OLVRbrYW74t5Y8pgZZmBHIJwOx6CvM/gx4K1nUtT0/xJp9xZxWllehJFldg7gAFwoCkcq2OSK8jEe1eKi0tFt6dT9DydZfDIa8ZVFzS+K99Ja8q89r6eZ7hP8PPDty4e6h1C4bG3M2qXT5H4yVQu/hb4bbm00yyV+CGu0luecjs0mMY7fjXeUV65+eHn0nw30W3iM0mn6YxXki00iAM3sNwb1rMXwRo8hmA0bWJMtuBNpZRfgPlX1r1SmuiyKVdVZT2IyKAPAdX8JwlZREmnWpbAh+0RwuyYPOQLhQ2fw6VmnwvGROxm0/JjCpHb20bqrd3wLgnn0J7DHv8AR8cUcQxEioPRRin0AfM13onmXUaRaLbvbJGwfYIiXbjYRugIHQ5BJ6jnjmBdC1+G3dodN0m3MjhikFyN0SZHylRDGhyAeQePQ19QUUAfMUMWsQtai30nTY1Qt9p+2aw6tgdBF5cyFj0Jyo4HTNadm3iK8mlEWkxNEqsYZLPxDJl2AyAyteqVzxj25IHSvoqq1xYWdypW4tbeVT1EkYYfqKAPHbS218tai9tdfsomiLTt9oupfKfH3VEd8xbnPOBUTrsvbyzuZdfe7iJeGFrfVG84bc5ybkJ1zxu+uK9eGhaQOmlWA+lun+FL/Yek/wDQLsP/AAHT/CgDyj+x5550M+nXZ+XO57a6YDpwR9t69fb3qC58ORSWUUsuhWouTjcr+F57lgM85JuSOB6E/j0r186JpR66ZYn/ALd0/wAKibw3ojAg6Pp2D1xbIM/pQB4tJ4dC3soh8P6a9n5AcNJ4IkYGTJBUgzBugB6d+varngrRrC78iK80jwjYXMspU2qeH7i1mK9t25xtf1HzAetesnwvom3amm28Q6/uR5ZH0K4xWnZ20VnbR29uGWKMYUMxYgfUkk0AYMngjw85GNOEeDnEU0kY/JWFaGkaBp2kNusIZEbBGXmkkOD/ALzGtSigAooooA5X4T/8ks8G/wDYFsv/AEQldVXK/Cf/AJJZ4N/7Atl/6ISuqoA5X4l/8i5Z/wDYa0n/ANONvXVVyvxL/wCRcs/+w1pP/pxt66qgAooooAKKKKACqWoaXZ6gyG8h8wp935iMfkau0UAc/f8Ah3TEt5p4rGyacLnfdgugHfOT6Zr5G8UalHq2v3t5BBBbwSSHy4oI9iKo4GB2z1PuTX2tNFHNE8UyLJE6lXRxkMDwQR3FfPvxP8K6DYfEnwnp1jp0dvbX80S3UUbMqurTBcdeOMjjFedmNOc4Kz0X/DH2fBeNw+FxU1Ui3OSdmraJJyf32M3wD4aPifQoLxYJp5LaQwt5arhSq8ZBPI2kcEYJ9SMjoE+HF5bBPsmnS7vMM0rmOBfNbBxuXyzuXJ6ZXoMV7B4b8N6R4atpLfRLJLSKQhnAZmLEdyWJJrXrtoxlGCjLdHzOY1qNfFVKtBNRk20nvr6Hz1c+D/Gcc+oGCxi8u5ChC5mIhwADsRJgBnGTx1zjFZk3gPxPFJGxs7O8SNduJNNeMswxy+5Zie/3TzmvpiitDiPl8eF/E0Uy3f8AYfhm1g2/vI7mxbzGbpwwt4wF6cE5PrT7Ww16J5vL0fw0l1IR5UWn6xJHvXd8wZDdR4ZR6DBPoK+najnt4bhds8Ucq+jqGH60AeHxQamguTNb6pbQwxBoPslxcytK4ySCIr19vYDucmmaRc3OoeU1rf8AiC5J+WYCPWIxEcZPLPzzxwD9K9ifw5ojnL6PprH3tUP9KdJ4f0aXHm6Rpz/71sh/pQB5W6ag2VWPXVw+0mW71lBjPXIQjHH+OKoyTJJKyjUp0KpuLTatrCZbPA3FQP6+1ett4V0I7tuk2aFupjiCH9MUr+G9NZCgF4g6fu72dCPoQ4x+FAHhlrrLTXenQRu0tzeBWCweNL2B41xli6TIMAdwPm9Aa9X8PaPe3tt9pbXdXtz91Vhv4ruP8GaLn8a3F8O2pZ1uZrq8tXG1rW8k8+I/g4J/WtGwsbTTrYW+n2sFrbgkiKCMIoJ68DigDDi0DVoZNy+LdVkGeVmt7Vh/47ED+tbtlDLBAEnuXuXyT5jqqk+2FAFT0UAFFFFAH5rfFj/kqfjL/sNXv/o96KPix/yVPxl/2Gr3/wBHvRQB9/8Awn/5JZ4N/wCwLZf+iErqq/NG08feMbO1htbPxZ4ggtoEWOKKLUplSNFGAqgNgAAAACpf+Fj+OP8AocvEn/g0n/8AiqAP0por81v+Fj+OP+hy8Sf+DSf/AOKo/wCFj+OP+hy8Sf8Ag0n/APiqAP0g1K0j1DTrqyn3CG5ieF9pwdrAg4/Oud+GvhE+CvDjaW1/9vZp3nM3k+V97AA27j0AHOa+Af8AhY/jj/ocvEn/AINJ/wD4qj/hY/jj/ocvEn/g0n/+KqeVX5upoq1RU3ST91u9ul11/E/SmivzW/4WP44/6HLxJ/4NJ/8A4qj/AIWP44/6HLxJ/wCDSf8A+KqjM/SmivzW/wCFj+OP+hy8Sf8Ag0n/APiqP+Fj+OP+hy8Sf+DSf/4qgD9KaK/Nb/hY/jj/AKHLxJ/4NJ//AIqj/hY/jj/ocvEn/g0n/wDiqAP0por81v8AhY/jj/ocvEn/AINJ/wD4qj/hY/jj/ocvEn/g0n/+KoA/SmivzW/4WP44/wChy8Sf+DSf/wCKo/4WP44/6HLxJ/4NJ/8A4qgD9KaK/Nb/AIWP44/6HLxJ/wCDSf8A+Ko/4WP44/6HLxJ/4NJ//iqAP0por81v+Fj+OP8AocvEn/g0n/8AiqP+Fj+OP+hy8Sf+DSf/AOKoA/SmivzW/wCFj+OP+hy8Sf8Ag0n/APiqP+Fj+OP+hy8Sf+DSf/4qgD9KaK/Nb/hY/jj/AKHLxJ/4NJ//AIqj/hY/jj/ocvEn/g0n/wDiqAP0por81v8AhY/jj/ocvEn/AINJ/wD4qj/hY/jj/ocvEn/g0n/+KoA+/wD4T/8AJLPBv/YFsv8A0QldVXK/Cf8A5JZ4N/7Atl/6ISuqoA5X4l/8i5Z/9hrSf/Tjb11VeYftMXM9n8FPEF1ZzSwXMD2kkUsTlXjdbuEhlI5BBAIIr4l/4WP44/6HLxJ/4NJ//iqAP0por81v+Fj+OP8AocvEn/g0n/8AiqP+Fj+OP+hy8Sf+DSf/AOKoA/SmivzW/wCFj+OP+hy8Sf8Ag0n/APiqP+Fj+OP+hy8Sf+DSf/4qgD9KaK/Nb/hY/jj/AKHLxJ/4NJ//AIqj/hY/jj/ocvEn/g0n/wDiqAP0prJ1Xw7pOrajY3+oWUc15YuHt5SSGQghh0PPIB5z+pr87P8AhY/jj/ocvEn/AINJ/wD4qj/hY/jj/ocvEn/g0n/+KpNKSsy6dSdKXNBtPy0P0por81v+Fj+OP+hy8Sf+DSf/AOKo/wCFj+OP+hy8Sf8Ag0n/APiqZB+lNFfmt/wsfxx/0OXiT/waT/8AxVH/AAsfxx/0OXiT/wAGk/8A8VQB+lNFfmt/wsfxx/0OXiT/AMGk/wD8VR/wsfxx/wBDl4k/8Gk//wAVQB+lNFfmt/wsfxx/0OXiT/waT/8AxVH/AAsfxx/0OXiT/wAGk/8A8VQB+lNFfmt/wsfxx/0OXiT/AMGk/wD8VR/wsfxx/wBDl4k/8Gk//wAVQB+lNFfmt/wsfxx/0OXiT/waT/8AxVH/AAsfxx/0OXiT/wAGk/8A8VQB+lNFfmt/wsfxx/0OXiT/AMGk/wD8VR/wsfxx/wBDl4k/8Gk//wAVQB+lNFfmt/wsfxx/0OXiT/waT/8AxVH/AAsfxx/0OXiT/wAGk/8A8VQAfFj/AJKn4y/7DV7/AOj3ormru5nvLqa6vJpZ7md2klllcs8jsclmJ5JJJJJooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left panel shows the tracheal dilator correctly advanced, following the guiding catheter and guidewire. However, if the guiding catheter is inadvertantly withdrawn into the dilator during dilation (right panel), force is directed to the posterior tracheal wall and can result in perforation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Trottier, SJ, Hazard, PB, Sakabu, SA, et al, Chest 1999; 115:1383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37824=[""].join("\n");
var outline_f36_60_37824=null;
var title_f36_60_37825="Indobufen: International drug information";
var content_f36_60_37825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indobufen: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ibustrin (AT, CZ, HR, IT, MX, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiplatelet Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of platelet aggregation which leads to thrombus formation",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 200-400 mg/day given in divided doses every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 100 mg, 200 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10395 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37825=[""].join("\n");
var outline_f36_60_37825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979060\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979055\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979058\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979054\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821239\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979057\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10395\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10395|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_60_37826="Angina PI";
var content_f36_60_37826=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Angina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37826=[""].join("\n");
var outline_f36_60_37826=null;
var title_f36_60_37827="Contrast MRI myocarditis";
var content_f36_60_37827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Contrast-enhanced MRI in acute myocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 543px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross-sectional magnetic resonance imaging (MRI), with contrast enhancement, in a patient with acute myocarditis. Panel A: On day 2 of symptoms, contrast enhancement reveals small foci of increased signal intensity in the posterior myocardium and in the basal septum. Panel B: On day 14, a more diffuse increase in myocardial signal intensity is seen, especially in the septum (arrow). Panel C: On day 84, no signal enhancement with contrast is seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Friedrich MG, Strohm O, Schulz-Menger J, et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998; 97:1802. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37827=[""].join("\n");
var outline_f36_60_37827=null;
var title_f36_60_37828="Standing teleogram";
var content_f36_60_37828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Standing teleogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Standing teleogram of bilateral lower extremities from hips to feet with patellas pointed straight ahead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Rosenfeld, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37828=[""].join("\n");
var outline_f36_60_37828=null;
var title_f36_60_37829="Chronic myeloid leukemia (CML) in adults";
var content_f36_60_37829=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/60/37829/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37829/contributors\" id=\"au5263\">",
"       Robert S Negrin, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37829/contributors\" id=\"au4589\">",
"       Charles A Schiffer, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/60/37829/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37829/contributors\" id=\"se3198\">",
"       Richard A Larson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/60/37829/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37829/contributors\" id=\"de1889\">",
"       Rebecca F Connor, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/60/37829?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CHRONIC MYELOID LEUKEMIA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Chronic myeloid leukemia (also called CML or chronic myelogenous leukemia) is a chronic (long term) disorder of the bone marrow. Bone marrow is the spongy, red tissue that fills the large bones. All of the blood cells are produced in the bone marrow.",
"    </p>",
"    <p>",
"     People with CML have acquired an abnormality that causes a section of one chromosome (a strand of genes) to break off and attach to another chromosome; this results in an abnormally short chromosome, known as the Philadelphia chromosome. This exchange of genetic information causes two genes, BCR and ABL, to fuse into one gene, called BCR-ABL.",
"    </p>",
"    <p>",
"     The BCR-ABL gene causes bone marrow cells to produce an abnormal enzyme (the BCR-ABL tyrosine kinase); this enzyme stimulates white blood cells to grow out of control, resulting in elevations of the white blood cell count and an increase in the size of the spleen. Eventually, the disease can transform into a more aggressive disease, called acute leukemia.",
"    </p>",
"    <p>",
"     People with acute leukemia have an increased number of immature white blood cells (called blast cells). The overgrowth of blast cells leads to an inadequate number of mature white blood cells, which limits production of other vital blood cells, including red blood cells and platelets. Having a decreased number of blood cells and platelets can increase the risk of developing infections or bleeding excessively.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PHASES OF CHRONIC MYELOID LEUKEMIA",
"     </span>",
"    </p>",
"    <p>",
"     There are three phases of CML:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Chronic phase",
"     </span>",
"     &nbsp;&mdash;&nbsp;In the chronic phase, there are less than 5 percent immature blast cells in the bone marrow. Approximately 85 percent of people are in the chronic phase when they are initially diagnosed. This phase generally lasts several years and is readily controlled with oral medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Accelerated phase",
"     </span>",
"     &nbsp;&mdash;&nbsp;During the accelerated phase, maturation of white blood cells becomes progressively impaired, and there are between 10 and 19 percent blast cells in the blood or bone marrow. The number of abnormal cells in the body is more difficult to control with medications, likely because of new mutations that develop in the blast cells.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Blast phase",
"     </span>",
"     &nbsp;&mdash;&nbsp;In blast crisis (blast phase), there are more than 20 to 30 percent blast cells in the blood or bone marrow. Before recent advances in treatment, blast crisis typically occurred within four to five years after diagnosis and was often unresponsive to treatment.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      CHRONIC MYELOID LEUKEMIA TREATMENT OPTIONS",
"     </span>",
"    </p>",
"    <p>",
"     Treatment decisions for people with CML are complex due to the variety of available options. Currently, the most frequently used treatment options include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Disease control with oral tyrosine kinase inhibitors such as imatinib (Gleevec&reg;), dasatinib (Sprycel&reg;), or nilotinib (Tasigna&reg;)",
"      </li>",
"      <li>",
"       Potential cure with hematopoietic stem cell transplantation (also called bone marrow transplantation), usually after the disease stops responding or relapses during treatment with a tyrosine kinase inhibitor",
"      </li>",
"      <li>",
"       Treatment to reduce symptoms with chemotherapy (hydroxyurea or interferon alpha with or without cytarabine)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The choice of therapy depends upon the phase of CML, the availability of a stem cell donor, the patient's candidacy for stem cell transplantation, and the patient's preference.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Response to treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;The primary goal of treatment is to reduce or eliminate the cells with the abnormal Philadelphia chromosome. This is measured as the",
"     <strong>",
"      cytogenetic response",
"     </strong>",
"     . Such treatment, if effective, will also return the blood counts to normal. This is measured as the",
"     <strong>",
"      hematologic response",
"     </strong>",
"     .",
"    </p>",
"    <p>",
"     While achieving a hematologic response will reduce the severity of symptoms associated with CML, progression to the accelerated or blast phase will continue unless a cytogenetic response is achieved. Achieving a hematologic response is important, but does not ensure that the disease is adequately controlled.",
"    </p>",
"    <p>",
"     Another way to determine how well the disease is controlled is to perform sensitive molecular testing. A person is said to have a complete",
"     <strong>",
"      molecular response",
"     </strong>",
"     when there is no evidence of the BCR-ABL gene. The goal of hematopoietic stem cell transplantation is to achieve this level of response. A molecular response is sometimes seen during longer term follow up of people treated with imatinib. Chemotherapy rarely, if ever, produces such a response.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      TYROSINE KINASE INHIBITORS (TKIS)",
"     </span>",
"    </p>",
"    <p>",
"     The consequence of the Philadelphia chromosome is the formation of a unique gene product, an abnormal enzyme called the BCR-ABL tyrosine kinase. Researchers directed their efforts at developing compounds that could selectively inhibit this abnormal enzyme, resulting in the development of a class of medications known as tyrosine kinase inhibitors (TKI). TKIs slow or stop the actions of BCR-ABL, which leads to the rapid death of cells containing the abnormal Philadelphia chromosome. Normal cells suffer fewer toxic effects from TKIs as compared to traditional chemotherapy treatments.",
"    </p>",
"    <p>",
"     Although they have not been proven to cure the disease, TKIs are able to achieve long-term control of CML in the majority of people; thus, they have become the initial treatment of choice for almost all people who are newly diagnosed with CML. All of the available TKIs are able to induce hematologic and cytogenetic responses in all stages of the disease [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/60/37829/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]. As a result, a choice among these medications is usually based upon the patient's medical history and the potential side effects of each medication.",
"    </p>",
"    <p>",
"     Many prescription and non-prescription medications can interact with TKIs, potentially making the treatment less effective or dangerously increasing the amount of drug in the bloodstream. Two non-prescription medications that should be avoided are acetaminophen (Tylenol&reg;) and St. John's wort (hypericum perforatum). Grapefruit juice should also be avoided.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Imatinib (Gleevec&reg;)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Imatinib mesylate is a tyrosine kinase inhibitor that can be used in people with all phases of CML. It is proven to have significant benefits. One study comparing imatinib to interferon plus cytarabine (a form of chemotherapy) for people with newly diagnosed, chronic phase CML found that 97 percent of people who were given imatinib had a complete hematologic response rate, and 76 percent achieved a complete cytogenetic response [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/60/37829/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Further follow-up is needed to determine how long responses will last, although the relapse rate has been remarkably low in people followed for seven or more years who achieved a complete cytogenetic response. At the current time, experts recommend continuing imatinib treatment indefinitely because the disease recurs, often within months, in the majority of people who stop taking it. Progression to blast crisis can occur despite imatinib treatment in people with accelerated phase disease and in those who acquire new genetic mutations.",
"    </p>",
"    <p>",
"     The recommended initial starting dose of imatinib is 400",
"     <span class=\"nowrap\">",
"      mg/day",
"     </span>",
"     for people in chronic phase and 600",
"     <span class=\"nowrap\">",
"      mg/day",
"     </span>",
"     for people in accelerated phase or blast crisis. The medication should be taken by mouth once daily, with a meal and a large glass of water.",
"    </p>",
"    <p>",
"     It is extremely important to take every single scheduled dose of your imatinib. Skipping pills can seriously jeopardize your chances of having a good response. One study showed that you need to take over 90 percent of your pills to have a chance of a sustained complete response [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/60/37829/abstract/4\">",
"      4",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=see_link&amp;anchor=H4#H4\">",
"      \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Resistance'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Imatinib is generally very well tolerated; most side effects are mild to moderate and do not cause the person to stop taking it. Less than five percent of people will be unable to tolerate long term treatment with imatinib.",
"    </p>",
"    <p>",
"     Common side effects include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Nausea and vomiting, although this is not usually a problem when the drug is taken with meals.",
"      </li>",
"      <li>",
"       Diarrhea is usually mild to moderate, but can be severe. It generally responds to treatment with loperamide (Imodium&reg;).",
"      </li>",
"      <li>",
"       Muscle cramps are perhaps the most bothersome long-term symptom associated with imatinib, most commonly affecting the calves, feet, and hands. There is no definitive treatment, although some people benefit from treatment with calcium or magnesium supplements.",
"      </li>",
"      <li>",
"       Skin rash is uncommon. When it occurs, it is usually mild and often resolves with continued treatment.",
"      </li>",
"      <li>",
"       Breast enlargement (gynecomastia) may occur in a small number of men.",
"      </li>",
"      <li>",
"       Mild anemia is not uncommon in people who use imatinib for long periods.",
"      </li>",
"      <li>",
"       Some patients note mild to moderate fatigue.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women and men who take imatinib usually have no increased difficulty achieving pregnancy. However, the risk of miscarriage and birth defects while taking imatinib is uncertain. Thus, men and women who take imatinib are strongly advised to use a birth control method during treatment.",
"    </p>",
"    <p>",
"     Women who take imatinib and become pregnant are left with a difficult choice:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Continuing imatinib may result in damage to the developing fetus.",
"      </li>",
"      <li>",
"       Stopping imatinib may allow CML to relapse in the mother.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In one series of women exposed to imatinib during pregnancy, 50 percent delivered a healthy baby, 28 percent elected to have a termination, 14 percent had a miscarriage, and approximately 10 percent had a baby with a birth defect [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/60/37829/abstract/5\">",
"      5",
"     </a>",
"     ]. In addition, imatinib is passed into breast milk, and breastfeeding women are advised to avoid imatinib. Women who become pregnant while taking imatinib should speak with their healthcare provider as soon as possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H122732129\">",
"     <span class=\"h2\">",
"      Dasatinib (Sprycel&reg;)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dasatinib is a second generation tyrosine kinase inhibitor that may be recommended for treatment of CML after imatinib. It can also be used as initial treatment instead of imatinib. It is taken by mouth once or twice daily.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H122732164\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Up to 35 percent of people who take dasatinib for advanced phase CML can develop a pleural effusion, a collection of fluid in space between the lining of the lung (the pleura) and the chest wall. In some cases, this complication required a reduction in the dose of dasatinib, a temporary break in treatment, or a procedure to drain the fluid. Pleural effusions occur in approximately 10 percent of patients treated with dasatinib in chronic phase and generally tend to be of less clinical severity than in patients with advanced CML.",
"    </p>",
"    <p>",
"     Women who are pregnant or breastfeeding should not use dasatinib due to the potential risk of harm to the infant; men and women are strongly encouraged to use a birth control method during treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H122732136\">",
"     <span class=\"h2\">",
"      Nilotinib (Tasigna&reg;)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nilotinib is another second generation tyrosine kinase inhibitor that may be recommended for treatment of CML after imatinib. It can also be used as initial treatment instead of imatinib. It should be taken by mouth on an empty stomach (one hour before or two hours after eating) every 12 hours; taking the medication with food can lead to excessive amounts of the drug in the bloodstream and is not recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H122732143\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effects of nilotinib include rash, itching, nausea, and constipation. An abnormal heart rhythm, known as QT prolongation, is a potential side effect of both dasatinib and nilotinib. QT prolongation can potentially cause sudden cardiac death, although this complication is very rare. People who have an electrolyte imbalance (low blood level of potassium or magnesium), an abnormal heart rhythm, or who take medication to regulate their heart rhythm should talk with their doctor about the need for additional monitoring while taking dasatinib or nilotinib.",
"    </p>",
"    <p>",
"     Women who are pregnant or breastfeeding should not use nilotinib; men and women are strongly encouraged to use a birth control method during treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      If the tyrosine kinase inhibitor fails",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who cannot tolerate, fail to respond, or stop responding to an initial tyrosine kinase inhibitor are faced with the decision of what treatment to try next. The options include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Control the disease with another tyrosine kinase inhibitor, and then proceed as soon as possible with hematopoietic cell transplantation.",
"      </li>",
"      <li>",
"       Control the disease with another tyrosine kinase inhibitor with plans to proceed with transplantation if the disease relapses a second time.",
"      </li>",
"      <li>",
"       If the disease relapses despite treatment with another tyrosine kinase inhibitor and transplantation is not an option, treatment with interferon alpha can help to reduce symptoms and prolong survival. (See",
"       <a class=\"local\" href=\"#H22\">",
"        'Interferon alpha'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Relapses during treatment with a TKI are often due to the development of a new mutation in the BCR-ABL gene, which allows the disease to become resistant to treatment. Testing to determine what mutations have developed in the BCR-ABL gene (called mutation analysis) can be performed. Some mutations (eg, T315I) will not respond to any of the available tyrosine kinase inhibitors (imatinib, dasatinib, or nilotinib); people with these mutations are generally encouraged to consider transplantation. (See",
"     <a class=\"local\" href=\"#H18\">",
"      'Hematopoietic stem cell transplantation'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     If transplantation is not an option, treatment with an investigational TKI may be available. (See",
"     <a class=\"local\" href=\"#H25\">",
"      'Clinical trials'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     A major cause of treatment &ldquo;failure&rdquo; is poor compliance with taking the medication. Therefore, it is critical that the doctor is certain that the patient was actually taking the TKI treatment before switching therapies.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      HEMATOPOIETIC STEM CELL TRANSPLANTATION",
"     </span>",
"    </p>",
"    <p>",
"     In hematopoietic stem cell transplantation (pronounced \"hee-mah-toh-poy-ET-ick\"), also referred to as bone marrow transplantation or stem cell transplantation, the patient's diseased bone marrow (hematopoietic) cells are replaced with healthy ones from a donor. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"      \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2970440\">",
"     <span class=\"h2\">",
"      Choice of donor",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of options are available when transplantation is considered:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hematopoietic stem (or progenitor) cells can be obtained from a patient or donor's bone marrow or blood, or from blood taken from the umbilical cord of an infant immediately after birth.",
"      </li>",
"      <li>",
"       The donor may be the patient (",
"       <strong>",
"        autologous transplant",
"       </strong>",
"       ) or an identical twin (syngeneic transplant). Autologous hematopoietic cell transplantation uses the patient's own blood cells or bone marrow for transplantation. The patient's own hematopoietic cells are removed from the body, chemotherapy is given to reduce the number of abnormal cells, and then the stored cells are reinfused and transplanted into the patient. However, autologous transplantation is not generally effective in CML and most people do not have an identical twin. In addition, in CML, the use of an identical twin has been associated with a higher risk of disease relapse compared to a matched related or unrelated donor.",
"      </li>",
"      <li>",
"       More commonly, the donor is a person other than the patient; this is called an",
"       <strong>",
"        allogeneic transplant",
"       </strong>",
"       . Allogeneic transplants can come from a relative (eg, sibling) or from an unrelated donor. Within a family, the best chance for a match comes from siblings who have the same parents as the patient. Each sibling has a one in four chance of matching an individual patient. Since many people do not have a sibling who matches, unrelated donors may be used.",
"      </li>",
"      <li>",
"       It is important to find a donor whose hematopoietic cells closely match those of the patient. Doctors look for matching proteins (human leukocyte antigen or HLA) on hematopoietic cells from the donor. The goal is for the donated hematopoietic stem cells (the graft) to be accepted (engrafted) by the patient's body (the host) and begin producing normal mature blood cells.",
"      </li>",
"      <li>",
"       Related or unrelated donors who are fully HLA-matched are preferred. Under some circumstances, partially or half-matched (haploidentical) donors can be used.",
"      </li>",
"      <li>",
"       Preparative treatments with chemotherapy",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       radiation that fully destroy bone marrow activity (called myeloablative treatment) or do not fully destroy bone marrow activity (called nonmyeloablative or reduced intensity treatment) must be used in order for the transplant to be effective.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In CML, the chances of success with hematopoietic stem cell transplantation are directly related to the phase of disease at the time of the transplant. In the past, transplantation of people in chronic phase within the first year resulted in the best outcomes. Several studies have suggested that treatment with a tyrosine kinase inhibitor prior to transplantation does not reduce the chance that transplantation will be successful, although additional studies are needed to confirm this finding.",
"    </p>",
"    <p>",
"     If a matched sibling donor can be found, 50 to 85 percent of people with CML transplanted in the first or second chronic phase of their disease achieve long-term remissions. Disease-free survival falls to 30 to 40 percent in people transplanted in the accelerated phase, and to 10 to 20 percent in people transplanted in blast phase.",
"    </p>",
"    <p>",
"     A patient's age has a major influence on the outcome after transplantation with cells from a sibling donor. In the subgroup of people under age 50 who undergo this procedure during the first year of diagnosis, 70 to 85 percent will be alive and free of disease five years later. However, people up to 60 years of age have successfully undergone allogeneic transplantation with treatments that completely destroy the bone marrow (myeloablative treatment). The development of reduced intensity regimens, which have reduced toxicity, has permitted even older people to be successfully transplanted.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Relapse after transplant",
"     </span>",
"     &nbsp;&mdash;&nbsp;Relapse or recurrence of CML may occur if cells containing the Philadelphia chromosome remain after the transplant procedure. However, finding residual disease with sensitive molecular tests in the first six months following transplantation is",
"     <strong>",
"      not",
"     </strong>",
"     associated with eventual relapse because the anti-tumor effects of the graft may eventually prevail.",
"    </p>",
"    <p>",
"     Relapse can be treated with imatinib, dasatinib, nilotinib, or with infusions of leukocytes from the original donor, with the hope of mounting a more effective graft-versus-tumor effect. Donor leukocyte infusions (DLIs) can be extremely effective, and remissions attained after DLI appear to be quite durable. However, graft-versus-host disease, and in some instances graft failure, may complicate DLI.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      DECIDING BETWEEN TRANSPLANTATION AND A TYROSINE KINASE INHIBITOR",
"     </span>",
"    </p>",
"    <p>",
"     Initial treatment with a tyrosine kinase inhibitor is well-tolerated and effective for at least eight years in most people with chronic phase CML. Successful allogeneic transplantation can produce long term suppression of CML with a very low chance of relapse because such people have a molecular, cytogenetic, and hematologic response.",
"    </p>",
"    <p>",
"     However, transplantation has some potentially serious risks, including graft-versus-host disease and even death. While there have not been any randomized clinical trials directly comparing tyrosine kinase inhibitors to hematopoietic cell transplantation in people newly diagnosed with chronic phase disease, most experts recommend initial treatment with a tyrosine kinase inhibitor, reserving transplantation for",
"     <span class=\"nowrap\">",
"      if/when",
"     </span>",
"     the disease relapses.",
"    </p>",
"    <p>",
"     Transplantation may be recommended as a part of the initial treatment in people who are diagnosed with accelerated or blast phase disease. Giving chemotherapy or a tyrosine kinase inhibitor prior to transplantation (to achieve chronic phase) is preferable to transplanting during the blast phase; the chance of a cure is greater when transplantation is done during the chronic phase.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      INTERFERON ALPHA",
"     </span>",
"    </p>",
"    <p>",
"     Interferon alpha (IFNa, Roferon-A&reg;) was commonly used in the past for treatment of CML. In up to 90 percent of people, interferon can induce a hematologic response, improve symptoms, and reduce or eliminate enlargement of the spleen (splenomegaly). However, tyrosine kinase inhibitors are clearly superior to IFNa in studies comparing the two treatments.",
"    </p>",
"    <p>",
"     As a result, interferon is considered to be a \"palliative\" treatment for CML since it is not curative and only rarely results in a prolonged complete cytogenetic response. A patient who cannot tolerate tyrosine kinase inhibitors might be offered IFNa with or without another chemotherapy medication, cytarabine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Side effects are a major problem with IFNa, and include fever, chills, and flu-like symptoms. Typically, the drug is started at a relatively low dose three days per week and then slowly increased. IFNa must be injected, and many people prefer to take their injection at night along with acetaminophen (Tylenol) and an antihistamine such as diphenhydramine (Benadryl) to minimize the side effects.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      RECOMMENDATIONS FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of CML is complex, and the optimal treatment is a source of considerable debate. Therefore, consultation with a physician familiar with the latest data is critical.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Tyrosine kinase inhibitors are preferred by most healthcare providers and people, and an expert panel has recommended their use as the initial treatment for people with newly diagnosed chronic phase CML.",
"      </li>",
"      <li>",
"       Allogeneic hematopoietic cell transplantation remains the only treatment that is known to cure CML. People who relapse during treatment with a tyrosine kinase inhibitor should discuss this option in detail with their physician. (See",
"       <a class=\"local\" href=\"#H12\">",
"        'If the tyrosine kinase inhibitor fails'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Because relapses occur frequently in people with accelerated phase CML and in virtually all people with blast phase CML who are treated with a tyrosine kinase inhibitor, allogeneic transplantation should be considered when possible, preferably after the person's disease has responded to the tyrosine kinase inhibitor.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Many people with CML will be asked about enrolling in a clinical (research) trial. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask your healthcare provider for more information, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"      www.cancer.gov/clinicaltrials/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov/",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804582895\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24618628\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/13/38098?source=see_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/58/12194?source=see_link\">",
"      Patient information: Chronic myeloid leukemia (CML) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24618660\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link\">",
"      Cellular and molecular biology of chronic myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41049?source=see_link\">",
"      Genetic abnormalities in hematologic and lymphoid malignancies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33066?source=see_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7034?source=see_link\">",
"      Initial treatment of chronic myeloid leukemia in chronic phase",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27111?source=see_link\">",
"      Interferon alpha for the treatment of chronic myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=see_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=see_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41225?source=see_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27976?source=see_link\">",
"      Treatment of chronic myeloid leukemia in accelerated phase",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7816?source=see_link\">",
"      Treatment of chronic myeloid leukemia in blast crisis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=see_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/\">",
"      www.cancer.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Leukemia &amp; Lymphoma Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.leukemia-lymphoma.org/\">",
"      www.leukemia-lymphoma.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Marrow Donor Program",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.marrow.org/\">",
"      www.marrow.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/60/37829/abstract/1,6-9\">",
"      1,6-9",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 9, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/60/37829?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37829/abstract/1\">",
"      O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37829/abstract/2\">",
"      Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37829/abstract/3\">",
"      Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37829/abstract/4\">",
"      Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37829/abstract/5\">",
"      Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111:5505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37829/abstract/6\">",
"      O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37829/abstract/7\">",
"      Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37829/abstract/8\">",
"      Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007; 357:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37829/abstract/9\">",
"      Kantarjian H, O'Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007; 109:1556.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f36_60_37829=[""].join("\n");
var outline_f36_60_37829=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CHRONIC MYELOID LEUKEMIA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PHASES OF CHRONIC MYELOID LEUKEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           CHRONIC MYELOID LEUKEMIA TREATMENT OPTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           TYROSINE KINASE INHIBITORS (TKIS)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           HEMATOPOIETIC STEM CELL TRANSPLANTATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           DECIDING BETWEEN TRANSPLANTATION AND A TYROSINE KINASE INHIBITOR",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           INTERFERON ALPHA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           RECOMMENDATIONS FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f36_60_37830="Overview of chronic daily headache";
var content_f36_60_37830=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of chronic daily headache",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37830/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37830/contributors\">",
"     Ivan Garza, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37830/contributors\">",
"     Todd J Schwedt, MD, MSCI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37830/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37830/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37830/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37830/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/60/37830/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic daily headache (CDH) is a descriptive term that encompasses several different specific headache diagnoses characterized by frequent headaches.",
"   </p>",
"   <p>",
"    Primary chronic daily headache subtypes of long duration (ie, four hours or more) are chronic migraine, chronic tension-type headache, medication overuse headache, hemicrania continua, and new daily persistent headache.",
"   </p>",
"   <p>",
"    Primary headache types of shorter duration that can be chronic and occur daily are chronic cluster headache, chronic paroxysmal hemicrania, hypnic headache, and primary stabbing headache.",
"   </p>",
"   <p>",
"    This topic will provide an overview of the subtypes of primary CDH. These headache subtypes are discussed in greater detail individually in appropriate separate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUBTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic daily headache (CDH) is not a specific headache type, but a syndrome that encompasses other primary and secondary headaches. The term \"chronic\" in CDH refers either to the frequency of headaches or to the duration of the disease, depending upon the specific headache type.",
"   </p>",
"   <p>",
"    The classification of CDH as a form of headache is based upon criteria originally proposed in 1996 by Silberstein and Lipton (the SL criteria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37830/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the current International Headache Society classification system - the International Classification of Headache Disorders 2nd edition (ICHD-2) - does not define CDH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37830/abstract/2\">",
"     2",
"    </a>",
"    ]. Rather, CDH is a descriptive term that encompasses five subtypes of frequent headaches defined by ICHD-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37830/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic migraine headache",
"     </li>",
"     <li>",
"      Chronic tension-type headache",
"     </li>",
"     <li>",
"      Medication overuse headache",
"     </li>",
"     <li>",
"      Hemicrania continua",
"     </li>",
"     <li>",
"      New daily persistent headache",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These headache types are characterized by prolonged headaches lasting four hours or longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37830/abstract/3\">",
"     3",
"    </a>",
"    ]. The term primary CDH is applied when the headache frequency is 15 or more days a month for longer than three months in the absence of organic pathology.",
"   </p>",
"   <p>",
"    Additional headache subtypes with shorter individual headaches (ie, less than four hours) are considered in the spectrum of primary CDH when the duration of the condition itself persists without remission. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic cluster headache (must persist for at least one year without remission)",
"     </li>",
"     <li>",
"      Chronic paroxysmal hemicrania (must persist for at least one year without remission)",
"     </li>",
"     <li>",
"      Hypnic headache",
"     </li>",
"     <li>",
"      Short-lasting, unilateral, neuralgiform headache attacks with conjunctival injection and tearing (SUNCT)",
"     </li>",
"     <li>",
"      Primary stabbing headache",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The subtypes of primary CDH are briefly reviewed in the following sections, and are discussed in greater detail in individual topic reviews as noted for each subtype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chronic migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic migraine typically occurs in those with a history of episodic migraine headache. Through a process known as migraine transformation, some patients with an episodic migraine pattern transition to a chronic migraine pattern (&ge;15 headache days a month). Many patients with chronic migraine have daily or near-daily headaches of low to moderate severity. Superimposed on this baseline are exacerbations of pain with more prominent migrainous features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7128?source=see_link\">",
"     \"Chronic migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic tension-type headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension-type headache is a bilateral, nonthrobbing \"featureless\" headache characterized by gradual onset and mild to moderate intensity with or without pericranial muscle tenderness. Chronic tension-type headache is diagnosed when the headache is present for 15 or more days a month. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=see_link\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Medication overuse headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medication overuse headache (MOH) was previously termed analgesic rebound headache, drug-induced headache, and medication-misuse headache. MOH is the classification used when a primary headache develops or markedly worsens during medication overuse. In practice, MOH is typically preceded by an episodic headache disorder, most often migraine or tension-type, that has been treated with frequent and excessive amounts of acute symptomatic medications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35879?source=see_link\">",
"     \"Medication overuse headache: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hemicrania continua",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemicrania continua is a strictly unilateral, continuous headache with superimposed exacerbations of moderate to severe intensity accompanied by autonomic features and sometimes by migrainous symptoms. It is responsive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43942?source=see_link\">",
"     \"Hemicrania continua\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     New daily persistent headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of new daily persistent headache is characterized by headache that begins rather abruptly and is daily and unremitting from onset or within three days of onset at most, typically in individuals without a prior headache history. Considerable variability is seen in the clinical features. The pain is often bilateral, pressing or tightening in quality, and of mild to moderate intensity. However, migrainous features such as unilateral headache, throbbing pain, and associated photophobia are common. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2968?source=see_link\">",
"     \"New daily persistent headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chronic cluster headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster headache is one of the trigeminal autonomic cephalalgias, a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features. Cluster headache is characterized by attacks of severe unilateral orbital, supraorbital, or temporal pain. Unilateral autonomic symptoms are ipsilateral to the pain and may include ptosis, miosis, lacrimation, conjunctival injection, rhinorrhea, and nasal congestion. Attacks usually last 15 to 180 minutes.",
"   </p>",
"   <p>",
"    In the episodic form, attacks occur daily, usually one to eight times a day for some weeks, followed by a period of remission. The chronic form of cluster headache lacks sustained remissions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic paroxysmal hemicrania",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like cluster headache, paroxysmal hemicrania is one of the trigeminal autonomic cephalalgias. Patients typically have unilateral, brief, severe attacks of pain associated with cranial autonomic features that recur several times per day. An individual headache attack usually lasts 2 to 30 minutes by definition. The mean attack frequency is 11 to 14 daily. About 80 percent of patients have the chronic form of paroxysmal hemicrania, in which either no remission occurs within one year, or the remissions last less than one month. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypnic headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypnic headache, also known as \"alarm clock headache\", occurs almost exclusively after the age of 50, and is characterized by episodes of dull head pain, often bilateral, that awaken the sufferer from sleep. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5700?source=see_link\">",
"     \"Hypnic headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     SUNCT headache syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) syndrome is one of the trigeminal autonomic cephalalgias. It is characterized by very frequent (up to 200 attacks per day), brief (5 to 120 seconds), severe, unilateral attacks of pain accompanied by ipsilateral conjunctival injection and lacrimation. The neuralgic pain typically involves the area around and behind the eye. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Primary stabbing headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary stabbing headache is characterized by transient, sharp jabbing pains that occur within a small, localized area of the scalp, exclusively or predominantly at variable locations within the first division of the trigeminal nerve. The stabs last from 1 to 10 seconds and occur at irregular intervals from once to many times each day. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13714?source=see_link\">",
"     \"Primary stabbing headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of CDH among adults worldwide is approximately 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37830/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Women are affected two to three times more often than men. The vast majority of CDH patients suffer from either chronic tension-type headache, chronic migraine, or medication overuse headache.",
"   </p>",
"   <p>",
"    CDH results in significant pain and suffering, reductions in quality of life, and enormous economic costs to society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37830/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of primary CDH is suspected on the basis of a compatible headache history. Other disorders causing secondary headache must be excluded.",
"   </p>",
"   <p>",
"    The diagnosis of CDH is made when there is a pattern of frequent headaches that fulfill diagnostic criteria for one of the forms of CDH characterized by prolonged headaches, which are chronic migraine (",
"    <a class=\"graphic graphic_table graphicRef56064 \" href=\"mobipreview.htm?33/14/34027\">",
"     table 1",
"    </a>",
"    ), chronic tension-type headache (",
"    <a class=\"graphic graphic_table graphicRef68892 \" href=\"mobipreview.htm?38/22/39275\">",
"     table 2",
"    </a>",
"    ), medication overuse headache (",
"    <a class=\"graphic graphic_table graphicRef71798 \" href=\"mobipreview.htm?8/35/8763\">",
"     table 3",
"    </a>",
"    ), hemicrania continua (",
"    <a class=\"graphic graphic_table graphicRef62652 \" href=\"mobipreview.htm?29/56/30603\">",
"     table 4",
"    </a>",
"    ), and new daily persistent headache (",
"    <a class=\"graphic graphic_table graphicRef76010 \" href=\"mobipreview.htm?34/48/35595\">",
"     table 5",
"    </a>",
"    ). Of note, some experts make the diagnosis of NDPH despite the presence of migrainous features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2968?source=see_link&amp;anchor=H8#H8\">",
"     \"New daily persistent headache\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is also made when there is persistence of headache subtypes with shorter individual headaches (ie, chronic cluster headache, chronic paroxysmal hemicrania, hypnic headache, or primary stabbing headache) for at least one year without remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic process of CDH does not differ from that of other headache types. The clinician must determine the level of suspicion for a secondary versus a primary headache disorder. This is based upon a careful medical and headache history and a comprehensive physical and neurologic examination. With all subtypes of CDH it is important to evaluate for the possibility of medication overuse as a causal or contributing factor in the production of CDH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35879?source=see_link\">",
"     \"Medication overuse headache: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Special attention should be directed to the carotid and temporal arteries, cervical paraspinal muscles, range of motion at the neck, temporomandibular joints, sinuses, and ocular fundi. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39704?source=see_link\">",
"     \"Evaluation of the adult with headache in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, patients with CDH have normal physical and neurologic examinations. However, some headache types may be associated with specific abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With tension-type headache, there may be pericranial muscle tenderness.",
"     </li>",
"     <li>",
"      Chronic migraine may have manifestations, such as hyperalgesia and allodynia, related to sensitization of primary nociceptors and central trigeminovascular neurons.",
"     </li>",
"     <li>",
"      With hemicrania continua or one of the trigeminal autonomic cephalalgias (eg, cluster headache, paroxysmal hemicrania, SUNCT), there may be evidence of autonomic activation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other abnormalities on examination should raise suspicion for a secondary headache disorder.",
"   </p>",
"   <p>",
"    The findings of the clinical history and examination determine whether further diagnostic testing is necessary. Investigations are considered on an individual basis and may include blood tests, brain imaging, neurovascular imaging (cerebral arteries",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    venous sinuses), cervical spine imaging, lumbar puncture, and others as indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Red flags",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of \"red flags\" (potentially worrisome features) in the history and abnormalities on examination increase the suspicion for a secondary headache disorder and thus decrease the threshold for ordering diagnostic tests.",
"   </p>",
"   <p>",
"    Worrisome historical features include, but are not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age of onset of headache (&gt;50 years of age)",
"     </li>",
"     <li>",
"      Acute onset (thunderclap) headache",
"     </li>",
"     <li>",
"      New headaches",
"     </li>",
"     <li>",
"      Significant change in the characteristics of prior headaches",
"     </li>",
"     <li>",
"      Signs or symptoms of systemic illness (eg, fever, chills, weight loss)",
"     </li>",
"     <li>",
"      Neurologic symptoms not consistent with typical aura symptoms",
"     </li>",
"     <li>",
"      Known systemic illnesses that predispose to secondary headaches (eg, cancer, HIV)",
"     </li>",
"     <li>",
"      Headaches associated with maneuvers that increase or decrease intracranial pressure (eg, orthostatic headaches, Valsalva-induced headaches)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of one or more of these features should prompt evaluation with appropriate studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37830/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a list of causes of secondary headaches would be exhaustive, it includes metabolic abnormalities, infections, mass lesions, intracranial hypotension, intracranial hypertension, cerebral venous sinus thrombosis, vasculitis, cervicogenic headache, post-traumatic headache, and many others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of CDH depends on the specific headache type and the presence or absence of medication overuse.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of chronic migraine should focus on prophylactic therapy while avoiding migraine triggers and limiting the use of acute headache medications to prevent medication overuse headache. Prophylactic interventions may include pharmacotherapy, behavioral therapy, or physical therapy. Management often requires the simultaneous use of these different modalities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7128?source=see_link&amp;anchor=H7#H7\">",
"       \"Chronic migraine\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For chronic tension-type headache, effective preventive treatment involves the use of daily prophylactic medications (eg, tricyclic antidepressants), behavioral therapies and physical therapy. Like chronic migraine, the combined use of these interventions is often optimal. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1433?source=see_link\">",
"       \"Tension-type headache in adults: Preventive treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34744?source=see_link&amp;anchor=H12#H12\">",
"       \"Tension-type headache in children\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For medication overuse headache, basic steps in the management are patient education, withdrawal of the offending medication, bridge therapy aimed at symptomatic relief during medication withdrawal, establishment of a headache treatment regimen appropriate for the underlying primary headache disorder, and relapse prevention. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/48/17161?source=see_link\">",
"       \"Medication overuse headache: Treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemicrania continua is responsive to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43942?source=see_link&amp;anchor=H12#H12\">",
"       \"Hemicrania continua\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      New daily persistent headache may be resistant to treatment. Although evidence is lacking, one suggested approach is to first classify the phenotype of new daily persistent headache as most similar to either migraine or chronic tension-type headache, and then treat with appropriate preventive headache therapy accordingly. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2968?source=see_link&amp;anchor=H17#H17\">",
"       \"New daily persistent headache\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For chronic cluster headache,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      is the preventive agent of choice. Other medications that may be effective include glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      , and methysergide. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3898?source=see_link&amp;anchor=H11#H11\">",
"       \"Cluster headache: Acute and preventive treatment\", section on 'Preventive treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For chronic paroxysmal hemicrania,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      is the treatment of choice. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/57/9112?source=see_link\">",
"       \"Paroxysmal hemicrania: Treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For hypnic headache, limited evidence suggests that several treatments are effective, including caffeine at bedtime,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      carbonate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5700?source=see_link&amp;anchor=H5#H5\">",
"       \"Hypnic headache\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SUNCT tends to be more refractory to treatment than other primary headaches. Preventive treatments with at least limited evidence for benefit include anticonvulsants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , valproic acid),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , and glucocorticoids. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2264?source=see_link\">",
"       \"SUNCT and SUNA headache syndromes: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary stabbing headache may respond to melatonin or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13714?source=see_link&amp;anchor=H6#H6\">",
"       \"Primary stabbing headache\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=see_link\">",
"       \"Patient information: Headache (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=see_link\">",
"       \"Patient information: Headache causes and diagnosis in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic daily headache (CDH) is not a specific headache type, but a syndrome that encompasses other primary headaches. The term \"chronic\" refers either to the frequency of headaches or to the duration of the disease, depending upon the specific headache type. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Subtypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With headache subtypes of long duration (ie, four hours or more), \"chronic\" indicates a headache frequency of 15 or more days a month for longer than three months in the absence of organic pathology. These headache subtypes are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chronic migraine headache (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Chronic migraine'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Chronic tension-type headache (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Chronic tension-type headache'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Medication overuse headache (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Medication overuse headache'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hemicrania continua (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Hemicrania continua'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      New daily persistent headache (see",
"      <a class=\"local\" href=\"#H7\">",
"       'New daily persistent headache'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With headache subtypes of shorter duration (ie, less than four hours), \"chronic\" refers to a prolonged duration of the condition itself without remission. The headache subtypes in this category are the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chronic cluster headache (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Chronic cluster headache'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Chronic paroxysmal hemicrania (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Chronic paroxysmal hemicrania'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hypnic headache (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Hypnic headache'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      SUNCT (see",
"      <a class=\"local\" href=\"#H11\">",
"       'SUNCT headache syndrome'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Primary stabbing headache (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Primary stabbing headache'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The worldwide prevalence of CDH among adults is approximately 4 percent. Most patients with CDH have either chronic tension-type headache or chronic migraine. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CDH is suspected on the basis of a compatible headache history. Other disorders causing secondary headache must be excluded. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of CDH depends on the specific headache type and the presence or absence of medication overuse. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37830/abstract/1\">",
"      Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996; 47:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37830/abstract/2\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37830/abstract/3\">",
"      Dodick DW. Clinical practice. Chronic daily headache. N Engl J Med 2006; 354:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37830/abstract/4\">",
"      Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998; 38:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37830/abstract/5\">",
"      Lu SR, Fuh JL, Chen WT, et al. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia 2001; 21:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37830/abstract/6\">",
"      Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology 2000; 54:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37830/abstract/7\">",
"      Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003; 290:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37830/abstract/8\">",
"      Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin 2001; 17 Suppl 1:s4.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3333 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37830=[""].join("\n");
var outline_f36_60_37830=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUBTYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chronic migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic tension-type headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Medication overuse headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hemicrania continua",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      New daily persistent headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chronic cluster headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic paroxysmal hemicrania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypnic headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUNCT headache syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Red flags",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3333\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3333|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/14/34027\" title=\"table 1\">",
"      Chronic migraine diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/22/39275\" title=\"table 2\">",
"      Chronic tension-type headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/35/8763\" title=\"table 3\">",
"      Medication overuse headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/56/30603\" title=\"table 4\">",
"      Hemicrania continua diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/48/35595\" title=\"table 5\">",
"      New daily persistent headache criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7128?source=related_link\">",
"      Chronic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3898?source=related_link\">",
"      Cluster headache: Acute and preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39704?source=related_link\">",
"      Evaluation of the adult with headache in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43942?source=related_link\">",
"      Hemicrania continua",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5700?source=related_link\">",
"      Hypnic headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35879?source=related_link\">",
"      Medication overuse headache: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/48/17161?source=related_link\">",
"      Medication overuse headache: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2968?source=related_link\">",
"      New daily persistent headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25545?source=related_link\">",
"      Paroxysmal hemicrania: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/57/9112?source=related_link\">",
"      Paroxysmal hemicrania: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13714?source=related_link\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2264?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=related_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1433?source=related_link\">",
"      Tension-type headache in adults: Preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34744?source=related_link\">",
"      Tension-type headache in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_60_37831="ERCP in patients with Roux-en-Y anatomy";
var content_f36_60_37831=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ERCP in patients with Roux-en-Y anatomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37831/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37831/contributors\">",
"     Christopher S Huang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37831/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37831/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37831/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37831/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/60/37831/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1850898136\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performing endoscopic retrograde cholangiopancreatography (ERCP) in patients with Roux-en-Y anatomy poses a major challenge to gastrointestinal endoscopists. In the current era of the obesity epidemic, this situation is encountered with increasing frequency due to the popularity of Roux-en-Y gastric bypass (RYGB) surgery (",
"    <a class=\"graphic graphic_figure graphicRef79256 \" href=\"mobipreview.htm?32/35/33329\">",
"     figure 1",
"    </a>",
"    ) and the high prevalence of gallstone disease in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link&amp;anchor=H17#H17\">",
"     \"Surgical management of severe obesity\", section on 'Roux-en-Y gastric bypass'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Roux-en-Y anatomy may also result from:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastric resection surgery (",
"      <a class=\"graphic graphic_figure graphicRef61753 \" href=\"mobipreview.htm?2/13/2261\">",
"       figure 2",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=see_link&amp;anchor=H7#H7\">",
"       \"Invasive gastric cancer: Surgery and prognosis\", section on 'Surgical treatment for localized disease'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pancreaticoduodenectomy (",
"      <a class=\"graphic graphic_figure graphicRef82519 \" href=\"mobipreview.htm?16/57/17303\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef60689 \" href=\"mobipreview.htm?5/43/5810\">",
"       figure 4",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43721?source=see_link\">",
"       \"Pancreaticoduodenectomy (Whipple procedure): Techniques\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Liver transplantation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25672?source=see_link&amp;anchor=H4#H4\">",
"       \"Living donor liver transplantation\", section on 'Surgical techniques and recipient outcomes'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other biliary tract surgeries, such as the repair of bile duct injuries or as part of the treatment of cholangiocarcinoma, resulting in the formation of a hepaticojejunostomy (",
"      <a class=\"graphic graphic_figure graphicRef67421 \" href=\"mobipreview.htm?29/21/30036\">",
"       figure 5",
"      </a>",
"      ) or choledochojejunostomy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6232?source=see_link&amp;anchor=H13#H13\">",
"       \"Repair of common bile duct injuries\", section on 'Repair options'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\", section on 'Surgical treatment and outcomes'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with Roux-en-Y anatomy, it is frequently impossible to access the papilla (or",
"    <span class=\"nowrap\">",
"     bilioenteric/pancreatoenteric",
"    </span>",
"    anastomosis) using a standard duodenoscope due to the length of bowel that must be traversed. For example, in the case of RYGB, an endoscope advanced through the \"anatomic route\" must traverse the esophagus, gastric pouch, and Roux limb (typically 100 to 150 cm in length), and then navigate the acute angle at the jejunojejunostomy into the biliopancreatic limb up to the papilla (an additional 80 to 100 cm). Moreover, in cases with a native papilla, the endoscopist is then faced with the challenge of cannulating the bile duct or pancreatic duct while approaching the papilla from a reverse position. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5415?source=see_link&amp;anchor=H6#H6\">",
"     \"ERCP after Billroth II reconstruction\", section on 'Cannulating the papilla from the reverse position'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To overcome these problems, non-standard approaches, innovative techniques, and specialized accessories have been developed to perform ERCP in patients with Roux-en-Y anatomy. Where available, percutaneous transhepatic cholangioscopy may be an option for patients in whom ERCP cannot be successfully performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18166?source=see_link\">",
"     \"Percutaneous transhepatic cholangioscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the different approaches to performing ERCP in patients with Roux-en-Y anatomy. An overview of endoscopy in patients who have undergone bariatric surgery, an overview of ERCP, the approach to ERCP in patients who have undergone a Billroth II reconstruction, and percutaneous transhepatic cholangioscopy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28489?source=see_link\">",
"     \"Endoscopy in patients who have undergone bariatric surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5415?source=see_link\">",
"     \"ERCP after Billroth II reconstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18166?source=see_link\">",
"     \"Percutaneous transhepatic cholangioscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898143\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to attempting endoscopic retrograde cholangiopancreatography (ERCP) in patients with Roux-en-Y anatomy, the endoscopist should review the operative note or, ideally, discuss the expected anatomy with the surgeon. Specifically, the endoscopist should obtain details about the anatomic resection, the type of reconstruction, the length of the limbs, the types of anastomoses (eg, end-to-side versus side-to-side), and the presence or absence of a native papilla. In addition, all relevant postoperative imaging studies should be reviewed, especially magnetic resonance cholangiopancreatography (MRCP) studies, if available.",
"   </p>",
"   <p>",
"    As a final consideration, it is important to be aware of the time interval following surgery. In the early postoperative period, it is important to weigh the risks of instrumentation with regards to anastomotic disruption against the potential benefits of ERCP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898150\">",
"    <span class=\"h2\">",
"     Choosing the best approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several techniques available to perform ERCP in patients with Roux-en-Y anatomy, each with advantages and disadvantages (",
"    <a class=\"graphic graphic_table graphicRef54031 \" href=\"mobipreview.htm?2/41/2717\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/4\">",
"     4",
"    </a>",
"    ]. No single approach has been identified as the best for all patients, so the endoscopist must select the approach on a case-by-case basis, taking the following factors into consideration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Roux limb length (long versus short)",
"     </li>",
"     <li>",
"      Whether the patient has a native papilla or a",
"      <span class=\"nowrap\">",
"       bilio/pancreato-enteric",
"      </span>",
"      anastomosis",
"     </li>",
"     <li>",
"      The indication for ERCP, including the likelihood of repeat procedures and the need for therapeutic maneuvers",
"     </li>",
"     <li>",
"      The availability of local expertise (deep enteroscopy, interventional radiology, surgery)",
"     </li>",
"     <li>",
"      The patient's surgical risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822821\">",
"    <span class=\"h3\">",
"     Native papilla",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a native papilla, the endoscopist should select a technique that allows for the use of a duodenoscope. A duodenoscope is preferred because it increases the chance of successful selective cannulation of the bile",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pancreatic duct in patients with a native papilla. Transoral advancement of a duodenoscope through the anatomic route can be attempted in patients with a short Roux limb, although this approach is arduous and frequently unsuccessful. (See",
"    <a class=\"local\" href=\"#H1850898164\">",
"     'ERCP using standard duodenoscope'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with a long Roux limb and a native papilla, the best option is often ERCP through a gastrostomy or jejunostomy or a laparoscopy-assisted ERCP. If repeated ERCPs are anticipated, access via a gastrostomy tube placed in the gastric remnant is recommended. The gastrostomy tube can be placed percutaneously by interventional radiology in patients who are poor surgical candidates. (See",
"    <a class=\"local\" href=\"#H1850898206\">",
"     'Surgical approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822828\">",
"    <span class=\"h3\">",
"     Bilioenteric or pancreatoenteric anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with bilioenteric and pancreatoenteric anastomoses, forward-viewing endoscopes are adequate for performing ERCP. Enteroscopes or colonoscopes can be used for patients with a short Roux limb, whereas deep enteroscopy techniques such as balloon-assisted enteroscopy or spiral enteroscopy are preferable in patients with a long Roux limb. (See",
"    <a class=\"local\" href=\"#H1850898171\">",
"     'ERCP using an enteroscope or pediatric colonoscope'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1850898178\">",
"     'ERCP using deep enteroscopy techniques'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898157\">",
"    <span class=\"h1\">",
"     TRANSORAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transoral approaches entail the use of duodenoscopes, pediatric colonoscopes, or enteroscopes advanced per os through the anatomic route.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898164\">",
"    <span class=\"h2\">",
"     ERCP using standard duodenoscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side-viewing duodenoscope is the ideal endoscope to perform ERCP, particularly for the cannulation of a native papilla. Unfortunately, the duodenoscope-only approach is frequently unsuccessful, as shown in one small series in which ERCP was successfully performed in only 33 percent of Roux-en-Y patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/5\">",
"     5",
"    </a>",
"    ]. Therefore, we reserve the transoral approach using a standard duodenoscope for patients with a short Roux limb.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898171\">",
"    <span class=\"h2\">",
"     ERCP using an enteroscope or pediatric colonoscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;An enteroscope or pediatric colonoscope may be an option for performing an ERCP when using a duodenoscope is not feasible. In one series, 18 patients with Roux-en-Y anatomy (including three Roux-en-Y gastric bypass patients) underwent a total of 25 attempted ERCPs using a pediatric colonoscope (164 cm working length)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enteroscope (240 cm working length) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/6\">",
"     6",
"    </a>",
"    ]. Successful advancement of the endoscope to the level of the papilla or the",
"    <span class=\"nowrap\">",
"     bilioenteric/pancreatoenteric",
"    </span>",
"    anastomosis was accomplished in 84 percent of attempted procedures. Biliary cannulation was successful in 94 percent (including five of six procedures performed on patients with intact papillae), and endoscopic treatment was performed in 86 percent.",
"   </p>",
"   <p>",
"    A disadvantage of this approach is that the forward-viewing perspective and the lack of an instrument elevator make selective duct cannulation more difficult when addressing an intact papilla. In addition, the maneuverability of the long enteroscope or colonoscope can be very limited due to torsion of the scope shaft and loop formation. Finally, deflection of the scope tip can make the introduction of accessories through the working channel difficult or impossible. To overcome these problems, forward-viewing endoscopes can be used initially to navigate the anatomic route. Once the papilla is reached, a guidewire is placed, over which a duodenoscope is subsequently advanced.",
"   </p>",
"   <p>",
"    One study described the use of this technique in a series of 15 patients with long-limb Roux-en-Y anatomy and an intact papilla, 11 of whom had undergone Roux-en-Y gastric bypass (RYGB) surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/7\">",
"     7",
"    </a>",
"    ]. On several occasions, a large diameter ERCP stone-extraction balloon was advanced over the wire and inflated in the biliopancreatic limb or bypassed stomach, serving as an anchor as the duodenoscope was passed over the catheter into the region of the papilla. Other maneuvers similar to those used during colonoscopy (straightening loops, changing patient position, and applying manual abdominal pressure) were performed to facilitate duodenoscope advancement. ERCP was ultimately successful in 10 of the 15 patients (67 percent), with the main reason for failure being the inability to pass an endoscope to the region of the papilla. Of note, the five patients in whom ERCP was not possible had all undergone RYGB, underscoring the need for alternative methods to perform successful ERCP in this important patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898178\">",
"    <span class=\"h2\">",
"     ERCP using deep enteroscopy techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is growing experience with the performance of ERCP using deep enteroscopy techniques, including double-balloon enteroscopy (DBE) (",
"    <a class=\"graphic graphic_picture graphicRef53187 \" href=\"mobipreview.htm?40/35/41524\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50391 \" href=\"mobipreview.htm?14/3/14392\">",
"     figure 6",
"    </a>",
"    ), single-balloon enteroscopy (SBE) (",
"    <a class=\"graphic graphic_figure graphicRef63179 \" href=\"mobipreview.htm?15/63/16374\">",
"     figure 7",
"    </a>",
"    ), and spiral enteroscopy (",
"    <a class=\"graphic graphic_picture graphicRef76104 \" href=\"mobipreview.htm?15/18/15662\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24649?source=see_link\">",
"     \"Overview of deep small bowel enteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While deep enteroscopy techniques represent a significant advancement for performing ERCP in patients with surgically-altered anatomy, they are not yet widely performed outside of specialized centers. Furthermore, they are fraught with the aforementioned limitations inherent to the use of enteroscopes for ERCP, including restricted maneuverability of the scope (related to looping, adhesions, sharp angulations, and depth of scope insertion), unfavorable orientation of the native papilla, lack of an instrument elevator, and relative paucity of enteroscope-compatible ERCP accessories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898185\">",
"    <span class=\"h3\">",
"     Double balloon enteroscope-assisted ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on data largely from case reports and a few case series, the papilla (or",
"    <span class=\"nowrap\">",
"     bilioenteric/pancreatoenteric",
"    </span>",
"    anastomosis) can be reached in over 90 percent of cases, and successful selective duct cannulation can be achieved in over 80 percent of cases using the double balloon enteroscope-assisted ERCP (DB-ERCP) technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/8-14\">",
"     8-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the first case series describing DB-ERCP in 13 patients with Roux-en-Y anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/8\">",
"     8",
"    </a>",
"    ], successful bile duct cannulation was achieved in 16 of 18 ERCPs, with therapy being performed in six cases (including stent insertion and removal and stone extraction). Of note, only one of the patients in this series had a native papilla, and ERCP was unsuccessful in this patient due to the inability to approach the papilla at the appropriate angle.",
"   </p>",
"   <p>",
"    As with other ERCPs using forward-viewing endoscopes, cannulation of the native papilla may be difficult with DB-ERCP. An additional problem when performing DB-ERCP is that there are a limited number of ERCP accessories that are compatible with a standard double balloon enteroscope due to its length. However, this issue can be overcome with the use of a \"short\" DBE system that has a 152 cm working length and is compatible with conventional accessories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. One study performed 55 ERCPs in 36 Roux-en-Y total gastrectomy patients using the \"short\" double balloon enteroscope, achieving successful bile duct cannulation in 50 of 55 procedures (91 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/15\">",
"     15",
"    </a>",
"    ]. A full spectrum of therapeutic maneuvers were performed, including sphincterotomy, stone extraction, balloon dilation, and the insertion of plastic stents, metal stents, and nasobiliary drainage tubes.",
"   </p>",
"   <p>",
"    If a \"short\" double balloon enteroscope is not available, the standard DBE or SBE overtube can be modified to permit the use of a conventional forward-viewing upper endoscope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. Once the papilla is reached, the enteroscope is removed from the overtube, which is left in place with the balloon inflated to maintain its position near the papilla. Next, a 12 mm aperture is created in the overtube at a point 100 cm from its tip on the side opposite the pressure line (so that the balloon remains inflated). A standard upper endoscope can then be inserted through the aperture and advanced down the overtube into position below the papilla.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898192\">",
"    <span class=\"h3\">",
"     Single balloon enteroscope-assisted ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performance of single balloon enteroscope-assisted ERCP (SB-ERCP) in patients with Roux-en-Y anatomy has been associated with diagnostic success rates ranging from 60 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. One series included 50 patients with Roux-en-Y anatomy who underwent a total of 56 SB-ERCPs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/18\">",
"     18",
"    </a>",
"    ]. Successful diagnostic ERCP was achieved in 39 of 56 procedures (70 percent). Therapeutic ERCP was required in 23 cases, of which 21 were successful (91 percent).",
"   </p>",
"   <p>",
"    In a second series, SB-ERCP was compared with ERCP using an adult or pediatric colonoscope in 90 patients with a Roux-en-Y biliary anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/21\">",
"     21",
"    </a>",
"    ]. A total of 199 procedures were performed. The rates of successful biliary cannulation were similar for SB-ERCP and ERCP using an adult colonoscope (76 versus 70 percent), whereas SB-ERCP had a higher rate of successful biliary cannulation when compared with ERCP using a pediatric colonoscope (76 versus 59 percent). Similarly, there was no statistically significant difference in the therapeutic success rates between SB-ERCP and ERCP using an adult colonoscope (71 versus 66 percent), but there was a higher success rate for SB-ERCP when it was compared with ERCP using a pediatric colonoscope (71 versus 54 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898199\">",
"    <span class=\"h3\">",
"     Spiral enteroscopy-assisted ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spiral enteroscopy utilizes a rotating overtube (",
"    <a class=\"graphic graphic_picture graphicRef76104 \" href=\"mobipreview.htm?15/18/15662\">",
"     picture 2",
"    </a>",
"    ) that pleats the small bowel onto the overtube and allows deep advancement of an enteroscope. Potential advantages of spiral enteroscopy-assisted ERCP (SE-ERCP) over DB-ERCP or SB-ERCP include relative ease of use, better endoscope control, and perhaps a shorter learning curve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of SE-ERCP in a variety of patients with Roux-en-Y anatomy have reported success rates of 55 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/22-28\">",
"     22-28",
"    </a>",
"    ]. The best available data come from a multi-center study of 129 patients with long-limb surgical bypass anatomy (64 of whom were status-post Roux-en-Y gastric bypass) who underwent a total of 180 ERCPs using DB-ERCP, SB-ERCP, or SE-ERCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/24\">",
"     24",
"    </a>",
"    ]. Enteroscopy was successful (ie, there was visualization of the papilla or bilioenteric anastomosis) in 74, 69, and 72 percent, respectively. In patients with enteroscopy success, ERCP was successful in 85, 87, and 90 percent, respectively. Of note, native papilla cannulation was successful in 46 of 73 patients (63 percent). The overall (intention-to-treat) ERCP success rates for the three methods were similar: 63 percent, 60 percent, and 65 percent for DB-ERCP, SB-ERCP, and SE-ERCP, respectively. Complications occurred in 16 of 129 patients (12 percent) and included pancreatitis, perforation, and bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898206\">",
"    <span class=\"h1\">",
"     SURGICAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a transoral approach to ERCP is not successful, a surgical approach may be required. The main advantage of a surgical approach in patients with Roux-en-Y anatomy is the ability to perform the procedure using a side-viewing duodenoscope with reliable access and a conventional approach to the papilla. In addition, all standard ERCP accessories can be used.",
"   </p>",
"   <p>",
"    Surgical approaches include ERCP through a gastrostomy or jejunostomy tract and laparoscopy-assisted ERCP. However, these approaches are more invasive than purely endoscopic approaches and are associated with the risks related to anesthesia and surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898213\">",
"    <span class=\"h2\">",
"     ERCP through a gastrostomy or jejunostomy tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first case of surgical gastrostomy placement as a means of performing ERCP in a patient with a Roux-en-Y gastric bypass (RYGB) was reported in 1998 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/29\">",
"     29",
"    </a>",
"    ]. Initially, an open Stamm gastrostomy of the bypassed stomach was created with the placement of a 24F Malecot tube. The gastrostomy tract was allowed to mature for two weeks, at which time the tube was removed and wire-guided dilation of the tract was performed, permitting insertion of the duodenoscope to perform the ERCP.",
"   </p>",
"   <p>",
"    Several other investigators have since described variations of this transgastrostomy approach in patients with Roux-en-Y anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. The gastrostomy can be placed using a laparoscopic or open surgical approach, or it can be placed percutaneously by interventional radiology. The ERCP can then be performed intraoperatively or after a delay to allow maturation of the tract. The tract can be maintained with a large bore feeding tube if repeated procedures are anticipated.",
"   </p>",
"   <p>",
"    The largest series published to date included 30 RYGB patients who underwent surgical gastrostomy for endoscopic access, 26 of whom underwent ERCP at the time of surgery in a single step procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/31\">",
"     31",
"    </a>",
"    ]. Successful ERCP was performed in all cases. In addition, these investigators identified additional unsuspected internal hernias in one third of patients, which were repaired at the time of the operation. Complications occurred in four patients and included pancreatitis, gastrostomy leak, and superficial wound infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898220\">",
"    <span class=\"h2\">",
"     Laparoscopy-assisted ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopy-assisted ERCP (LA-ERCP) involves the laparoscopic creation of an access point into the gastric remnant or small bowel. A sterilized duodenoscope is then inserted into the peritoneum through a trocar placed in the left upper quadrant and advanced into the gastrointestinal tract under laparoscopic guidance. This approach requires a great deal of coordination between the surgery and endoscopy teams, and it is not yet widely performed.",
"   </p>",
"   <p>",
"    The published experience with this approach suggests a high technical success rate (90 to 100 percent) with a low complication rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/34-40\">",
"     34-40",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 10 patients with Roux-en-Y anatomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/35\">",
"       35",
"      </a>",
"      ], biliary cannulation via LA-ERCP was successful in nine (90 percent), and pancreatography was successful in three of three patients. During laparoscopy, internal hernias were diagnosed and corrected in four patients, and an additional patient underwent lysis of adhesions. Mild post-ERCP pancreatitis developed in two patients, and one patient developed a tension pneumothorax related to an indwelling percutaneous transhepatic cholangiography catheter that allowed gas to track into the chest.",
"     </li>",
"     <li>",
"      A second study compared LA-ERCP with balloon enteroscope-assisted ERCP (BEA-ERCP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37831/abstract/40\">",
"       40",
"      </a>",
"      ]. The study included 24 patients who underwent LA-ERCP and 32 who underwent BAE-ERCP. LA-ERCP was superior to BEA-ERCP with regard to papilla identification (100 versus 72 percent), cannulation rate (100 versus 59 percent), and therapeutic success (100 versus 59 percent). A cost analysis based upon the results of the study found that an approach that started with BEA-ERCP, reserving LA-ERCP for failed attempts at BEA-ERCP, was associated with a savings of $1015 per patient compared with an approach that started with LA-ERCP. BEA-ERCP remained the preferred strategy when only patients with roux limbs less than 150 cm were considered (savings of $2388), but when patients with roux limbs 150 cm or longer were considered, BEA-ERCP was the more expensive strategy (increased cost of $593).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850898227\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performing endoscopic retrograde cholangiopancreatography (ERCP) in patients with Roux-en-Y anatomy is a challenging, frequently arduous task, but there are now several techniques available to endoscopists. There is no single best technique for all patients, so the approach must be selected on a case-by-case basis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a native papilla and a short Roux limb, a transoral approach using a duodenoscope can be attempted, although it is still frequently unsuccessful. (See",
"      <a class=\"local\" href=\"#H1850898164\">",
"       'ERCP using standard duodenoscope'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If a transoral approach using a duodenoscope is unsuccessful, a colonoscope or enteroscope may be used to perform the ERCP (recognizing the limitations of forward viewing endoscopes and the relative lack of compatible ERCP accessories) or to initially navigate the anatomic route and facilitate guidewire-assisted duodenoscope insertion into the biliopancreatic limb. (See",
"      <a class=\"local\" href=\"#H1850898171\">",
"       'ERCP using an enteroscope or pediatric colonoscope'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a native papilla and a long Roux limb (as in most Roux-en-Y gastric bypass patients), deep enteroscopy techniques can be considered. However, ERCP through a gastrostomy or laparoscopy-assisted ERCP are preferable in good surgical candidates. These approaches are preferred because they provide rapid, reliable access to the descending duodenum with visualization of the papilla in the usual orientation for ERCP, and they allow the use of a therapeutic duodenoscope and all standard ERCP accessories. (See",
"      <a class=\"local\" href=\"#H1850898178\">",
"       'ERCP using deep enteroscopy techniques'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1850898206\">",
"       'Surgical approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without a native papilla (ie, patients with a",
"      <span class=\"nowrap\">",
"       bilioenteric/pancreatoenteric",
"      </span>",
"      anastomosis) and a short Roux limb, a forward-viewing endoscope such as a colonoscope or enteroscope can be used in most cases. (See",
"      <a class=\"local\" href=\"#H1850898171\">",
"       'ERCP using an enteroscope or pediatric colonoscope'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without a native papilla and a long Roux limb, deep enteroscopy techniques (double balloon, single balloon, spiral enteroscopy) should be attempted, if available. Alternatively, ERCP through a gastrostomy or laparoscopy-assisted ERCP can be considered. (See",
"      <a class=\"local\" href=\"#H1850898178\">",
"       'ERCP using deep enteroscopy techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/1\">",
"      Nguyen NT, Root J, Zainabadi K, et al. Accelerated growth of bariatric surgery with the introduction of minimally invasive surgery. Arch Surg 2005; 140:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/2\">",
"      Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab 2008; 93:S89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/3\">",
"      Shiffman ML, Sugerman HJ, Kellum JH, et al. Gallstones in patients with morbid obesity. Relationship to body weight, weight loss and gallbladder bile cholesterol solubility. Int J Obes Relat Metab Disord 1993; 17:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/4\">",
"      Lopes TL, Wilcox CM. Endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y anatomy. Gastroenterol Clin North Am 2010; 39:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/5\">",
"      Hintze RE, Adler A, Veltzke W, Abou-Rebyeh H. Endoscopic access to the papilla of Vater for endoscopic retrograde cholangiopancreatography in patients with billroth II or Roux-en-Y gastrojejunostomy. Endoscopy 1997; 29:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/6\">",
"      Elton E, Hanson BL, Qaseem T, Howell DA. Diagnostic and therapeutic ERCP using an enteroscope and a pediatric colonoscope in long-limb surgical bypass patients. Gastrointest Endosc 1998; 47:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/7\">",
"      Wright BE, Cass OW, Freeman ML. ERCP in patients with long-limb Roux-en-Y gastrojejunostomy and intact papilla. Gastrointest Endosc 2002; 56:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/8\">",
"      Aabakken L, Bretthauer M, Line PD. Double-balloon enteroscopy for endoscopic retrograde cholangiography in patients with a Roux-en-Y anastomosis. Endoscopy 2007; 39:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/9\">",
"      Emmett DS, Mallat DB. Double-balloon ERCP in patients who have undergone Roux-en-Y surgery: a case series. Gastrointest Endosc 2007; 66:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/10\">",
"      Itoi T, Ishii K, Sofuni A, et al. Long- and short-type double-balloon enteroscopy-assisted therapeutic ERCP for intact papilla in patients with a Roux-en-Y anastomosis. Surg Endosc 2011; 25:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/11\">",
"      Lopes TL, Baron TH. Endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y anatomy. J Hepatobiliary Pancreat Sci 2011; 18:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/12\">",
"      M&ouml;nkem&uuml;ller K, Fry LC, Bellutti M, et al. ERCP with the double balloon enteroscope in patients with Roux-en-Y anastomosis. Surg Endosc 2009; 23:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/13\">",
"      Moreels TG, Hubens GJ, Ysebaert DK, et al. Diagnostic and therapeutic double-balloon enteroscopy after small bowel Roux-en-Y reconstructive surgery. Digestion 2009; 80:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/14\">",
"      Parlak E, Ci&ccedil;ek B, Di��ibeyaz S, et al. Endoscopic retrograde cholangiography by double balloon enteroscopy in patients with Roux-en-Y hepaticojejunostomy. Surg Endosc 2010; 24:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/15\">",
"      Shimatani M, Matsushita M, Takaoka M, et al. Effective \"short\" double-balloon enteroscope for diagnostic and therapeutic ERCP in patients with altered gastrointestinal anatomy: a large case series. Endoscopy 2009; 41:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/16\">",
"      Itoi T, Ishii K, Sofuni A, et al. Single-balloon enteroscopy-assisted ERCP in patients with Billroth II gastrectomy or Roux-en-Y anastomosis (with video). Am J Gastroenterol 2010; 105:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/17\">",
"      Dellon ES, Kohn GP, Morgan DR, Grimm IS. Endoscopic retrograde cholangiopancreatography with single-balloon enteroscopy is feasible in patients with a prior Roux-en-Y anastomosis. Dig Dis Sci 2009; 54:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/18\">",
"      Saleem A, Baron TH, Gostout CJ, et al. Endoscopic retrograde cholangiopancreatography using a single-balloon enteroscope in patients with altered Roux-en-Y anatomy. Endoscopy 2010; 42:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/19\">",
"      Wang AY, Sauer BG, Behm BW, et al. Single-balloon enteroscopy effectively enables diagnostic and therapeutic retrograde cholangiography in patients with surgically altered anatomy. Gastrointest Endosc 2010; 71:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/20\">",
"      Neumann H, Fry LC, Meyer F, et al. Endoscopic retrograde cholangiopancreatography using the single balloon enteroscope technique in patients with Roux-en-Y anastomosis. Digestion 2009; 80:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/21\">",
"      Azeem N, Tabibian JH, Baron TH, et al. Use of a single-balloon enteroscope compared with variable-stiffness colonoscopes for endoscopic retrograde cholangiography in liver transplant patients with Roux-en-Y biliary anastomosis. Gastrointest Endosc 2013; 77:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/22\">",
"      Kogure H, Watabe H, Yamada A, et al. Spiral enteroscopy for therapeutic ERCP in patients with surgically altered anatomy: actual technique and review of the literature. J Hepatobiliary Pancreat Sci 2011; 18:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/23\">",
"      et al. ERCP using spiral enteroscopy in patients with altered gastrointestinal anatomy. Am J Gastroenterol 2009; 104:S384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/24\">",
"      Shah RJ, Smolkin M, Yen R, et al. A multicenter, U.S. experience of single-balloon, double-balloon, and rotational overtube-assisted enteroscopy ERCP in patients with surgically altered pancreaticobiliary anatomy (with video). Gastrointest Endosc 2013; 77:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/25\">",
"      Hegde S, Downey S, Iffrig K. Overtube-assisted ERCP in patients with surgically altered anatomy: a single center one-year experience. Gastrointest Endosc 2009; 69:AB193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/26\">",
"      Kerstetter D, Akerman P. Spiral enteroscopy for therapeutic ERCP in patients with roux-en-Y gastric bypass. Am J Gastroenterol 2009; 104:S519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/27\">",
"      Wagh MS, Draganov PV. Prospective evaluation of spiral overtube-assisted ERCP in patients with surgically altered anatomy. Gastrointest Endosc 2012; 76:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/28\">",
"      Lennon AM, Kapoor S, Khashab M, et al. Spiral assisted ERCP is equivalent to single balloon assisted ERCP in patients with Roux-en-Y anatomy. Dig Dis Sci 2012; 57:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/29\">",
"      Baron TH, Vickers SM. Surgical gastrostomy placement as access for diagnostic and therapeutic ERCP. Gastrointest Endosc 1998; 48:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/30\">",
"      Baron TH, Chahal P, Ferreira LE. ERCP via mature feeding jejunostomy tube tract in a patient with Roux-en-Y anatomy (with video). Gastrointest Endosc 2008; 68:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/31\">",
"      Gutierrez JM, Lederer H, Krook JC, et al. Surgical gastrostomy for pancreatobiliary and duodenal access following Roux en Y gastric bypass. J Gastrointest Surg 2009; 13:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/32\">",
"      Matlock J, Ikramuddin S, Lederer H, et al. Bypassing the bypass: ERCP via gastrostomy after bariatric surgery. Gastrointest Endosc 2005; 61:AB98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/33\">",
"      Pimentel RR, Mehran A, Szomstein S, Rosenthal R. Laparoscopy-assisted transgastrostomy ERCP after bariatric surgery: case report of a novel approach. Gastrointest Endosc 2004; 59:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/34\">",
"      Ceppa FA, Gagn&eacute; DJ, Papasavas PK, Caushaj PF. Laparoscopic transgastric endoscopy after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2007; 3:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/35\">",
"      Lopes TL, Clements RH, Wilcox CM. Laparoscopy-assisted ERCP: experience of a high-volume bariatric surgery center (with video). Gastrointest Endosc 2009; 70:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/36\">",
"      Lopes TL, Clements RH, Wilcox CM. Laparoscopy-assisted transjejunal ERCP in a patient with Roux-en-Y reconstruction following partial gastrectomy. J Laparoendosc Adv Surg Tech A 2010; 20:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/37\">",
"      Nguyen NT, Hinojosa MW, Slone J, et al. Laparoscopic transgastric access to the biliary tree after Roux-en-Y gastric bypass. Obes Surg 2007; 17:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/38\">",
"      Peters M, Papasavas PK, Caushaj PF, et al. Laparoscopic transgastric endoscopic retrograde cholangiopancreatography for benign common bile duct stricture after Roux-en-Y gastric bypass. Surg Endosc 2002; 16:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/39\">",
"      Roberts KE, Panait L, Duffy AJ, et al. Laparoscopic-assisted transgastric endoscopy: current indications and future implications. JSLS 2008; 12:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37831/abstract/40\">",
"      Schreiner MA, Chang L, Gluck M, et al. Laparoscopy-assisted versus balloon enteroscopy-assisted ERCP in bariatric post-Roux-en-Y gastric bypass patients. Gastrointest Endosc 2012; 75:748.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15864 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37831=[""].join("\n");
var outline_f36_60_37831=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1850898227\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898136\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898143\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898150\">",
"      Choosing the best approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3822821\">",
"      - Native papilla",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3822828\">",
"      - Bilioenteric or pancreatoenteric anastomosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898157\">",
"      TRANSORAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898164\">",
"      ERCP using standard duodenoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898171\">",
"      ERCP using an enteroscope or pediatric colonoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898178\">",
"      ERCP using deep enteroscopy techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898185\">",
"      - Double balloon enteroscope-assisted ERCP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898192\">",
"      - Single balloon enteroscope-assisted ERCP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898199\">",
"      - Spiral enteroscopy-assisted ERCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898206\">",
"      SURGICAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898213\">",
"      ERCP through a gastrostomy or jejunostomy tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898220\">",
"      Laparoscopy-assisted ERCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1850898227\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/15864\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15864|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/35/33329\" title=\"figure 1\">",
"      Roux en Y gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/13/2261\" title=\"figure 2\">",
"      Total gastrectomy with reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/57/17303\" title=\"figure 3\">",
"      Conventional pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/43/5810\" title=\"figure 4\">",
"      Pylorus-preserving pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/21/30036\" title=\"figure 5\">",
"      Biliary reconstruction with Roux-en-Y hepaticojejunostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/3/14392\" title=\"figure 6\">",
"      Double balloon technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/63/16374\" title=\"figure 7\">",
"      Single balloon enteroscopy technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15864|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/35/41524\" title=\"picture 1\">",
"      Double balloon endoscopy system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/18/15662\" title=\"picture 2\">",
"      Spiral enteroscopy overtube",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15864|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/41/2717\" title=\"table 1\">",
"      Approaches for ERCP in patients with Roux-en-Y anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5415?source=related_link\">",
"      ERCP after Billroth II reconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28489?source=related_link\">",
"      Endoscopy in patients who have undergone bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=related_link\">",
"      Invasive gastric cancer: Surgery and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25672?source=related_link\">",
"      Living donor liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24649?source=related_link\">",
"      Overview of deep small bowel enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43721?source=related_link\">",
"      Pancreaticoduodenectomy (Whipple procedure): Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18166?source=related_link\">",
"      Percutaneous transhepatic cholangioscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6232?source=related_link\">",
"      Repair of common bile duct injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=related_link\">",
"      Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_60_37832="Epidemiology and risk factors for skin cancer in solid organ transplant recipients";
var content_f36_60_37832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and risk factors for skin cancer in solid organ transplant recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37832/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37832/contributors\">",
"     Thomas Stasko, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37832/contributors\">",
"     Allison M Hanlon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37832/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37832/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37832/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37832/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/60/37832/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7860379\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term immunosuppressive therapy required to maintain host tolerance of a transplanted organ contributes to an increased risk for malignancy in organ transplant recipients. Skin is the most common site for the development malignancy; in particular, cutaneous squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) are frequently detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/1\">",
"     1",
"    </a>",
"    ]. A variety of factors, including the intensity and duration of immunosuppression, patient ethnic background, patient sun exposure history, and geographic location, can influence the likelihood for the development of skin cancer in these patients.",
"   </p>",
"   <p>",
"    The most common skin cancers that develop in solid organ transplant recipients will be reviewed here. The management of skin cancer in solid organ transplant recipients and information on other malignancies in organ transplant recipients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2186?source=see_link\">",
"     \"Management of skin cancer in solid organ transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7860386\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin cancers account for almost 40 percent of malignancies in organ transplant recipients, and develop in more than 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The most commonly reported skin cancers in this population include squamous cell carcinoma (SCC), basal cell carcinoma (BCC), melanoma, and Kaposi&rsquo;s sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the pathways that lead to an elevated risk for cutaneous malignancy in organ transplant recipients are not fully understood, it generally is accepted that immunosuppressive medications used to induce tolerance to the donor organ play an important role. Proposed mechanisms through which immunosuppression may contribute to the development of skin cancer include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced immune surveillance, thereby facilitating the survival and proliferation of atypical cells",
"     </li>",
"     <li>",
"      Direct carcinogenic effects of immunosuppressive agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H7860421\">",
"       'Role of specific immunosuppressants'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Proliferation of oncogenic viruses in the setting of immunosuppression (See",
"      <a class=\"local\" href=\"#H7860393\">",
"       'Squamous cell and basal cell carcinoma'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H2293501\">",
"       'Kaposi's sarcoma'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of immunosuppression on skin cancer development is supported by the results of a French series of 181 immunosuppressed renal transplant patients that included 15 patients with cutaneous malignancies. In this study, patients who developed skin cancer had significantly lower CD4 cell counts than patients without skin cancer (330 &plusmn;",
"    <span class=\"nowrap\">",
"     179/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    versus 503 &plusmn;",
"    <span class=\"nowrap\">",
"     338/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7860393\">",
"    <span class=\"h1\">",
"     SQUAMOUS CELL AND BASAL CELL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) account for more than 90 percent of cutaneous malignancies in organ transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. As in immunocompetent patients, SCC typically presents as a scaly erythematous papule, nodule, or plaque within an area of actinic damage (",
"    <a class=\"graphic graphic_picture graphicRef82358 graphicRef60026 graphicRef50112 \" href=\"mobipreview.htm?29/51/30522\">",
"     picture 1A-C",
"    </a>",
"    ). In some organ transplant recipients, particularly fair-skinned individuals with histories of extensive sun exposure, areas such as the back of the hand or balding scalp may develop numerous SCCs and actinic keratoses (",
"    <a class=\"graphic graphic_picture graphicRef69827 \" href=\"mobipreview.htm?40/29/41428\">",
"     picture 2",
"    </a>",
"    ). Like SCC, BCC mimics its appearance in the general population, typically manifesting as pearly papules with or without ulceration or erythematous macules or patches in photoexposed areas (",
"    <a class=\"graphic graphic_picture graphicRef57990 graphicRef76863 graphicRef65704 graphicRef56527 graphicRef68274 graphicRef81632 \" href=\"mobipreview.htm?42/62/44010\">",
"     picture 3A-F",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442714\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the general population, in which the incidence of BCC exceeds that of SCC, most estimates of the ratio of SCC to BCC in organ transplant recipients range from 1.5:1 to 5:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/3,9-13\">",
"     3,9-13",
"    </a>",
"    ]. Some authors have reported much higher ratios; in one retrospective study of 312 heart transplant recipients in the United States, out of 1395 skin cancers that developed in the study population over the course of 2097 person-years, 1236 were SCCs (89 percent), and 151 were BCCs (11 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with the general population, organ transplant recipients are approximately 65 to 250 times more likely to develop SCC, and 10 to 16 times more likely to develop BCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In an Australian study of 361 organ transplant recipients with Fitzpatrick skin type I to IV, the incidence of new skin cancers rose as the time from transplantation increased. Among patients who had been immunosuppressed for less than 5, 5.1 to 10, 10.1 to 20, or more than 20.1 years, 29, 52, 72, and 82 percent, respectively, had developed at least one nonmelanoma skin cancer after organ transplantation (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"mobipreview.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although SCC and BCC are considered the most common skin cancers in organ transplant recipients, it must be noted that these carcinomas are much less common in transplant recipients with dark skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/6,15,16\">",
"     6,15,16",
"    </a>",
"    ]. In a retrospective study of 542 renal transplant patients in South Africa followed for a mean of 6.3 years, SCC or BCC developed in 10 out of 185 white patients and none of the non-white patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/15\">",
"     15",
"    </a>",
"    ]. Additionally, a retrospective study of 295 patients in the United Kingdom found no cases of SCC or BCC among 33 black African or Asian patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442687\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraviolet radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/1,2,12,17-21\">",
"     1,2,12,17-21",
"    </a>",
"    ] and fair phenotypic features (Fitzpatrick Types I to III with light colored hair and eyes) are known risk factors for the development of SCC and BCC in the general population, and also increase the risk for SCC or BCC in organ transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/12,19,22-24\">",
"     12,19,22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=see_link\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=see_link\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple other risk factors have been associated with the development of post-transplant SCC or BCC. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pre-transplant history of SCC, BCC, or actinic keratoses &ndash;",
"      </strong>",
"      In a series of 361 Caucasian renal transplant recipients in Australia, a history of either SCC or BCC prior to organ transplantation significantly increased risk for the development of SCC or BCC after transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/19\">",
"       19",
"      </a>",
"      ]. The presence of greater than 100 actinic keratoses prior to organ transplantation also was strongly associated with the occurrence of skin cancer.",
"     </li>",
"     <li>",
"      <strong>",
"       Post-transplant history of SCC or BCC &ndash;",
"      </strong>",
"      Many patients who develop one SCC or BCC after organ transplantation will develop additional lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/14,22,25\">",
"       14,22,25",
"      </a>",
"      ]. In a retrospective study of 239 renal transplant recipients with SCC or BCC in the Netherlands, the cumulative incidence of new skin cancer after the development of an initial lesion was 32 percent after one year, 59 percent after three years, and 72 percent after five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/22\">",
"       22",
"      </a>",
"      ]. A separate retrospective study of cardiac transplant patients in the United States found cumulative incidence rates of a second SCC at the same time points of 44, 67, and 76 percent, respectively. [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/14\">",
"       14",
"      </a>",
"      ]. The cumulative incidence rates for a second BCC were 32, 49, and 51 percent.",
"     </li>",
"     <li>",
"      <strong>",
"       Geographic location &ndash;",
"      </strong>",
"      The incidence of skin cancer in organ transplant recipients varies geographically. Estimates of nonmelanoma skin cancer incidence after organ transplantation in the United States and western Europe have ranged from 5 percent at two years, 10 to 27 percent at 10 years, and 40 to 60 percent after 20 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/9\">",
"       9",
"      </a>",
"      ]. However, the rates of nonmelanoma skin cancer are higher in Australia, a finding that is likely related to greater solar exposure in a predominantly fair-skinned population. Between 70 and 82 percent of organ transplant recipients in Australia are diagnosed with nonmelanoma skin cancer within 20 years after transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Intensity and duration of immunosuppressive therapy",
"      </strong>",
"      &ndash; The results of several studies suggest that the degree and duration of immunosuppression influence the risk for nonmelanoma skin cancer, particularly SCC. Examples include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a retrospective cohort study of 262 renal transplant recipients in the United Kingdom that compared treatment with a three-drug regimen (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      ) to a two-drug regimen (azathioprine and prednisolone), patients treated with the three-drug regimen had a significantly greater incidence of SCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/16\">",
"       16",
"      </a>",
"      ]. The difference in BCC incidence between the two groups was not significant.",
"     </li>",
"     <li>",
"      In an uncontrolled prospective study of 300 heart transplant recipients in Italy (mean follow-up 4.6 years), patients who exhibited greater signs of organ rejection, which would have required treatment with higher levels of immunosuppression, had a significantly higher rate of SCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent nonrandomized prospective study in 230 heart transplant patients from the same institution found that the risk for SCC (but not BCC) three years after transplantation correlated with the overall level immunosuppression, rather than with a specific immunosuppressive drug [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Type of transplant",
"      </strong>",
"      &ndash; The results of some observational studies have suggested that the risk for nonmelanoma skin cancer is greater in heart or pancreas-kidney transplant recipients than in kidney transplant patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/26,27\">",
"       26,27",
"      </a>",
"      ], and is lowest in liver transplant recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/28\">",
"       28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a cohort study of 2561 heart transplant recipients and renal transplant recipients in Norway, heart transplant recipients were 2.9 times more likely to develop SCC than renal transplant patients (95% CI 1.3-6.2) after adjustment for age at transplantation and immunosuppressive regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/26\">",
"       26",
"      </a>",
"      ]. However, a French cohort study that included 121 renal transplant patients and 67 heart transplant patients followed for up to five years found that among patients who had developed one post-transplant SCC, greater numbers of subsequent nonmelanoma skin tumors (SCCs, BCCs, Bowen&rsquo;s disease, premalignant keratoses, and keratoacanthomas) developed in the renal transplant patients (mean number of tumors 9.7 versus 4.6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Age at transplantation &ndash;",
"      </strong>",
"      Greater age at transplantation may increase the likelihood of nonmelanoma skin cancer, and may be associated with development of lesions earlier in the post-transplant period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/3,12,18,21\">",
"       3,12,18,21",
"      </a>",
"      ]. In a population-based study of renal transplant recipients in Ireland, the incidence for nonmelanoma skin cancers peaked at approximately six years after transplantation in patients older than 50 years, compared with 10 to 12 years post-transplantation in younger patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/4\">",
"       4",
"      </a>",
"      ]. Of note, the increase in risk was extraordinarily high for the young transplant patients compared to an age-matched nontransplanted population; the risk for skin cancer was 200 times greater for these patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Genetic factors &ndash;",
"      </strong>",
"      A common polymorphism in the folate pathway has been associated with an increased risk of cutaneous SCC in transplant patients. In a cohort of 367 renal transplant patients, those who carried the polymorphism MTHFR:C677T had a statistically significant increase in risk for SCC (OR = 2.54) compared to those who did not have the polymorphism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/29\">",
"       29",
"      </a>",
"      ]. More studies are necessary to explore the role of MTHFR:C677T in the development of SCC.",
"     </li>",
"     <li>",
"      <strong>",
"       Viral infection &ndash;",
"      </strong>",
"      The role of human papillomavirus (HPV) in the development of cutaneous SCC remains uncertain. HPV has been detected at a greater frequency in lesional versus nonlesional skin in organ transplant recipients with SCC (90 versus 11 to 32 percent of specimens positive for HPV) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Other &ndash;",
"      </strong>",
"      Particular forms of DNA damage in immunosuppressed organ transplant recipients may contribute to increased risk for SCC or aggressive tumor behavior [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. In one study, a significant reduction in allelic balance in the D9S162 locus on chromosome 9p21-22 was detected in SCCs from immunosuppressed organ transplant recipients compared with SCCs from immunocompetent patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/31\">",
"       31",
"      </a>",
"      ]. Further study is necessary to determine the etiology and clinical relevance of this finding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7860400\">",
"    <span class=\"h1\">",
"     MELANOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trunk, upper limbs, head, and neck are the most common sites for melanoma development in organ transplant recipients (",
"    <a class=\"graphic graphic_picture graphicRef71893 graphicRef82173 graphicRef75881 \" href=\"mobipreview.htm?5/35/5690\">",
"     picture 4A-C",
"    </a>",
"    ). In a series of 177 organ transplant recipients with post-transplant melanoma, 68 percent of cases occurred in men, and melanoma was detected an average of 61 months after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/20/16713?source=see_link&amp;anchor=H81531006#H81531006\">",
"     \"Skin examination and clinical features of melanoma\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies conflict on the relationship between organ transplantation and melanoma risk. Estimates have ranged from negligible differences in risk to a six to eight-fold greater likelihood for melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/4,34,35\">",
"     4,34,35",
"    </a>",
"    ]. The largest published investigation, a population-based study of 89,786 renal transplant recipients in the United States followed over a 10 year period, identified 246 patients with melanoma and a 3.6 times greater likelihood for the development of melanoma in organ transplant recipients compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/36\">",
"     36",
"    </a>",
"    ]. In particular, the risk for melanoma among African-American patients increased greatly; the incidence for melanoma was 17.2 times greater than in the African-American general population.",
"   </p>",
"   <p>",
"    As with nonmelanoma skin cancer, the intensity and duration of immunosuppression may be an important determinant of melanoma risk in organ transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/37\">",
"     37",
"    </a>",
"    ]. Although transmission of melanoma from organ donors to organ recipients also has been reported, the risk for donor-transmitted malignancies appears to be low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link&amp;anchor=H26#H26\">",
"     \"Development of malignancy following solid organ transplantation\", section on 'Transmission from the donor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2293501\">",
"    <span class=\"h1\">",
"     KAPOSI'S SARCOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kaposi sarcoma (KS) is a tumor of endothelial cell origin associated with herpes human virus-8 (HHV-8) infection that occurs with increased frequency in the setting of immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Most cases of organ transplant-related Kaposi&rsquo;s sarcoma have occurred in individuals of Mediterranean, Jewish, Arabic, Caribbean, or African descent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. In a South African cohort study, Kaposi&rsquo;s sarcoma was the most common cancer detected in non-white renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kaposi&rsquo;s sarcoma often develops relatively quickly after organ transplantation; the mean interval to diagnosis is 13 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/2\">",
"     2",
"    </a>",
"    ]. Men are more likely to be affected than women. The clinical manifestations typically resemble those of classic Kaposi&rsquo;s carcinoma. Approximately 90 percent of patients develop cutaneous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucosal lesions, and lesions on the lower extremities are common (",
"    <a class=\"graphic graphic_picture graphicRef69584 graphicRef81468 graphicRef54707 \" href=\"mobipreview.htm?33/33/34329\">",
"     picture 5A-C",
"    </a>",
"    ). Visceral involvement develops in 25 to 30 percent of renal transplant recipients and 50 percent of heart or liver transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment?source=see_link\">",
"     \"Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7860407\">",
"    <span class=\"h1\">",
"     MERKEL CELL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Merkel cell carcinoma (MCC) is a rare tumor of neuroendocrine origin that usually presents as a red or red-blue papule or nodule in a sun-exposed area (",
"    <a class=\"graphic graphic_picture graphicRef50573 graphicRef70535 graphicRef52988 \" href=\"mobipreview.htm?2/3/2106\">",
"     picture 6A-C",
"    </a>",
"    ). An increased risk for MCC in the organ transplant population was suggested by the findings of a review that found that the ratio of posttransplant melanoma to MCC was 6:1 in organ transplant recipients, compared to 65:1 in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/39\">",
"     39",
"    </a>",
"    ]. Further studies are necessary to determine the relative risk for MCC in organ transplant recipients.",
"   </p>",
"   <p>",
"    MCC in organ transplant recipients occurs most commonly in males, on the head, neck, or extremities, and in patients with a history of another nonmelanoma skin cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The mean age for diagnosis is lower than in the general population (47 versus 68 years), and the mean time to lesion development after transplantation is approximately seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Merkel cell polyomavirus infection has been linked to the development of MCC. Additional studies are necessary to explore the relationship between this viral infection and MCC in organ transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6712?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin\", section on 'Merkel cell polyomavirus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297499\">",
"    <span class=\"h1\">",
"     OTHER CANCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased rates of sebaceous carcinoma, cutaneous T and B cell lymphomas, angiosarcoma, malignant fibrous histiocytoma, leiomyosarcoma, and natural killer cell lymphoma in organ transplant recipients have been proposed by some authors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/7\">",
"     7",
"    </a>",
"    ]. However, additional studies are necessary to validate this assertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7860421\">",
"    <span class=\"h1\">",
"     ROLE OF SPECIFIC IMMUNOSUPPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a role of immunosuppression as an inciting factor for the development of skin cancer in organ transplant recipients is generally accepted, the impact of specific immunosuppressive agents remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/1,7,9\">",
"     1,7,9",
"    </a>",
"    ]. Although the overall level of immunosuppression appears to be an important factor in the development of skin cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/12,42,43\">",
"     12,42,43",
"    </a>",
"    ], the contribution of individual immunosuppressive agents may not be equivalent (",
"    <a class=\"graphic graphic_table graphicRef62170 \" href=\"mobipreview.htm?18/12/18636\">",
"     table 2",
"    </a>",
"    ). Data from a retrospective study suggested that immunosuppression with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil may be associated with lower risk for skin malignancy compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    -based regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, a randomized trial identified a lower risk for skin malignancies in patients managed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    than with other immunosuppressive regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link&amp;anchor=H15#H15\">",
"     \"Development of malignancy following solid organ transplantation\", section on 'Type, extent, and duration of immunosuppressive therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2186?source=see_link&amp;anchor=H2294614#H2294614\">",
"     \"Management of skin cancer in solid organ transplant recipients\", section on 'Mammalian target of rapamycin (mTOR) inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link&amp;anchor=H19#H19\">",
"     \"Development of malignancy following solid organ transplantation\", section on 'Sirolimus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    has been linked to the development of skin cancer in multiple clinical studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/18,22,26,44,46-48\">",
"     18,22,26,44,46-48",
"    </a>",
"    ], and the results of laboratory studies have suggested that these agents may also influence the development of skin cancer through non-immunological pathways. Mutagenic effects have been observed following cellular exposure to the combination of ultraviolet light and azathioprine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/49-53\">",
"     49-53",
"    </a>",
"    ], and changes in cell morphology and inhibition of DNA repair, apoptosis, and p53 function have been associated with exposure to cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/7,54-56\">",
"     7,54-56",
"    </a>",
"    ]. Additional studies are necessary to determine the clinical relevance of these observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7860449\">",
"    <span class=\"h1\">",
"     VORICONAZOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    , a second-generation triazole broad spectrum antifungal medication commonly used after lung transplantation, has been linked with the development of aggressive squamous cell carcinomas in immunocompromised patients, including a renal transplant recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37832/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7860561\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organ transplant recipients require chronic immunosuppression, which contributes to an increased risk for skin cancer. More than 50 percent of organ transplant recipients develop at least one cutaneous malignancy. (See",
"      <a class=\"local\" href=\"#H7860379\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7860386\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) account for the majority of skin cancers in organ transplant recipients. Multiple factors, including patient specific characteristics, the intensity and duration of immunosuppression, and geographic location influence the risk for the development of these lesions. (See",
"      <a class=\"local\" href=\"#H7860393\">",
"       'Squamous cell and basal cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The appearance of skin cancer lesions in organ transplant recipients generally resembles lesions in immunocompetent patients. SCC, BCC, melanoma and Merkel cell carcinoma frequently develop on sun-exposed areas. The lower legs are a common site of involvement in Kaposi&rsquo;s sarcoma. (See",
"      <a class=\"local\" href=\"#H7860393\">",
"       'Squamous cell and basal cell carcinoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7860400\">",
"       'Melanoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2293501\">",
"       'Kaposi's sarcoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7860407\">",
"       'Merkel cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The impact of specific immunosuppressants on the development of skin cancer is unclear. Evidence from some studies suggests that the risk for skin malignancy may be lower with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -based regimens than for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      -based regimens, respectively. (See",
"      <a class=\"local\" href=\"#H7860421\">",
"       'Role of specific immunosuppressants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/1\">",
"      Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/2\">",
"      Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/3\">",
"      Greenberg JN, Zwald FO. Management of Skin Cancer in Solid-organ Transplant Recipients: A Multidisciplinary Approach. Dermatol Clin 2011; 29:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/4\">",
"      Moloney FJ, Comber H, O'Lorcain P, et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/5\">",
"      Moosa MR. Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation. Medicine (Baltimore) 2005; 84:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/6\">",
"      Espa&ntilde;a A, Mart&iacute;nez-Gonz&aacute;lez MA, Garc&iacute;a-Granero M, et al. A prospective study of incident nonmelanoma skin cancer in heart transplant recipients. J Invest Dermatol 2000; 115:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/7\">",
"      Athar M, Walsh SB, Kopelovich L, Elmets CA. Pathogenesis of nonmelanoma skin cancers in organ transplant recipients. Arch Biochem Biophys 2011; 508:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/8\">",
"      Ducloux D, Carron PL, Racadot E, et al. CD4 lymphocytopenia in long-term renal transplant recipients. Transplant Proc 1998; 30:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/9\">",
"      Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients--where do we stand today? Am J Transplant 2008; 8:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/10\">",
"      Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996; 61:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/11\">",
"      Ramsay HM, Fryer AA, Hawley CM, et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/12\">",
"      Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102:III222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/13\">",
"      Harwood CA, Proby CM, McGregor JM, et al. Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series. J Am Acad Dermatol 2006; 54:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/14\">",
"      Brewer JD, Colegio OR, Phillips PK, et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol 2009; 145:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/15\">",
"      Moosa MR, Gralla J. Skin cancer in renal allograft recipients--experience in different ethnic groups residing in the same geographical region. Clin Transplant 2005; 19:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/16\">",
"      Glover MT, Deeks JJ, Raftery MJ, et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997; 349:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/17\">",
"      Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/18\">",
"      Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 2002; 8:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/19\">",
"      Ramsay HM, Fryer AA, Hawley CM, et al. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/20\">",
"      Ramsay HM, Fryer AA, Reece S, et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000; 36:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/21\">",
"      Fortina AB, Piaserico S, Caforio AL, et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol 2004; 140:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/22\">",
"      Wisgerhof HC, Edelbroek JR, de Fijter JW, et al. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 2010; 89:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/23\">",
"      Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/24\">",
"      Gogia R, Binstock M, Hirose R, et al. Fitzpatrick skin phototype is an independent predictor of squamous cell carcinoma risk after solid organ transplantation. J Am Acad Dermatol 2013; 68:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/25\">",
"      Tessari G, Naldi L, Boschiero L, et al. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. Arch Dermatol 2010; 146:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/26\">",
"      Jensen P, Hansen S, M&oslash;ller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/27\">",
"      Wisgerhof HC, van der Boog PJ, de Fijter JW, et al. Increased risk of squamous-cell carcinoma in simultaneous pancreas kidney transplant recipients compared with kidney transplant recipients. J Invest Dermatol 2009; 129:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/28\">",
"      Perera GK, Child FJ, Heaton N, et al. Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients. Br J Dermatol 2006; 154:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/29\">",
"      Laing ME, Dicker P, Moloney FJ, et al. Association of methylenetetrahydrofolate reductase polymorphism and the risk of squamous cell carcinoma in renal transplant patients. Transplantation 2007; 84:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/30\">",
"      Nindl I, Gottschling M, Stockfleth E. Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers 2007; 23:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/31\">",
"      M&uuml;hleisen B, Petrov I, Frigerio S, et al. Pronounced allelic imbalance at D9S162 in skin squamous cell carcinoma of organ transplant recipients. Arch Dermatol 2012; 148:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/32\">",
"      de Graaf YG, Rebel H, Elghalbzouri A, et al. More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. Exp Dermatol 2008; 17:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/33\">",
"      Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/34\">",
"      Zwald FO, Christenson LJ, Billingsley EM, et al. Melanoma in solid organ transplant recipients. Am J Transplant 2010; 10:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/35\">",
"      Le Mire L, Hollowood K, Gray D, et al. Melanomas in renal transplant recipients. Br J Dermatol 2006; 154:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/36\">",
"      Hollenbeak CS, Todd MM, Billingsley EM, et al. Increased incidence of melanoma in renal transplantation recipients. Cancer 2005; 104:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/37\">",
"      Vajdic CM, van Leeuwen MT, Webster AC, et al. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev 2009; 18:2297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/38\">",
"      Penn I. Transmission of cancer from organ donors. Ann Transplant 1997; 2:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/39\">",
"      Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev 1999; 8:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/40\">",
"      Kanitakis J, Euvrard S, Chouvet B, et al. Merkel cell carcinoma in organ-transplant recipients: report of two cases with unusual histological features and literature review. J Cutan Pathol 2006; 33:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/41\">",
"      Penn I, First MR. Merkel's cell carcinoma in organ recipients: report of 41 cases. Transplantation 1999; 68:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/42\">",
"      Gallagher MP, Kelly PJ, Jardine M, et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010; 21:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/43\">",
"      Marc&eacute;n R, Galeano C, Fern&aacute;ndez-Rodriguez A, et al. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. Transplant Proc 2010; 42:3055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/44\">",
"      Einollahi B, Nemati E, Lessan-Pezeshki M, et al. Skin cancer after renal transplantation: Results of a multicenter study in Iran. Ann Transplant 2010; 15:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/45\">",
"      Salgo R, Gossmann J, Sch&ouml;fer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/46\">",
"      Taylor AE, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol 1992; 72:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/47\">",
"      Doesch AO, M&uuml;ller S, Konstandin M, et al. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal. Transplant Proc 2010; 42:3694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/48\">",
"      Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/49\">",
"      Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987; 44:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/50\">",
"      Brem R, Li F, Karran P. Reactive oxygen species generated by thiopurine/UVA cause irreparable transcription-blocking DNA lesions. Nucleic Acids Res 2009; 37:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/51\">",
"      Zhang X, Jeffs G, Ren X, et al. Novel DNA lesions generated by the interaction between therapeutic thiopurines and UVA light. DNA Repair (Amst) 2007; 6:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/52\">",
"      Ren X, Xu YZ, Karran P. Photo-oxidation of 6-thioguanine by UVA: the formation of addition products with low molecular weight thiol compounds. Photochem Photobiol 2010; 86:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/53\">",
"      O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/54\">",
"      Yarosh DB, Pena AV, Nay SL, et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/55\">",
"      Norman KG, Canter JA, Shi M, et al. Cyclosporine A suppresses keratinocyte cell death through MPTP inhibition in a model for skin cancer in organ transplant recipients. Mitochondrion 2010; 10:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/56\">",
"      Wu X, Nguyen BC, Dziunycz P, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010; 465:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/57\">",
"      Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37832/abstract/58\">",
"      Vanacker A, Fabr&eacute; G, Van Dorpe J, et al. Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant 2008; 8:877.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16332 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-D201336892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37832=[""].join("\n");
var outline_f36_60_37832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7860561\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7860379\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7860386\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7860393\">",
"      SQUAMOUS CELL AND BASAL CELL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H442714\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H442687\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7860400\">",
"      MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2293501\">",
"      KAPOSI'S SARCOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7860407\">",
"      MERKEL CELL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2297499\">",
"      OTHER CANCERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7860421\">",
"      ROLE OF SPECIFIC IMMUNOSUPPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7860449\">",
"      VORICONAZOLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7860561\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/16332\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16332|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/34/39464\" title=\"picture 1A\">",
"      Squamous cell carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/37/41553\" title=\"picture 1B\">",
"      Cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/15/40191\" title=\"picture 1C\">",
"      Squamous cell carcinoma skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/29/41428\" title=\"picture 2\">",
"      Actinic damage renal transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/50/17188\" title=\"picture 3A\">",
"      Superficial basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/62/35812\" title=\"picture 3B\">",
"      Superficial basal cell CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/56/17283\" title=\"picture 3C\">",
"      Nodular basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/33/533\" title=\"picture 3D\">",
"      Infiltrative basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/13/43217\" title=\"picture 3E\">",
"      Large basal cell carcinoma on nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/28/44483\" title=\"picture 3F\">",
"      Large basal cell carcinoma on ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/3/37939\" title=\"picture 4A\">",
"      Superficial spreading melanoma 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/53/850\" title=\"picture 4B\">",
"      Superficial spreading melanoma 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/31/26098\" title=\"picture 4C\">",
"      Subungual melanoma - advanced",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/27/18866\" title=\"picture 5A\">",
"      Classic Kaposi sarcoma - papules and plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/21/35152\" title=\"picture 5B\">",
"      Classic Kaposi sarcoma - patches and plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/37/16979\" title=\"picture 5C\">",
"      Classic Kaposi sarcoma - nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/41/8852\" title=\"picture 6A\">",
"      Merkel cell carcinoma - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/61/2001\" title=\"picture 6B\">",
"      Merkel cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/49/25362\" title=\"picture 6C\">",
"      Merkel cell carcinoma - forearm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16332|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/37/15963\" title=\"table 1\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/12/18636\" title=\"table 2\">",
"      Immunosuppressants and skin cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment?source=related_link\">",
"      Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6712?source=related_link\">",
"      Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2186?source=related_link\">",
"      Management of skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/20/16713?source=related_link\">",
"      Skin examination and clinical features of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_60_37833="Etiology, clinical features, and diagnosis of neonatal hypertension";
var content_f36_60_37833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology, clinical features, and diagnosis of neonatal hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37833/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37833/contributors\">",
"     Joseph T Flynn, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37833/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37833/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37833/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37833/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/60/37833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2915529\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension can be detected in 1 to 2.5 percent of all neonates (both term and preterm infants) admitted to neonatal intensive care units (NICUs). The clinician needs to be knowledgeable about normative blood pressure (BP) values, the optimal method to measure BP in newborns, the underlying etiologies, and clinical manifestations, in order to identify and treat neonatal hypertension.",
"   </p>",
"   <p>",
"    The definition, etiology, clinical features, and diagnostic evaluation of neonatal hypertension will be reviewed here. Treatment of hypertension in infants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/59/42936?source=see_link\">",
"     \"Management of hypertension in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915536\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children and adolescents, hypertension is defined as systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic blood pressure (BP) &ge;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile based on normative data for age, gender, and weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although this operative definition may also be used to define neonatal hypertension, there is a lack of robust normative BP data in this age group. In addition, there are a number of factors that affect normal BP values during the neonatal period (defined as the first 28 days of life). As a result, it is challenging to assemble reliable normative data for clinical use in this age group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915543\">",
"    <span class=\"h2\">",
"     Normal BP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal BP in newborns varies with gestational age, postmenstrual (also referred to as postconceptual) age, and birth weight. BP values increase following birth, with greater rates of increase seen in preterm infants compared to term infants.",
"   </p>",
"   <p>",
"    Useful data on BP in newborns were obtained in a study of 608 newborns admitted to 14 NICUs in the Philadelphia area (",
"    <a class=\"graphic graphic_figure graphicRef50321 \" href=\"mobipreview.htm?11/3/11312\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71407 \" href=\"mobipreview.htm?38/24/39311\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/2\">",
"     2",
"    </a>",
"    ]. Systolic BP and diastolic BP were measured by oscillometric device every eight hours for 1 to 99 days after delivery. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On day one, systolic and diastolic BP correlated strongly with birth weight and gestational age.",
"     </li>",
"     <li>",
"      During the first five days after birth, systolic BP and diastolic BP progressively rose by 2.2 to 2.7",
"      <span class=\"nowrap\">",
"       mmHg/day",
"      </span>",
"      and 1.6 to 2.0",
"      <span class=\"nowrap\">",
"       mmHg/day,",
"      </span>",
"      respectively, regardless of gestational age or birth weight.",
"     </li>",
"     <li>",
"      Systolic and diastolic BP continued to increase after the fifth day of age, but at more gradual increments (0.24 to 0.27",
"      <span class=\"nowrap\">",
"       mmHg/day",
"      </span>",
"      and 0 to 0.15",
"      <span class=\"nowrap\">",
"       mmHg/day,",
"      </span>",
"      respectively).",
"     </li>",
"     <li>",
"      In a multiple regression analysis, the primary determinant of BP was postconceptual age (gestational plus postnatal age) (",
"      <a class=\"graphic graphic_figure graphicRef62005 \" href=\"mobipreview.htm?22/50/23343\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were noted in a study of 373 hemodynamically stable infants (292 preterm and 81 term neonates) admitted to the NICU, in whom BP data were obtained utilizing an oscillometric device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/3\">",
"     3",
"    </a>",
"    ]. In this cohort, BP on day one of life correlated with gestational age and birth weight. In all infants regardless of gestational age, BP increased at a faster rate over the first week of life, followed by subsequent slowing. The rate of rise was more rapid in preterm infants compared with term infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthy term infants cared for in the normal nursery demonstrate a somewhat different pattern from the above studies. This was illustrated in an Australian prospective study of 406 term infants with a mean gestational age of 40 weeks born between 2003 and 2005, in whom blood pressure measurements were determined by oscillometry methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/5\">",
"     5",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 12 to 24 hours of life, median systolic, diastolic, and mean BPs were 65 (range 46 to 94), 45 (range 24 to 57), and 48 (range 31 to 63), respectively. Unlike what was seen in the studies of preterm infants, no difference in BP was seen on day one of life based on birth weight, length, or gestational age.",
"     </li>",
"     <li>",
"      Blood pressure measurements increased over the next four successive days by 1 to 2",
"      <span class=\"nowrap\">",
"       mmHg/day.",
"      </span>",
"      On days two, three, and four of life, median systolic BP measurements were 68, 69.5, and 70, respectively; median diastolic BPs were 43, 44.5, and 46, respectively; and median mean BPs were 51, 52, and 54, respectively. The differences between days three and four were not significant, suggesting an earlier leveling off of BP than observed in preterm infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the following observations about normal neonatal BP can be concluded from the above studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary determinant of neonatal BP is postconceptional age.",
"     </li>",
"     <li>",
"      In neonates admitted to the NICU, BP varies with gestational age, postconceptional age, and birth weight. In all infants regardless of gestation, the rise in BP is higher during the first week of life. The rate of rise is more rapid in preterm compared with term infants.",
"     </li>",
"     <li>",
"      In healthy term infants, BP does not vary based on growth parameters or gestational age. BP does increase over the first three to four days of life but levels off sooner than what is observed in preterm infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results demonstrate how challenging it is to establish normative values for neonatal BP, especially in preterm infants, because of the effects of gestational age and maturation on BP values. These issues, plus the lack of large scale, prospective, multicenter studies of neonatal BP, further complicate the problem of defining normative BP data for neonates, especially premature and ill term infants.",
"   </p>",
"   <p>",
"    Nevertheless, based on a review of these data, a reference table of normal BP values at or after two weeks of age in infants between 26 and 44 weeks postconceptional age has been published (",
"    <a class=\"graphic graphic_table graphicRef76354 \" href=\"mobipreview.htm?15/56/16270\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/6\">",
"     6",
"    </a>",
"    ]. This table, which is based on the best available data through 2010, can be used clinically to identify infants with hypertension defined as persistent BP elevation greater than the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile. These infants require further evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment. (See",
"    <a class=\"local\" href=\"#H198347821\">",
"     'Evaluation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/59/42936?source=see_link\">",
"     \"Management of hypertension in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915550\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of neonatal hypertension varies depending upon the clinical setting. In otherwise healthy term infants, hypertension is exceedingly uncommon with a reported rate of 0.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In infants admitted to a NICU, the incidence is higher with reported rates ranging from 0.7 to 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. Risk factors for hypertension in patients admitted to the NICU include low gestational age and birth weight, specific diseases (eg, bronchopulmonary dysplasia [BPD], cardiac disease, and renal injury), use of umbilical artery catheters and increasing severity of illness.",
"   </p>",
"   <p>",
"    In an analysis of data from Pediatric Health Information System of 123,847 infants discharged from NICUs between 2005 and 2009, 1.7 percent had a diagnosis of hypertension encoded at the time of discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/12\">",
"     12",
"    </a>",
"    ]. After patients with cardiac disease were omitted, 1 percent of patients (n = 764) were diagnosed with hypertension of the remaining 78,986 patients cared for at 36 different institutions. In a multivariate analysis of these hypertensive patients without cardiac disease, risk factors for hypertension included low birth weight, renal disease or failure, neonatal abstinence syndrome, the use of extracorporeal membrane oxygenation, and increasing severity of illness.",
"   </p>",
"   <p>",
"    In a retrospective Australian study of 2572 newborn infants born between 2001 and 2005, and admitted to the NICU, 1.3 percent of infants were diagnosed with hypertension (defined as systolic or mean blood pressure (BP) &gt;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile for gestational age) at a median postnatal age of five days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/11\">",
"     11",
"    </a>",
"    ]. Hypertensive infants were more likely to have a lower gestational age, birth weight, and length than normotensive infants. Other factors associated with hypertension included antenatal steroid administration, maternal hypertension, umbilical arterial catheterization, postnatal acute renal injury, patent ductus arteriosus, and BPD.",
"   </p>",
"   <p>",
"    Hypertension is also reported after NICU discharge. In a study of 654 infants seen in a neonatal follow-up clinic, 17 (2.6 percent) were found to have hypertension (defined as systolic BP &gt;113 mmHg by Doppler) at a mean postconceptional age of 49 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/10\">",
"     10",
"    </a>",
"    ]. Compared to a control group of 212 normotensive infants, the hypertensive infants tended to have lower birth weights, lower one minute Apgar scores, and longer lengths of stay in the NICU, but none of the differences were statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915557\">",
"    <span class=\"h1\">",
"     MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparison of an infant's blood pressure (BP) to normative values requires proper measurement. BP can be measured invasively or noninvasively. The ideal setting to measure BP is while the infant is sleeping or resting, because crying, pain, feeding, and agitation all can increase BP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915564\">",
"    <span class=\"h2\">",
"     Intra-arterial measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct intraarterial measurement through a catheter placed in the aorta or the radial artery is the most accurate technique. It also provides continuous readings. The degree to which radial pressures correlate with aortic pressures is uncertain. In adults, radial artery systolic BP measurements may be 20 to 30 percent higher than central values, although mean and diastolic measurements are comparable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/14\">",
"     14",
"    </a>",
"    ]. However, radial pressures appear to more closely mimic aortic pressures in newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications associated with intraarterial catheters include thrombosis and infection. Thus, they should be used to monitor BP only when the catheter is needed for a significant clinical indication, such as frequent blood sampling, hypotension requiring pressor support, or severe hypertension requiring treatment with intravenous antihypertensives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915571\">",
"    <span class=\"h2\">",
"     Noninvasive measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous noninvasive devices are available to measure blood pressure. The most common technique is oscillometry, which permits continuous measurement of blood pressure and correlates well with direct measurements. Automated oscillometric devices measure the mean arterial pressure and calculate the systolic and diastolic pressures. The algorithms used for these calculations vary between manufacturers, so different devices may give different BP values in the same patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915578\">",
"    <span class=\"h3\">",
"     Cuff size",
"    </span>",
"    &nbsp;&mdash;&nbsp;A critical component of noninvasive blood pressure measurement is use of an appropriate-size cuff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/1\">",
"     1",
"    </a>",
"    ]. The cuff bladder should measure two-thirds the length of the extremity, and 0.44 to 0.55 of the arm circumference. If the choice is between a cuff that is too small or one that is too large, use of the larger cuff will result in less error. Most normal blood pressure values are derived from upper arm measurements. Thus, BP usually is measured in an arm. In the term infant with a maximum arm circumference of 10 cm, the usual dimensions of an appropriated-size cuff bladder are 4 cm in width and 8 cm in length [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a leg is used, an appropriate size cuff should be selected, that is, one that is two-thirds the length of the extremity. With appropriate size cuffs, lower- and upper-extremity BPs are nearly identical in the neonatal period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/16\">",
"     16",
"    </a>",
"    ]. The medical record should note the site of measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112801316\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For non-critically ill infants in whom hypertension is suspected, we use the following standard protocol to measure BP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      BP measured by oscillometric device",
"     </li>",
"     <li>",
"      BP measurement preferentially performed 1.5 hours after a feed or medical intervention",
"     </li>",
"     <li>",
"      Infant lying in a prone or supine position",
"     </li>",
"     <li>",
"      Use of an appropriate sized BP cuff",
"     </li>",
"     <li>",
"      BP measurement performed in the right upper arm",
"     </li>",
"     <li>",
"      After cuff placement, the blood pressure should be measured several minutes after the infant has settled into a calm state.",
"     </li>",
"     <li>",
"      BP measurement performed while the infant is asleep or in quiet awake state",
"     </li>",
"     <li>",
"      Three successive BP readings are obtained at 2 min intervals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915585\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although numerous causes have been identified, the most common causes of neonatal hypertension are umbilical artery catheter-associated thromboembolism, chronic lung disease and renal parenchymal disease (",
"    <a class=\"graphic graphic_table graphicRef51246 \" href=\"mobipreview.htm?26/11/26813\">",
"     table 2",
"    </a>",
"    ). However, sometimes no cause is identified. In patients with no identified cause, hypertension may be due to the presence of an undetectable renovascular event. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915592\">",
"    <span class=\"h2\">",
"     Vascular disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112801428\">",
"    <span class=\"h3\">",
"     UAC-associated thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common renovascular abnormality associated with neonatal hypertension is thrombosis associated with umbilical artery catheter (UAC) placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Thrombi that form on the tip or surface of the catheter can partially or completely occlude the abdominal aorta, thereby decreasing renal perfusion. These thrombi may then embolize into the renal vasculature, resulting in local areas of infarction and increased renin release.",
"   </p>",
"   <p>",
"    Thrombi are common in newborns with UACs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study, 18 of 19 patients had evidence of thrombus formation detected by contrast aortography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/20\">",
"       20",
"      </a>",
"      ]. In addition, there were several instances of clot fragmentation and embolization. Thrombosis was also seen at autopsy in 7 of 12 infants who had died.",
"     </li>",
"     <li>",
"      In a study using serial ultrasonography, abdominal aortic thrombi were detected in 32 of 99 consecutive patients (32 percent) after removal of an UAC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, 11 of 12 newborns with hypertension had renal artery thrombosis demonstrated by radionuclide scan",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angiography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/21\">",
"       21",
"      </a>",
"      ]. Blood pressure (BP) normalized with antihypertensive therapy and remained normal after discontinuation of treatment. At follow-up at a mean age of 5.75 years, scans remained abnormal, and five patients had unilateral renal atrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of UAC-associated thrombosis increases with increasing duration of UAC use, high UAC placement (ie, catheter above the diaphragm versus low placement, just above the aortic bifurcation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/22\">",
"     22",
"    </a>",
"    ], the lack of use of heparinized infusate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/23\">",
"     23",
"    </a>",
"    ], and trauma to the endothelial surface while the catheter is in situ or during catheter insertion. In addition to hypertension, other serious long-term sequelae of umbilical artery catheterization include coarctation of the abdominal aorta due to scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/24\">",
"     24",
"    </a>",
"    ] and aneurysmal dilatation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112801435\">",
"    <span class=\"h3\">",
"     Other vascular causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other vascular causes of neonatal hypertension include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coarctation of the aorta, which may be recognized by absent or diminished femoral pulses or a differential in BP between the upper and lower extremities. A rare variety of coarctation is the mid-aorta syndrome, in which there is segmental narrowing of the distal thoracic aorta or abdominal aorta and stenosis of branch vessels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal vein thrombosis, which classically presents with the triad of a flank mass, gross hematuria, and thrombocytopenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/16/14600?source=see_link&amp;anchor=H7#H7\">",
"       \"Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn\", section on 'Renal vein thrombosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal artery stenosis is a rare cause of neonatal hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Fibromuscular dysplasia accounts for the majority of cases of renal artery stenosis in childhood, although renal artery stenosis can be seen in genetic syndromes such as neurofibromatosis and Williams Syndrome. Renovascular disease is sometimes associated with congenital rubella infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10010?source=see_link&amp;anchor=H28489691#H28489691\">",
"       \"Congenital rubella syndrome: Clinical features and diagnosis\", section on 'Vascular effects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42105?source=see_link&amp;anchor=H17#H17\">",
"       \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\", section on 'Renovascular disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rare vascular causes include congenital abdominal aortic aneurysm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/33\">",
"       33",
"      </a>",
"      ] and idiopathic arterial calcification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915599\">",
"    <span class=\"h2\">",
"     Renal parenchymal conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal parenchymal conditions associated with hypertension can be separated into congenital and acquired disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198347405\">",
"    <span class=\"h3\">",
"     Congenital disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital renal and urologic disorders that are associated with neonatal hypertension include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polycystic kidney disease &ndash; Both autosomal recessive (ARPKD) and autosomal dominant (ADPKD) polycystic kidney disease are frequently accompanied by hypertension. In a large series of children with ARPKD diagnosed after 1990 (median age 5.4 years), 65 percent had hypertension, which was detected at a median age of 16 days (range 5 to 165 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/35\">",
"       35",
"      </a>",
"      ]. ADPKD also can present in newborns, and in these patients, hypertension, although rare, may be present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29913?source=see_link&amp;anchor=H25823482#H25823482\">",
"       \"Autosomal recessive polycystic kidney disease in children\", section on 'Hypertension'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28584?source=see_link&amp;anchor=H104026438#H104026438\">",
"       \"Autosomal dominant polycystic kidney disease in children\", section on 'Renal manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast, hypertension is unusual in newborns with unilateral multicystic dysplastic kidney, although some cases have been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/36\">",
"       36",
"      </a>",
"      ]. It sometimes occurs in later infancy or childhood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2712?source=see_link&amp;anchor=H3#H3\">",
"       \"Renal cystic diseases in children\", section on 'Multicystic dysplastic kidney'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obstructive uropathy &ndash; Hypertension may accompany obstructive uropathy, such as ureteropelvic junction obstruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. The BP usually normalizes with surgical correction of the obstruction, but persistent hypertension has been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26680?source=see_link\">",
"       \"Congenital ureteropelvic junction obstruction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915620\">",
"    <span class=\"h3\">",
"     Acquired renal parenchymal diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired renal diseases associated with neonatal hypertension include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute kidney injury &ndash; Approximately 10 to 20 percent of newborns with acute kidney injury have hypertension. The most common cause in newborns is acute tubular necrosis, which is usually due to perinatal asphyxia, sepsis, or other causes of inadequate renal perfusion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27114?source=see_link&amp;anchor=H4#H4\">",
"       \"Acute kidney injury (acute renal failure) in the newborn\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephrocalcinosis is common in preterm infants. Affected infants rarely have hypertension, unless an obstructive calculus forms. However, infants with persistent nephrocalcinosis may develop hypertension. This was illustrated in a series of 83 of 201 preterm infants who had persistent nephrocalcinosis at term postmenstrual age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/41\">",
"       41",
"      </a>",
"      ]. Of these, systolic and diastolic blood pressures were &gt;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile at one and two years of age in 39 and 48 percent and 30 and 34 percent, respectively. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26356?source=see_link\">",
"       \"Nephrocalcinosis in neonates\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915634\">",
"    <span class=\"h2\">",
"     Bronchopulmonary dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic hypertension is common in infants with bronchopulmonary dysplasia (BPD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. The incidence ranges from 5 to 40 percent, depending upon birth weight and severity of lung disease.",
"   </p>",
"   <p>",
"    In a study of 73 very low birth weight infants (birth weight &lt;1500 g), the incidence of hypertension was twice as great in those with BPD (n = 41 infants) compared with the overall cohort (12 versus 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/44\">",
"     44",
"    </a>",
"    ]. The risk of hypertension appears to increase with severity of pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of hypertension in BPD is uncertain and may include increases in sympathetic activity and angiotensin II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/45\">",
"     45",
"    </a>",
"    ]. The association between hypertension and more severe BPD also suggests that hypoxemia may play a role, which may be based on a genetic predisposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/24/15753?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of bronchopulmonary dysplasia\", section on 'Systemic blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertension may not present until four to five months of age. It often is associated with the use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    or other glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. If related to these drugs, it usually abates when therapy is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44630?source=see_link\">",
"     \"Hypertension in infants between one month and one year of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915641\">",
"    <span class=\"h2\">",
"     Iatrogenic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic causes of neonatal hypertension include fluid overload and medications. Medications that can cause hypertension include corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/47-49\">",
"     47-49",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/0/34821?source=see_link\">",
"     pancuronium",
"    </a>",
"    , and topical mydriatic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915648\">",
"    <span class=\"h2\">",
"     Endocrine causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrine causes include hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/51\">",
"     51",
"    </a>",
"    ] and mineralocorticoid excess, which, in neonates, is most often due to congenital adrenal hyperplasia (CAH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/52\">",
"     52",
"    </a>",
"    ]. Hypertension and frequently hypokalemia, which are due to excess deoxycorticosterone, are typically present in CAH due to CYP11B1 (11-beta-hydroxylase) and CYP17 (17-alpha-hydroxylase) deficiencies. In neonates, CYP11B1 deficiency also is associated with ambiguous genitalia in females (clitoral enlargement, labial fusion, formation of a urogenital sinus), and penile enlargement in males. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15878?source=see_link\">",
"     \"Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35641?source=see_link&amp;anchor=H2#H2\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\", section on 'CYP17 deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915655\">",
"    <span class=\"h2\">",
"     Miscellaneous causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other reported causes of neonatal hypertension include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Masses in or near the kidney, including mesoblastic nephroma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/53\">",
"       53",
"      </a>",
"      ], neuroblastoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/54\">",
"       54",
"      </a>",
"      ], and Wilms tumor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/55\">",
"       55",
"      </a>",
"      ]. (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=see_link\">",
"       \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2249?source=see_link\">",
"       \"Presentation, diagnosis, and staging of Wilms tumor\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased intracranial pressure from cerebral edema or intracranial hemorrhage. (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=see_link\">",
"       \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypertension occurs in 40 to 60 percent of patients during extracorporeal membrane oxygenation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. The underlying mechanism is unknown but is believed to be multifactorial, including fluid overload, altered renal sodium and water handling. Development of hypertension does not appear to be related to increased plasma renin activity, sodium or colloid loads, or their rates of infusion.",
"     </li>",
"     <li>",
"      Approximately one-third to almost one-half of neonates has hypertension after closure of abdominal wall defects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/58\">",
"       58",
"      </a>",
"      ]. The mechanism is attributed to increased intra-abdominal pressure causing transient changes in renal blood flow, rennin-angiotensin system, urine flow, and increased catecholamine secretion. The hypertension is usually transient and does not require any antihypertensive medication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postoperative or procedural pain (eg, endotracheal intubation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/60\">",
"       60",
"      </a>",
"      ] or suctioning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]). (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31863?source=see_link\">",
"       \"Assessment of neonatal pain\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Maternal cocaine and heroin use have been reported to cause persistent neonatal hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/63\">",
"       63",
"      </a>",
"      ]. Withdrawal from long-term use of sedative",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      analgesics may also be associated with hypertension. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28746?source=see_link\">",
"       \"Infants of mothers with substance abuse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For infants receiving prolonged parenteral nutrition (TPN), hypertension may result from salt and water overload, or from hypercalcemia caused either directly by excessive calcium intake or indirectly by vitamin A or D intoxication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915662\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most hypertensive newborns are asymptomatic, and the diagnosis is made by routine blood pressure (BP) measurement. In patients with signs or symptoms, the magnitude of hypertension may not correlate with its presence or severity. These nonverbal patients may not manifest any symptoms even with severe hypertension.",
"   </p>",
"   <p>",
"    Hypertension may be associated with the following cardiorespiratory, neurologic, and renal symptoms, and nonspecific signs such as lethargy, poor feeding, apnea, and irritability (",
"    <a class=\"graphic graphic_table graphicRef78185 \" href=\"mobipreview.htm?13/18/13612\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/64\">",
"     64",
"    </a>",
"    ]. In some instances, the underlying cause of hypertension is also responsible for the associated clinical manifestations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiorespiratory signs include tachypnea, tachycardia, cyanosis, cardiomegaly, mottling, and, in severe cases, heart failure. Most resolve with correction of hypertension.",
"     </li>",
"     <li>",
"      Neurologic symptoms include irritability, lethargy, hypotonia, hypertonia, seizures, hemiparesis, nerve palsies, and hypertensive retinopathy (eg, vascular tortuosity, hemorrhages, exudates, and increased ratio of venous to arterial caliber) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/65\">",
"       65",
"      </a>",
"      ]. Some of these findings may be due to coexisting central nervous system abnormalities, such as intraventricular hemorrhage or cerebral thrombosis.",
"     </li>",
"     <li>",
"      Renal abnormalities include oliguria, polyuria, hematuria, sodium wasting, renal or bladder enlargement, and nephrotic range proteinuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/66\">",
"       66",
"      </a>",
"      ]. Acute kidney injury may cause hypertension and most of these findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915669\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the evaluation is to confirm the diagnosis of hypertension by repeated, accurate measurements. In general, the diagnosis is supported by three or more elevated blood pressure (BP) measurements over a 6- to 12-hour period. As noted previously, a standardized protocol for BP measurement when oscillometric devices are being used will help to ensure that accurate readings are obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H112801316\">",
"     'Our approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198347821\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of hypertension is confirmed, an evaluation is performed to identify the underlying cause of hypertension, which may potentially be corrected. This includes a focused history, followed by physical examination and selected laboratory testing and imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915676\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A focused history reviews pertinent prenatal exposures, neonatal course, and concurrent conditions. (See",
"    <a class=\"local\" href=\"#H2915585\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prenatal history examines the possibility of maternal use of prescribed and illicit drugs, history of perinatal asphyxia, or prenatal ultrasound findings indicative of congenital renal or urologic disease.",
"     </li>",
"     <li>",
"      Neonatal history reviews the use of umbilical arterial catheter, current and past medications, and the presence of concurrent conditions associated with hypertension (eg, bronchopulmonary dysplasia, and congenital anomalies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      syndromes associated with hypertension). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198347903\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination may indicate the primary etiology of hypertension and may also detect pathophysiologic effects of hypertension, such as heart failure, hypertensive retinopathy, or neurologic abnormality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All infants with hypertension should have blood pressures (BPs) measured in all four extremities to rule out coarctation of the aorta or an aortic thrombus occluding the thoracic or abdominal aorta. In these conditions, the femoral pulses typically are decreased or absent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link&amp;anchor=H1088178828#H1088178828\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Blood pressure and pulses'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal distension or mass might be indicative of obstructive uropathy, polycystic kidney disease, hematocolpos, or",
"      <span class=\"nowrap\">",
"       abdominal/renal",
"      </span>",
"      tumors.",
"     </li>",
"     <li>",
"      Signs of peripheral thrombi (eg, &ldquo;cath toes&rdquo;, bluish discoloration of the toes caused by decrease perfusion) may sometimes be seen in hypertension associated with a umbilical arterial catheter. &nbsp;",
"     </li>",
"     <li>",
"      Newborns with hyperthyroidism may have tachycardia, flushing, and low birth weight. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/97?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation and management of neonatal Graves' disease\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Newborns with CYP11B1 deficiency typically have ambiguous genitalia in females (clitoral enlargement, labial fusion, formation of a urogenital sinus), and penile enlargement in males. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15878?source=see_link&amp;anchor=H4#H4\">",
"       \"Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency\", section on 'Clinical presentation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=see_link&amp;anchor=H26#H26\">",
"       \"Evaluation of the infant with ambiguous genitalia\", section on 'Congenital adrenal hyperplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dysmorphic features may suggest an underlying syndrome (eg, Williams syndrome) that includes hypertension as one of its clinical manifestations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5287?source=see_link&amp;anchor=H17783481#H17783481\">",
"       \"Williams-Beuren syndrome\", section on 'Hypertension'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915683\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often the underlying cause is identified by the history and physical examination. Initial laboratory testing is directed towards assessing renal function and determining whether renal parenchymal disease is present. Routine testing includes urinalysis, urine culture, and measurement of blood urea nitrogen and serum creatinine, electrolytes, and calcium.",
"   </p>",
"   <p>",
"    In some infants with renal artery thrombosis or embolism associated with a UAC, hypertension may occur in the absence of hematuria, proteinuria, or azotemia. Thus, their absence does not exclude this mechanism of hypertension. Conversely, mild and transient hematuria, and proteinuria are common and nonspecific findings in ill newborns, and they cannot be used to diagnose renovascular disease.",
"   </p>",
"   <p>",
"    Further testing is guided by the initial evaluation and individualized for the infant, and may include measurement of thyroid function tests, serum aldosterone, and plasma renin activity. Other studies may be needed to detect neurologic, drug, endocrine, or metabolic causes of neonatal hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2915690\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal ultrasonography with Doppler evaluation is the imaging modality of choice in neonatal hypertension and should always be obtained as part of the initial evaluation, when the cause has not been ascertained by the initial evaluation. It can identify renal masses, urinary tract obstruction, tumors, calculi, and renal cystic disease. Doppler flow studies can assist in detecting renal and aortic thrombi, and monitoring their course. Doppler studies are also essential to the diagnosis of renal venous thrombosis.",
"   </p>",
"   <p>",
"    Radionuclide imaging is sometimes recommended when sonography is non-diagnostic. While a variety of isotopes are available to evaluate differential renal blood flow and glomerular filtration, useful diagnostic images are difficult to obtain in the neonatal period due to the immaturity of renal function. Given this, it may be best to defer radionuclide imaging until the infant has reached at least 44 weeks post-conceptional age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/30/32231?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Dynamic renal scan'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/30/32231?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Static renal scan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In infants with severe hypertension and no etiology detected by sonography, angiography should be considered. Although this test is invasive, it is the gold standard for the diagnosis of renovascular hypertension. Institutional expertise should guide the decision to perform angiography. In many instances, it will be appropriate to control the hypertension medically until the baby reaches a size at which angiography can be performed safely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/67\">",
"     67",
"    </a>",
"    ]. Noninvasive renal angiography, including computed tomography and magnetic resonance imaging, should not be ordered in infants because these techniques do not have sufficient resolution to reveal branch vessel disease in this age group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293485094\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An echocardiogram should be obtained to detect possible left ventricular hypertrophy, left ventricular systolic dysfunction, or left atrial dilation and aortomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/5\">",
"     5",
"    </a>",
"    ]. As in older children, detecting cardiac involvement would favor early institution of treatment with antihypertensive medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37833/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/59/42936?source=see_link&amp;anchor=H155183129#H155183129\">",
"     \"Management of hypertension in infants\", section on 'Who should be treated?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198348029\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal hypertension is defined as persistent systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic blood pressure (BP) that exceeds the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile for postconceptional age (",
"    <a class=\"graphic graphic_figure graphicRef62005 \" href=\"mobipreview.htm?22/50/23343\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76354 \" href=\"mobipreview.htm?15/56/16270\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2915536\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of neonatal hypertension varies depending upon the clinical setting. It is uncommon in healthy term infants with a reported incidence of 0.2 percent. The incidence is higher in infants who are admitted to the neonatal intensive care unit (0.7 to 3 percent), especially in very premature ill infants who are more likely to have risk factors for hypertension (eg, umbilical arterial catheter placement [UAC] and bronchopulmonary dysplasia [BPD]). (See",
"      <a class=\"local\" href=\"#H2915550\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      BP can be measured either directly through intra-arterial measurement or noninvasively. Each center that cares for neonates should establish a standard approach for obtaining BP to ensure accuracy and consistency. In our center, we obtain BP measurements while the infant is either asleep or in a quiet state, and in a prone or supine lying position. For non-critically ill infants, BP is measured by an oscillometric device after an appropriate sized BP cuff is positioned on the right upper arm and preferably 1.5 hours after a feed or medical intervention. (See",
"      <a class=\"local\" href=\"#H2915557\">",
"       'Measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are numerous causes of neonatal hypertension (",
"      <a class=\"graphic graphic_table graphicRef51246 \" href=\"mobipreview.htm?26/11/26813\">",
"       table 2",
"      </a>",
"      ). The most common etiology is umbilical artery catheter-associated thromboembolism, followed by chronic lung disease and renal parenchymal disease. (See",
"      <a class=\"local\" href=\"#H2915585\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most hypertensive newborns are asymptomatic. In those who are symptomatic, the magnitude of hypertension may not correlate with its presence or severity. Hypertension may be manifested by cardiorespiratory, neurologic, and renal symptoms, and nonspecific signs such as lethargy, poor feeding, apnea, and irritability (",
"      <a class=\"graphic graphic_table graphicRef78185 \" href=\"mobipreview.htm?13/18/13612\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2915662\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of hypertensions is confirmed by repeated accurate measurements that demonstrate either systolic or diastolic BP that persistently exceeds the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile for postconceptional age (",
"      <a class=\"graphic graphic_figure graphicRef62005 \" href=\"mobipreview.htm?22/50/23343\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef76354 \" href=\"mobipreview.htm?15/56/16270\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2915669\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of neonatal hypertension is confirmed, an evaluation is performed to identify the underlying cause of hypertension, which may potentially be corrected. This assessment includes a focused history, followed by physical examination and selected laboratory testing and imaging studies. (See",
"      <a class=\"local\" href=\"#H198347821\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/59/42936?source=see_link&amp;anchor=H195796885#H195796885\">",
"       \"Management of hypertension in infants\", section on 'Correcting underlying cause'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/1\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/2\">",
"      Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol 1995; 15:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/3\">",
"      Pejovic B, Peco-Antic A, Marinkovic-Eric J. Blood pressure in non-critically ill preterm and full-term neonates. Pediatr Nephrol 2007; 22:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/4\">",
"      Nwankwo MU, Lorenz JM, Gardiner JC. A standard protocol for blood pressure measurement in the newborn. Pediatrics 1997; 99:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/5\">",
"      Kent AL, Kecskes Z, Shadbolt B, Falk MC. Normative blood pressure data in the early neonatal period. Pediatr Nephrol 2007; 22:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/6\">",
"      Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management and outcome. Pediatr Nephrol 2012; 27:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/7\">",
"      American Academy of Pediatrics Committee on Fetus and Newborn: Routine evaluation of blood pressure, hematocrit, and glucose in newborns. Pediatrics 1993; 92:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/8\">",
"      Skalina ME, Kliegman RM, Fanaroff AA. Epidemiology and management of severe symptomatic neonatal hypertension. Am J Perinatol 1986; 3:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/9\">",
"      Singh HP, Hurley RM, Myers TF. Neonatal hypertension. Incidence and risk factors. Am J Hypertens 1992; 5:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/10\">",
"      Buchi KF, Siegler RL. Hypertension in the first month of life. J Hypertens 1986; 4:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/11\">",
"      Seliem WA, Falk MC, Shadbolt B, Kent AL. Antenatal and postnatal risk factors for neonatal hypertension and infant follow-up. Pediatr Nephrol 2007; 22:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/12\">",
"      Blowey DL, Duda PJ, Stokes P, Hall M. Incidence and treatment of hypertension in the neonatal intensive care unit. J Am Soc Hypertens 2011; 5:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/13\">",
"      MOSS AJ, DUFFIE ER Jr, EMMANOUILIDES G. BLOOD PRESSURE AND VASOMOTOR REFLEXES IN THE NEWBORN INFANT. Pediatrics 1963; 32:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/14\">",
"      Pauca AL, Wallenhaupt SL, Kon ND, Tucker WY. Does radial artery pressure accurately reflect aortic pressure? Chest 1992; 102:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/15\">",
"      Gevers M, Hack WW, Ree EF, et al. Arterial blood pressure wave forms in radial and posterior tibial arteries in critically ill newborn infants. J Dev Physiol 1993; 19:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/16\">",
"      Park MK, Lee DH. Normative arm and calf blood pressure values in the newborn. Pediatrics 1989; 83:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/17\">",
"      Goetzman BW, Stadalnik RC, Bogren HG, et al. Thrombotic complications of umbilical artery catheters: A clinical and radiographic study. Pediatrics 1975; 56:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/18\">",
"      Seibert JJ, Taylor BJ, Williamson SL, et al. Sonographic detection of neonatal umbilical-artery thrombosis: clinical correlation. AJR Am J Roentgenol 1987; 148:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/19\">",
"      Boo NY, Wong NC, Zulkifli SS, Lye MS. Risk factors associated with umbilical vascular catheter-associated thrombosis in newborn infants. J Paediatr Child Health 1999; 35:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/20\">",
"      Neal WA, Reynolds JW, Jarvis CW, Williams HJ. Umbilical artery catheterization: demonstration of arterial thrombosis by aortography. Pediatrics 1972; 50:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/21\">",
"      Adelman RD. Long-term follow-up of neonatal renovascular hypertension. Pediatr Nephrol 1987; 1:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/22\">",
"      Barrington KJ. Umbilical artery catheters in the newborn: effects of position of the catheter tip. Cochrane Database Syst Rev 2000; :CD000505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/23\">",
"      Barrington KJ. Umbilical artery catheters in the newborn: effects of heparin. Cochrane Database Syst Rev 2000; :CD000507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/24\">",
"      Adelman RD, Morrell RE. Coarctation of the abdominal aorta and renal artery stenosis related to an umbilical artery catheter placement in a neonate. Pediatrics 2000; 106:E36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/25\">",
"      Adelman RD. Abdominal aortic aneurysm 18 years after apparent resolution of an umbilical catheter-associated aortic thrombosis. J Pediatr 1998; 132:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/26\">",
"      Connolly JE, Wilson SE, Lawrence PL, Fujitani RM. Middle aortic syndrome: distal thoracic and abdominal coarctation, a disorder with multiple etiologies. J Am Coll Surg 2002; 194:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/27\">",
"      Sethna CB, Kaplan BS, Cahill AM, et al. Idiopathic mid-aortic syndrome in children. Pediatr Nephrol 2008; 23:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/28\">",
"      Mocan H, Beattie TJ, Murphy AV. Renal venous thrombosis in infancy: long-term follow-up. Pediatr Nephrol 1991; 5:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/29\">",
"      Hegde S, Wright C, Shenoy M, et al. Renovascular hypertension commencing during fetal life. Arch Dis Child Fetal Neonatal Ed 2007; 92:F301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/30\">",
"      Estepa R, Gallego N, Orte L, et al. Renovascular hypertension in children. Scand J Urol Nephrol 2001; 35:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/31\">",
"      Esterly JR, Oppenheimer EH. Vascular lesions in infants with congenital rubella. Circulation 1967; 36:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/32\">",
"      Daniels SR, Loggie JM, McEnery PT, Towbin RB. Clinical spectrum of intrinsic renovascular hypertension in children. Pediatrics 1987; 80:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/33\">",
"      Kim ES, Caiati JM, Tu J, et al. Congenital abdominal aortic aneurysm causing renovascular hypertension, cardiomyopathy, and death in a 19-day-old neonate. J Pediatr Surg 2001; 36:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/34\">",
"      Milner LS, Heitner R, Thomson PD, et al. Hypertension as the major problem of idiopathic arterial calcification of infancy. J Pediatr 1984; 105:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/35\">",
"      Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 2003; 111:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/36\">",
"      Sukthankar S, Watson AR. Unilateral multicystic dysplastic kidney disease: defining the natural history. Anglia Paediatric Nephrourology Group. Acta Paediatr 2000; 89:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/37\">",
"      Webb NJ, Lewis MA, Bruce J, et al. Unilateral multicystic dysplastic kidney: the case for nephrectomy. Arch Dis Child 1997; 76:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/38\">",
"      Munoz AI, Baralt JF, Melendez MT. Arterial hypertension in infants with hydronephrosis. Report of six cases. Am J Dis Child 1977; 131:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/39\">",
"      Braren V, West JC Jr, Boerth RC, Harmon CM. Management of children with hypertension from reflux or obstructive nephropathy. Urology 1988; 32:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/40\">",
"      Gilboa N, Urizar RE. Severe hypertension in newborn after pyeloplasty of hydronephrotic kidney. Urology 1983; 22:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/41\">",
"      Schell-Feith EA, Kist-van Holthe JE, van Zwieten PH, et al. Preterm neonates with nephrocalcinosis: natural course and renal function. Pediatr Nephrol 2003; 18:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/42\">",
"      Abman SH, Warady BA, Lum GM, Koops BL. Systemic hypertension in infants with bronchopulmonary dysplasia. J Pediatr 1984; 104:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/43\">",
"      Anderson AH, Warady BA, Daily DK, et al. Systemic hypertension in infants with severe bronchopulmonary dysplasia: associated clinical factors. Am J Perinatol 1993; 10:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/44\">",
"      Alagappan A, Malloy MH. Systemic hypertension in very low-birth weight infants with bronchopulmonary dysplasia: incidence and risk factors. Am J Perinatol 1998; 15:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/45\">",
"      Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 2002; 87:F15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/46\">",
"      Dagle JM, Fisher TJ, Haynes SE, et al. Cytochrome P450 (CYP2D6) genotype is associated with elevated systolic blood pressure in preterm infants after discharge from the neonatal intensive care unit. J Pediatr 2011; 159:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/47\">",
"      Smets K, Vanhaesebrouck P. Dexamethasone associated systemic hypertension in low birth weight babies with chronic lung disease. Eur J Pediatr 1996; 155:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/48\">",
"      Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics 2001; 108:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/49\">",
"      Greenough A, Emery EF, Gamsu HR. Dexamethasone and hypertension in preterm infants. Eur J Pediatr 1992; 151:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/50\">",
"      Merritt JC, Kraybill EN. Effect of mydriatics on blood pressure in premature infants. J Pediatr Ophthalmol Strabismus 1981; 18:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/51\">",
"      Pijnenburg MW, Zweens MJ, Bink MT, et al. Hypertensive encephalopathy in a patient with neonatal thyrotoxicosis. Eur J Pediatr 1999; 158:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/52\">",
"      Veenhoven RH, Vande Walle JG, Donckerwolcke RA, et al. A neonate with idiopathic hyperaldosteronism. Pediatr Nephrol 1991; 5:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/53\">",
"      Miller OF, Kolon TF. Hyperreninemia and congenital mesoblastic nephroma: case report and review of the literature. Urology 2000; 55:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/54\">",
"      Lindner W, Behnisch W, Kunz U, et al. Congenital neuroblastoma mimicking early onset sepsis. Eur J Pediatr 2001; 160:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/55\">",
"      Glick RD, Hicks MJ, Nuchtern JG, et al. Renal tumors in infants less than 6 months of age. J Pediatr Surg 2004; 39:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/56\">",
"      Boedy RF, Goldberg AK, Howell CG Jr, et al. Incidence of hypertension in infants on extracorporeal membrane oxygenation. J Pediatr Surg 1990; 25:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/57\">",
"      Becker JA, Short BL, Martin GR. Cardiovascular complications adversely affect survival during extracorporeal membrane oxygenation. Crit Care Med 1998; 26:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/58\">",
"      Adelman RD, Sherman MP. Hypertension in the neonate following closure of abdominal wall defects. J Pediatr 1980; 97:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/59\">",
"      Cachat F, Van Melle G, McGahren ED, et al. Arterial hypertension after surgical closure of omphalocele and gastroschisis. Pediatr Nephrol 2006; 21:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/60\">",
"      Marshall TA, Deeder R, Pai S, et al. Physiologic changes associated with endotracheal intubation in preterm infants. Crit Care Med 1984; 12:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/61\">",
"      Burgess GH, Oh W, Brann BS 4th, et al. Effects of phenobarbital on cerebral blood flow velocity after endotracheal suctioning in premature neonates. Arch Pediatr Adolesc Med 2001; 155:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/62\">",
"      Durand M, Sangha B, Cabal LA, et al. Cardiopulmonary and intracranial pressure changes related to endotracheal suctioning in preterm infants. Crit Care Med 1989; 17:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/63\">",
"      Horn PT. Persistent hypertension after prenatal cocaine exposure. J Pediatr 1992; 121:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/64\">",
"      Flynn JT. Neonatal hypertension: diagnosis and management. Pediatr Nephrol 2000; 14:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/65\">",
"      Skalina ME, Annable WL, Kliegman RM, Fanaroff AA. Hypertensive retinopathy in the newborn infant. J Pediatr 1983; 103:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/66\">",
"      Cachat F, Bogaru A, Micheli JL, et al. Severe hypertension and massive proteinuria in a newborn with renal artery stenosis. Pediatr Nephrol 2004; 19:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37833/abstract/67\">",
"      Bendel-Stenzel M, Najarian JS, Sinaiko AR. Renal artery stenosis in infants: long-term medical treatment before surgery. Pediatr Nephrol 1996; 10:147.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5001 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-57354D163F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37833=[""].join("\n");
var outline_f36_60_37833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H198348029\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2915529\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2915536\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915543\">",
"      Normal BP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2915550\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2915557\">",
"      MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915564\">",
"      Intra-arterial measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915571\">",
"      Noninvasive measurement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2915578\">",
"      - Cuff size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112801316\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2915585\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915592\">",
"      Vascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112801428\">",
"      - UAC-associated thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112801435\">",
"      - Other vascular causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915599\">",
"      Renal parenchymal conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H198347405\">",
"      - Congenital disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2915620\">",
"      - Acquired renal parenchymal diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915634\">",
"      Bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915641\">",
"      Iatrogenic causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915648\">",
"      Endocrine causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915655\">",
"      Miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2915662\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2915669\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H198347821\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915676\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H198347903\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915683\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2915690\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293485094\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H198348029\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5001\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5001|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/3/11312\" title=\"figure 1\">",
"      Neonatal BP gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/24/39311\" title=\"figure 2\">",
"      Neonatal BP birth weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/50/23343\" title=\"figure 3\">",
"      BP by post-conceptual age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5001|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/56/16270\" title=\"table 1\">",
"      Neonatal blood pressures and potential treatment parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/11/26813\" title=\"table 2\">",
"      Causes of neonatal hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/18/13612\" title=\"table 3\">",
"      Clin features NB hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27114?source=related_link\">",
"      Acute kidney injury (acute renal failure) in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31863?source=related_link\">",
"      Assessment of neonatal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28584?source=related_link\">",
"      Autosomal dominant polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15878?source=related_link\">",
"      Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10010?source=related_link\">",
"      Congenital rubella syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26680?source=related_link\">",
"      Congenital ureteropelvic junction obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42105?source=related_link\">",
"      Epidemiology, risk factors, and etiology of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/97?source=related_link\">",
"      Evaluation and management of neonatal Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/30/32231?source=related_link\">",
"      Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44630?source=related_link\">",
"      Hypertension in infants between one month and one year of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/24/15753?source=related_link\">",
"      Management of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/59/42936?source=related_link\">",
"      Management of hypertension in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26356?source=related_link\">",
"      Nephrocalcinosis in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/16/14600?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2249?source=related_link\">",
"      Presentation, diagnosis, and staging of Wilms tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2712?source=related_link\">",
"      Renal cystic diseases in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35641?source=related_link\">",
"      Uncommon causes of congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5287?source=related_link\">",
"      Williams-Beuren syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_60_37834="Pharmacotherapy of allergic rhinitis";
var content_f36_60_37834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacotherapy of allergic rhinitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37834/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37834/contributors\">",
"     Richard D deShazo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37834/contributors\">",
"     Stephen F Kemp, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37834/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37834/contributors\">",
"     Jonathan Corren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/60/37834/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/60/37834/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/60/37834/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25107326\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic rhinitis is characterized by paroxysms of sneezing, rhinorrhea, nasal obstruction, and itching of the eyes, nose, and palate. It is also frequently associated with postnasal drip, cough, irritability, and fatigue.",
"   </p>",
"   <p>",
"    The pharmacologic management of allergic rhinitis is presented in this topic review. The clinical manifestations, diagnosis, differential diagnosis, and pathogenesis of allergic rhinitis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6775?source=see_link\">",
"     \"Pathogenesis of allergic rhinitis (rhinosinusitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107333\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of allergic rhinitis involves the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergen avoidance, which is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=see_link\">",
"       \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacotherapy, which is discussed here.",
"     </li>",
"     <li>",
"      Allergen immunotherapy (when appropriate), which is reviewed elsewhere. Of note, immunotherapy helps prevent the development of asthma in children with allergic rhinitis, and thus should be given special consideration in the pediatric population. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=see_link\">",
"       \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107340\">",
"    <span class=\"h1\">",
"     AVAILABLE MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with allergic rhinitis require pharmacotherapy, in addition to allergen avoidance, for satisfactory symptom control. As more medications become available without a prescription, patients can extensively self-treat, although the side effects of some over-the-counter allergy medications, particularly excessive sedation and anticholinergic effects, can be significant. Therefore, the current challenge for clinicians is to assure that patients with moderate to severe allergic rhinitis are adequately treated with medications that do not cause undue side effects.",
"   </p>",
"   <p>",
"    Consensus guidelines have been published for the management of allergic rhinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/1-10\">",
"     1-10",
"    </a>",
"    ]. The recommendations in this topic review are consistent with these guidelines.",
"   </p>",
"   <p>",
"    The most effective single therapy for patients with persistent and significant nasal symptoms is a glucocorticoid nasal spray. Other therapies include oral antihistamines, antihistamine nasal sprays, mast cell stabilizers (the cromoglycates), leukotriene modifiers, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    . The features and efficacy of the various agents are reviewed in this section.",
"   </p>",
"   <p>",
"    In contrast, nasal decongestant sprays and systemic glucocorticoids should NOT be used for routine treatment of allergic rhinitis. (See",
"    <a class=\"local\" href=\"#H25107487\">",
"     'Therapies requiring caution'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107347\">",
"    <span class=\"h2\">",
"     Intranasal glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical intranasal glucocorticoids (INGCs) are presently the most effective single maintenance therapy for allergic rhinitis and cause few side effects at the recommended doses. INGCs are particularly effective in the treatment of nasal congestion. Specific agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33392?source=see_link\">",
"     flunisolide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    propionate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36080?source=see_link\">",
"     mometasone",
"    </a>",
"    furoate, fluticasone furoate, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33488?source=see_link\">",
"     ciclesonide",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef55833 \" href=\"mobipreview.htm?16/18/16685\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107354\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;INGCs are more effective than oral antihistamines for relief of nasal blockage, nasal discharge, sneezing, nasal itch, postnasal drip, and total nasal symptoms, as demonstrated in various randomized trials and a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/11-16\">",
"     11-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies have favored INGCs over intranasal antihistamines sprays, as reviewed below. (See",
"    <a class=\"local\" href=\"#H25107431\">",
"     'Antihistamine nasal sprays'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus, in our opinion, INGCs are the",
"    <strong>",
"     first-line",
"    </strong>",
"    treatment for allergic rhinitis that is significant enough to cause a patient to seek medical advice. Comparative studies among different INGC preparations have not demonstrated significant differences in efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3675056\">",
"    <span class=\"h3\">",
"     Onset of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most INGCs have an onset of action of a few hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. However, maximal effect may require several days or weeks in patients with long-standing untreated symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107361\">",
"    <span class=\"h3\">",
"     Mechanisms of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids inhibit allergic inflammation in the nose at many levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. These agents downregulate inflammatory responses by binding to intracellular glucocorticoid receptors in the cytoplasm of inflammatory cells. The receptors undergo conformational changes upon activation, entering the cell nucleus where they bind with glucocorticoid response elements located on antiinflammatory genes. These activated genes transcribe messenger RNA for antiinflammatory proteins. At the same time, activated glucocorticoid receptors suppress the transcription of most cytokine and chemokine genes, whose products promote inflammation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107368\">",
"    <span class=\"h3\">",
"     Safety in children and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available topical nasal steroids are pharmacological derivatives of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , in which the molecular structure of the hydrocortisone molecule has been altered to increase potency. First-pass metabolism by the liver decreases drug bioavailability, and the lipophilicity facilitates glucocorticoid penetration into the cell. (See",
"    <a class=\"local\" href=\"#H25107375\">",
"     'Optimal use'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Intranasal corticosteroids may be divided into first and second generation preparations. These products are equally efficacious, although the total bioavailability (oral and nasal) of second and third generation intranasal steroids is markedly lower than that of first generation agents, resulting in lower risk of systemic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First generation:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33392?source=see_link\">",
"       flunisolide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (10 to 50 percent bioavailability)",
"     </li>",
"     <li>",
"      Second generation:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      propionate (&lt;2 percent),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36080?source=see_link\">",
"       mometasone",
"      </a>",
"      furoate (undetectable), and fluticasone furoate (&lt;1 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local irritation of the nasal mucosa, including drying and burning, and discomfort from the run-off into the throat of the liquid medication, is reported by 2 to 10 percent of patients using sprays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/29\">",
"     29",
"    </a>",
"    ]. Formulations containing alcohol or propylene glycol are more irritating than aqueous preparations (",
"    <a class=\"graphic graphic_table graphicRef55833 \" href=\"mobipreview.htm?16/18/16685\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are two types of nosebleed problems with the use of INGCs: frank epistaxis and scant blood found in the nasal mucus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant epistaxis is reported with both INGCs and placebo in clinical trials and may therefore partly result from mechanical trauma of repeated spraying, although when placebo rates were subtracted, nosebleed was still noted in 2 to 12 percent of patients using different INGC preparations. Frank epistaxis is often hard to prevent, and once it occurs, may require future avoidance of INGCs.",
"     </li>",
"     <li>",
"      The problem of traces of blood in the mucus is often remedied by simply stopping treatment on the side of the nose where blood mucus has been noted for a few days, and then restarting therapy. Sometimes patients can minimize these complications by using proper administration technique and by gradually reducing the dose once symptoms are controlled, to the lowest effective dosage for that individual. It is helpful to demonstrate proper use of all inhaled medications at the time of initial prescription and again at follow-up visits. Aqueous pump and dry powder sprays have different instructions for use. (See",
"      <a class=\"local\" href=\"#H25107375\">",
"       'Optimal use'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nasal sprays should always be directed away from the septum. There are rare reports of nasal septal perforation with INGCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/30\">",
"     30",
"    </a>",
"    ], although long-term studies of large numbers of patients have not found evidence of damage to the nasal mucosa despite years of use in the majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/31\">",
"     31",
"    </a>",
"    ]. A patient information topic on rhinitis, which reviews techniques for optimal use of INGCs, is provided separately. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=see_link\">",
"     \"Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential for systemic absorption of intranasal steroids with effects on the HPA axis and growth in children has been evaluated in many studies. Most studies, especially those with the second generation agents, showed no or limited HPA suppression at recommended doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/32-39\">",
"     32-39",
"    </a>",
"    ]. As examples, a double-blind study of 150 children (3.5 to 9 years of age) with perennial allergic rhinitis treated with intranasal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    (200 mcg daily) for one year showed no effects on growth rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/35\">",
"     35",
"    </a>",
"    ]. Other studies using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36080?source=see_link\">",
"     mometasone",
"    </a>",
"    furoate (100 mcg daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    (64 mcg daily) also showed no effects on growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/34,40\">",
"     34,40",
"    </a>",
"    ]. Agents that are dosed once daily are preferred in children, since these are believed to, although not documented to, be less likely to impact the HPA axis and growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longer term studies of the effects on growth caused by inhaled glucocorticoids administered for asthma treatment (which deliver higher doses per dose) are also reassuring. Despite these reassuring data, the adverse effects of INGC can be additive with those of other glucocorticoid preparations, such as inhaled agents for concomitant asthma or topical glucocorticoids for atopic dermatitis, and therefore caution is needed. Growth in children should be monitored when any glucocorticoid-containing medication is prescribed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link&amp;anchor=H10#H10\">",
"     \"Major side effects of inhaled glucocorticoids\", section on 'Growth deceleration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small number of studies have examined the effects of INGC therapy on bone mineral density and intraocular pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Some studies have demonstrated detrimental effects, although it is currently unclear whether these are large enough to result in clinically important outcomes over time, such as increased rates of fractures, glaucoma, or cataracts. A practice guideline on rhinitis concluded that studies in both children and adults have failed to demonstrate these adverse effects are consistent or clinically relevant to INGC use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/2\">",
"     2",
"    </a>",
"    ]. Until more is known, it seems reasonable to inform patients that the risks of these outcomes are likely small, although the impact over a lifetime is not yet understood.",
"   </p>",
"   <p>",
"    INGCs of any type should be tapered to the lowest effective dose in all patients once symptoms are controlled. Conversely, there is no convincing evidence that doses greater than the recommended maximum for each preparation increase efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2446146\">",
"    <span class=\"h3\">",
"     Possible drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant adrenal suppression has been reported with the combination of intranasal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    and strong inhibitors of CYP3A4 enzymes (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    ) in a small number of case reports (three at the time of this review) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/44\">",
"     44",
"    </a>",
"    ]. Although it is unclear how frequently this adverse outcome occurs, we suggest that patients receiving treatment with ritonavir or other strong inhibitors of CYP3A4 be treated with an INCG",
"    <strong>",
"     other",
"    </strong>",
"    than fluticasone, at the lowest effective dose, or that the treating clinician at least be vigilant for signs and symptoms of Cushing&rsquo;s syndrome.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     Budesonide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33392?source=see_link\">",
"     flunisolide",
"    </a>",
"    appear to be safer options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107375\">",
"    <span class=\"h3\">",
"     Optimal use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors start therapy with the maximal dose for age. Once symptoms are adequately controlled, we \"step down\" the dose at one week intervals to the lowest effective dose. Patients with severe symptoms will require daily use on a chronic basis. Some patients can reduce the use of INCGs gradually, and maintain symptom control with every other day or as needed use. Newer INGCs act rapidly (within 3 to 12 hours), and as needed use appears to be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/14\">",
"     14",
"    </a>",
"    ]. This may be sufficient in patients with episodic symptoms. (See",
"    <a class=\"local\" href=\"#H25107551\">",
"     'Mild or episodic symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinicians should become comfortable with several INGC preparations, since each has its advantages and disadvantages relating to added fragrances, taste,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    irritation.",
"   </p>",
"   <p>",
"    To optimize the effects of this therapy and compliance with treatment, we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If mucous crusting is present, patients can rinse the nose with a saline nasal spray or irrigation before the nasal glucocorticoid is applied. Treatment failures can occur if mucus or other debris prevents the medication from coating the nasal mucosa. Saline irrigation is reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12250?source=see_link\">",
"       \"Chronic nonallergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preparations with once-daily dosing are convenient and can help optimize compliance. All INGC formulations (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      propionate,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36080?source=see_link\">",
"       mometasone",
"      </a>",
"      furoate,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33488?source=see_link\">",
"       ciclesonide",
"      </a>",
"      , and fluticasone furoate) have a once-daily recommended dosing except for one,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33392?source=see_link\">",
"       flunisolide",
"      </a>",
"      (which is twice daily).",
"     </li>",
"     <li>",
"      With the aqueous (nonaerosol) INGCs, patients should be instructed to keep their head pointed slightly downward during spraying and avoid tilting the head back, as this can cause drainage of the medicine from the nose to the throat. In addition, they should avoid pointing the spray at the septum, which can become irritated. A patient information topic on rhinitis, which reviews techniques for use of INGCs, is provided separately. (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=see_link\">",
"       \"Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3895306\">",
"    <span class=\"h4\">",
"     Dry powder formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States in 2012, two new products became available that use a &ldquo;dry&rdquo; aerosol delivery system,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    dipropionate HFA (Qnasl",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33488?source=see_link\">",
"     ciclesonide",
"    </a>",
"    HFA (Zetonna&trade;). These may be more agreeable to patients who dislike the wet run-off or taste side effects that are seen with some of the aqueous sprays (",
"    <a class=\"graphic graphic_table graphicRef55833 \" href=\"mobipreview.htm?16/18/16685\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    With the aerosol products, patients should be instructed to tilt the head back slightly, dispense the spray, hold the breath for a few seconds, and then exhale through the mouth. The product insert also advises to avoid blowing the nose for 15 minutes after use. The nosepiece should be wiped with a clean, dry tissue weekly, although not cleaned with water.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11910521\">",
"    <span class=\"h3\">",
"     Combined with decongestant sprays",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be a role for once-daily treatment with the combination of an INGC combined with a",
"    <span class=\"nowrap\">",
"     vasoconstrictor/decongestant",
"    </span>",
"    spray therapy in adult patients who do not respond optimally to INGC alone. Combined therapy with topical nasal steroids and topical decongestants was evaluated in a randomized trial of sixty adult subjects with perennial allergic rhinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/45\">",
"     45",
"    </a>",
"    ]. Participants were randomly assigned to receive once-nightly treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    furoate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/54/33632?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    hydrochloride, the combination of both, or placebo. They were monitored for four weeks of therapy and for two weeks post-therapy. Both symptom scores and objective nasal volume, determined with acoustic rhinometry, improved with combination therapy, relative to placebo or oxymetazoline alone. Nasal symptoms were less in the combination group compared with the fluticasone monotherapy group, although nasal volumes were not statistically different. There was no evidence of rhinitis medicamentosa in the combination group. Further study is needed, although we have noted preliminary success in several adult patients in our clinical practice, including some who had reverted to using oral decongestant preparations because INCGs were not providing adequate relief. We attempt to discontinue the vasoconstrictor spray once symptoms are controlled. (See",
"    <a class=\"local\" href=\"#H25107494\">",
"     'Nasal decongestant sprays'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H236313\">",
"    <span class=\"h3\">",
"     Combined with antihistamine sprays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of a topical antihistamine and a topical glucocorticoid may be helpful for patients who do not obtain sufficient relief with one agent. In a randomized trial, 3398 patients with moderate to severe allergic rhinitis were treated for two weeks with either the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    , fluticasone alone, azelastine alone, or placebo, with complete or near complete resolution of total symptoms in 12, 9, 7, and 4 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/46\">",
"     46",
"    </a>",
"    ]. A combination spray containing azelastine hydrochloride 137 mcg and fluticasone propionate 50 mcg (Dymista) became available in the US in 2012 and is approved for children older than 12 years and adults. The dose is one actuation per nostril, twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107382\">",
"    <span class=\"h2\">",
"     Oral antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihistamines typically reduce itching, sneezing, and rhinorrhea, with less impact on nasal congestion, compared with intranasal glucocorticoids. H1 antihistamines are divided into first generation and second generation agents.",
"   </p>",
"   <p>",
"    Data suggest that H1 antihistamines, by virtue of their ability to downregulate constitutive H1-receptor activity, are not actually receptor antagonists. Rather, they are inverse agonists that shift the equilibrium from the active form of the H1 receptor to the inactive form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/47\">",
"     47",
"    </a>",
"    ]. Some antihistamines also reduce eosinophil survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24818398\">",
"    <span class=\"h3\">",
"     First generation agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;First generation antihistamines include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/29/39381?source=see_link\">",
"     brompheniramine",
"    </a>",
"    , and others. These are available over-the-counter, both as single agents and in combination with other drugs. They are similarly efficacious compared to each other, with minor differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107389\">",
"    <span class=\"h4\">",
"     Adverse effects and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;First generation antihistamines cause significant sedation because they are lipophilic and easily cross the blood brain barrier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/49\">",
"     49",
"    </a>",
"    ]. Central nervous system symptoms are reported by 20 percent or more of patients, and adverse effects on intellectual and motor function are well-documented, even in the absence of subjective awareness of sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impairments affect driving performance and have been implicated in fatal motor vehicle accidents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/51-55\">",
"       51-55",
"      </a>",
"      ]. First generation antihistamines are prohibited in many states for some transportation workers (eg, pilots, bus drivers), and individuals taking these agents are considered to be under the influence of drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/56\">",
"       56",
"      </a>",
"      ]. Despite this, a report from the Federal Aviation Administration noted increasing pilot use of these drugs over the past 15 years, and reported detection of these agents in 4 and 11 percent of",
"      <span class=\"nowrap\">",
"       fatalities/accidents",
"      </span>",
"      in 1990 and 2004, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/57\">",
"       57",
"      </a>",
"      ]. Other measures of cognitive effects include performance defects on tests of divided attention, working memory, vigilance, and speed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/58-60\">",
"       58-60",
"      </a>",
"      ]. Adverse effects are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef65742 \" href=\"mobipreview.htm?7/5/7260\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      First generation antihistamines are problematic in children. In school age children, both untreated allergic rhinitis and the use of sedating antihistamines are associated with impaired school performance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/52,59,60\">",
"       52,59,60",
"      </a>",
"      ]. In very young children, first generation antihistamines can cause paradoxical agitation and over-the-counter cold remedies containing them have been linked to a small number of deaths in children &lt;2 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13146?source=see_link&amp;anchor=H199065563#H199065563\">",
"       \"The common cold in children: Treatment and prevention\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      First generation antihistamines may also be problematic in older adults, who are more susceptible to their anticholinergic effects, including dry mouth and eyes, urinary hesitancy, and confusion (",
"      <a class=\"graphic graphic_table graphicRef65742 \" href=\"mobipreview.htm?7/5/7260\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107396\">",
"    <span class=\"h4\">",
"     Role in therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;First generation antihistamines have a limited role in the treatment of most patients, because of their numerous adverse effects. The strategy of combining a second generation antihistamine during the day and a first generation antihistamine before bed has been proposed to reduce costs, although it has been shown to cause residual daytime sedation due to the persistence of active metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. As mentioned previously, we avoid these medications completely in small children and the elderly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107403\">",
"    <span class=\"h3\">",
"     Second and third generation antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second generation antihistamines include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"     olopatadine",
"    </a>",
"    . These lipophobic agents were developed primarily to avoid the unwanted central nervous system effects of the first generation drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/51\">",
"     51",
"    </a>",
"    ]. Onset of action is within one hour for most agents, and peak serum levels are attained in two to three hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. They are also longer-acting, and are dosed once or twice daily. Like older H1 antihistamines, they have less impact on nasal congestion compared to intranasal glucocorticoids (INGCs). The oral second generation agents appear to be similarly efficacious to each other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/1,67-71\">",
"     1,67-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metabolites of second generation antihistamines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    (the metabolite of terfenadine),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12934?source=see_link\">",
"     desloratadine",
"    </a>",
"    (the metabolite of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/45/44757?source=see_link\">",
"     levocetirizine",
"    </a>",
"    (a purified isomer of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    ), are sometimes classified as \"third generation antihistamines\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/72\">",
"     72",
"    </a>",
"    ]. These compounds were designed to have fewer central nervous system effects than the second generation agents, although whether this is true has not been confirmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/51,73,74\">",
"     51,73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In experimental models, second and third generations antihistamines also have a variety of antiinflammatory properties, including decreased mast cell mediator release and downregulation of adhesion molecule expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/75\">",
"     75",
"    </a>",
"    ]. Inhibition of IL-4 and IL-13 production may explain reports of their dose-dependent beneficial effect in asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107410\">",
"    <span class=\"h4\">",
"     Role in therapy and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second generation antihistamines are a popular option for many patients, especially those with mild or intermittent symptoms. Patients who experience adverse effects with the second generation antihistamines (which is rare), or who prefer a local therapy, are also better treated with INGCs. We prefer INGCs for patients with chronic or more significant symptoms, because of their superior efficacy.",
"   </p>",
"   <p>",
"    The following general statements can be made concerning the efficacy of second and third generation antihistamines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antihistamines are less effective than topical nasal steroids, as previously presented [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/12,14,16\">",
"       12,14,16",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H25107354\">",
"       'Efficacy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Second generation antihistamines are equally or more efficacious than cromolyn in relieving symptoms (see",
"      <a class=\"local\" href=\"#H25107445\">",
"       'Cromolyn sodium'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no evidence that pharmacologic tolerance develops to antihistamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/78\">",
"     78",
"    </a>",
"    ]. In addition, the specific allergic sensitivities a patient has does not impact the antihistamine that is prescribed, although agents are sometimes marketed as effective for perennial or seasonal, or indoor or outdoor, allergies. This marketing simply reflects the clinical trials that were performed.",
"   </p>",
"   <p>",
"    Clinical studies do not support the use of combinations of H1 and H2 antagonists (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    ) to treat allergic rhinitis. There is no evidence that doses of second generation antihistamines greater than those maximally recommended increase efficacy for allergic rhinitis, with higher-than-recommended doses being associated with sedation in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107417\">",
"    <span class=\"h4\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second generation antihistamines are less sedating than the first generation agents, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    is sedating for approximately 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/80-82\">",
"     80-82",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"     Loratadine",
"    </a>",
"    is nonsedating for most adults at the customary dose of 10 mg once daily, although sedation can occur at higher doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/82\">",
"     82",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"     Fexofenadine",
"    </a>",
"    is nonsedating at recommended doses, and even at higher-than-recommended doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/81,83-85\">",
"     81,83-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Second generation antihistamines have varying degrees of anticholinergic effects. Drying of the eyes, in particular, is noticeable to some patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some oral antihistamines may be associated with weight gain, although it is unclear if this is due to stimulation of appetite or reduced activity secondary to sedation and fatigue. Like other central nervous system effects, weight gain is more prominent with the older, first generation agents, although it can occur in some patients with the second generation agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/87\">",
"       87",
"      </a>",
"      ]. Weight gain would be predicted to be minimal with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/88\">",
"       88",
"      </a>",
"      ], although we are aware of no studies directly assessing the second generation agents for this particular untoward effect and our experience suggests that increased hunger and weight gain with nonsedating antihistamines is minimal to none in most patients.",
"     </li>",
"     <li>",
"      St. John's wort may decrease",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      levels, making these antihistamines less effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/89-94\">",
"       89-94",
"      </a>",
"      ]. However, the magnitude and significance of the interaction is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107431\">",
"    <span class=\"h2\">",
"     Antihistamine nasal sprays",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"     Azelastine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"     olopatadine",
"    </a>",
"    are available as prescription nasal sprays. These agents appear to have some antiinflammatory effect and can improve nasal congestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. They are similarly effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Antihistamine nasal sprays have a rapid onset of action (less than 15 minutes) and can be administered \"on demand\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/3\">",
"     3",
"    </a>",
"    ]. The onset of action is somewhat faster than the intranasal glucocorticoids (INGCs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/20\">",
"     20",
"    </a>",
"    ]. However, azelastine has a bitter taste that can be bothersome to some patients (which has been corrected in newer preparations) and was mildly sedating in some of the clinical trials performed in getting the medication on the market, although not in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines generally suggest INGCs in preference to antihistamine sprays, based upon the fact that the majority of comparison studies favor INGCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/6,101\">",
"     6,101",
"    </a>",
"    ]. In noninferiority trials, both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"     olopatadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    compared favorably to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    propionate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/102-104\">",
"     102-104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107438\">",
"    <span class=\"h2\">",
"     Oral antihistamine/decongestant combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsedating antihistamines combined with the decongestant,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    , provide better symptom relief than antihistamines alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/105\">",
"     105",
"    </a>",
"    ]. However, decongestants have a variety of adverse effects, including hypertension, insomnia, irritability, and headache (",
"    <a class=\"graphic graphic_table graphicRef65742 \" href=\"mobipreview.htm?7/5/7260\">",
"     table 2",
"    </a>",
"    ). There are numerous first generation antihistamine-decongestant combination products which have been available without a prescription for years. Available second generation combination agents include",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"      loratadine",
"     </a>",
"     /pseudoephedrine,",
"    </span>",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"      cetirizine",
"     </a>",
"     /pseudoephedrine,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"      fexofenadine",
"     </a>",
"     /pseudoephedrine.",
"    </span>",
"   </p>",
"   <p>",
"    In",
"    the United States, increasing abuse of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    (both as a stimulant in athletics and in the illegal production of methamphetamines) has lead to the substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    for pseudoephedrine in many over-the-counter first generation combination preparations. However, phenylephrine is less effective for the treatment of rhinitis symptoms, and may not be superior to placebo at the 10 mg dose that is commonly available over-the-counter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/106,107\">",
"     106,107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decongestants are relatively contraindicated in patients with hypertension, contraindicated in those receiving monoamine oxidase inhibitor therapy, and should be used with caution in patients with closed angle glaucoma, cardiovascular or cerebrovascular disease, hyperthyroidism, or bladder neck obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107445\">",
"    <span class=\"h2\">",
"     Cromolyn sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"     Cromolyn sodium",
"    </a>",
"    is a mast cell stabilizer that decreases allergic inflammation by inhibiting the intermediate conductance chloride channel pathways of mast cells, eosinophils, epithelial and endothelial cells, fibroblasts, and sensory neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/108\">",
"     108",
"    </a>",
"    ]. It inhibits mast cell release of histamine and other inflammatory mediators.",
"   </p>",
"   <p>",
"    Cromolyn blocks symptoms associated with the immediate and late phase nasal allergen challenge and is effective in doing so even when used shortly before allergen inhalation. This makes cromolyn particularly useful for individuals who experience episodic symptoms to allergens, such as a cat, where it may be used 30 minutes prior to exposure. For seasonal allergic rhinitis, it is most effective when initiated just prior to the pollen season, rather than after symptoms have begun.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"     Cromolyn sodium",
"    </a>",
"    has no serious side effects and is available over-the-counter. A nasal spray is available in the United States. Frequent dosing (1 to 2 sprays per nostril four times daily) is required to attain a good effect in seasonal allergic rhinitis. Dosage frequency can be reduced after the first two to three weeks of treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"     Cromolyn sodium",
"    </a>",
"    is more effective than placebo in the treatment of seasonal allergic rhinitis. However, most studies show it to be less effective than intranasal glucocorticoids (INGCs) or second generation antihistamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/12,13,109\">",
"     12,13,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    is extremely safe, but its utility is limited by the need for frequent dosing and lower efficacy relative to other agents. It may be tried if nonsedating antihistamines do not work or are not well-tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107466\">",
"    <span class=\"h2\">",
"     Montelukast",
"    </span>",
"    &nbsp;&mdash;&nbsp;In experimental allergic rhinitis, nasal congestion correlates best with leukotriene C4 (LTC4) levels, whereas sneezing and nasal itching correlate with histamine levels. In the US, there are three antileukotriene agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    ) currently available for use in asthma, although only montelukast is approved for the management of allergic rhinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/110-112\">",
"     110-112",
"    </a>",
"    ]. Montelukast is less effective than intranasal glucocorticoids (INGCs) for the symptoms of allergic rhinitis, as reviewed previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/113-116\">",
"     113-116",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25107347\">",
"     'Intranasal glucocorticoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     Montelukast",
"    </a>",
"    has been compared to various other therapies or combinations of therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       Montelukast",
"      </a>",
"      provided relief of symptoms that was similar to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      in a systematic review of eight randomized trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       Montelukast",
"      </a>",
"      plus a second generation oral antihistamine (eg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      ) provided more relief than either agent alone in at least two randomized trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/77,117\">",
"       77,117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       Montelukast",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      provided similar symptom relief as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19190?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      , although patients receiving the latter combination did not sleep as well, perhaps due to the presence of the decongestant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intranasal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      (200 micrograms per day) was superior to the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      and an oral antihistamine in one study, while others found the efficacy of these two approaches comparable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/16,116\">",
"       16,116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, we prefer INGCs over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    in any age group with allergic rhinitis. However, the patient who cannot tolerate or refuses nasal sprays may be a candidate for montelukast alone or combined with an antihistamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/119\">",
"     119",
"    </a>",
"    ]. In addition, montelukast may be useful in patients with concomitant allergic rhinitis and asthma or coexistent nasal polyposis. It also provides some relief of allergic conjunctivitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2336638\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall safety profile of leukotriene agents is very good. However, neuropsychiatric changes have been reported in association with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    , including dream abnormalities, insomnia, anxiety, depression, suicidal thinking and in rare cases, suicide. Therefore, we do not prescribe montelukast to patients with active, pre-existing anxiety, depression, or symptoms that suggest psychiatric disorders. When initially prescribing this medication, we inform all patients about this potential side effect and advise them to stop the medication if they perceive adverse mood effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=see_link&amp;anchor=H14#H14\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107480\">",
"    <span class=\"h2\">",
"     Ipratropium bromide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     Ipratropium",
"    </a>",
"    bromide, in the form of a 0.03 percent nasal spray, can be useful for decreasing rhinorrhea. It is a congener of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    and may act by decreasing the release of substance P. However, it is less effective than intranasal glucocorticoids (INGCs) for sneezing, pruritus, or nasal obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/121\">",
"     121",
"    </a>",
"    ]. Ipratropium bromide is also available in a stronger formulation (0.06 percent), although this is specifically labeled for reduction of rhinorrhea associated with colds.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     Ipratropium",
"    </a>",
"    is not recommended as a first-line drug in allergic rhinitis. It is sometimes useful in children or adults who have profuse rhinorrhea not otherwise controlled with topical nasal steroids, a complaint most commonly observed in adult patients with concomitant allergic and nonallergic (or vasomotor) rhinitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12250?source=see_link&amp;anchor=H18#H18\">",
"     \"Chronic nonallergic rhinitis\", section on 'Prominent rhinorrhea without other symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107487\">",
"    <span class=\"h2\">",
"     Therapies requiring caution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal decongestant sprays and systemic glucocorticoids are therapies that can be highly effective if used infrequently and with caution, and very problematic if used incorrectly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107494\">",
"    <span class=\"h3\">",
"     Nasal decongestant sprays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical vasoconstrictor decongestants available include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/54/33632?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    , xylometazoline, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/24/33152?source=see_link\">",
"     naphazoline",
"    </a>",
"    . Nasal decongestant sprays are",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended as monotherapy in the chronic treatment of allergic rhinitis, as downregulation of the alpha-adrenergic receptor develops after three to seven days and rebound nasal congestion may result, ultimately resulting in a cycle of nasal congestion both caused by and temporarily relieved by the medication, leading to escalating use and eventual dependency. This disorder is called rhinitis medicamentosa. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/30999?source=see_link&amp;anchor=H7#H7\">",
"     \"An overview of rhinitis\", section on 'Topical nasal medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the combination of a topical nasal decongestant and topical glucocorticoid may effectively treat symptoms without causing rhinitis medicamentosa. This is discussed separately. (See",
"    <a class=\"local\" href=\"#H11910521\">",
"     'Combined with decongestant sprays'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nasal decongestants are helpful when used just before air travel in patients who have difficulties with middle ear",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sinus equilibration with flying, or in patients who have problems with altitude changes. The long-acting agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/54/33632?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    , is administered twice a day and is approved for limited use in children older than six years and adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107501\">",
"    <span class=\"h3\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short courses (ie, a few days) of oral glucocorticoids usually abolish symptoms of allergic rhinitis and may be indicated for severe allergic rhinitis symptoms that are preventing the patient from sleeping or working [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/6\">",
"     6",
"    </a>",
"    ]. This approach was more widely used before nasal glucocorticoids and nonsedating antihistamines became available. However, systemic glucocorticoids should not be given repeatedly or for prolonged periods of time for the management of allergic rhinitis. Similarly, we do not recommend injections of long-acting corticosteroids for this condition because of unpredictable absorption and the inability to dose-adjust if side effects occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107508\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE AND OTHER THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107516\">",
"    <span class=\"h2\">",
"     Nasal saline irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal irrigation with saline can be used alone for mild symptoms or just before other topical medications, so that the mucosa is freshly cleansed when the medications are applied (",
"    <a class=\"graphic graphic_table graphicRef71059 \" href=\"mobipreview.htm?42/33/43548\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A variety of over-the-counter devices, including squeeze bottles and bulb syringes are effective, provided the system delivers an adequate volume of solution (&gt;200 mL per side) into the nose. Nasal irrigation with warmed saline can be performed as needed only, daily at baseline, or twice daily for increased symptoms.",
"   </p>",
"   <p>",
"    Nasal irrigation is associated with improvement in a variety of rhinitis conditions and carries little risk if properly performed. Direct evidence for benefit in allergic rhinitis specifically includes the following studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/122-124\">",
"     122-124",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One randomized study of the impact of nasal irrigation in children with acute sinusitis found that among those with concomitant allergic rhinitis, nasal irrigation significantly improved rhinorrhea, nasal congestion, throat itching, sleep quality symptoms, and nasal air flow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/122\">",
"       122",
"      </a>",
"      ]. A second study in children found that the effects of nasal irrigation were additive with those of intranasal glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/124\">",
"       124",
"      </a>",
"      ]. Nasal irrigation is particularly helpful when there are crusted nasal secretions due to chronic, thick, drainage.",
"     </li>",
"     <li>",
"      Another randomized study of pregnant women found nasal saline irrigation to be beneficial for treatment of allergic rhinitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients can make their own irrigation solutions or buy commercially-prepared solutions or kits. Patients should use distilled, sterilized, or previously boiled water, because a small number of cases of primary amebic meningoencephalitis (PAM) have been contracted from using tap water that was contaminated with the amoeba",
"    <em>",
"     Naegleria fowleri",
"    </em>",
"    to perform sinus irrigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. Although rare, PAM is usually fatal.",
"    <em>",
"     N. fowleri",
"    </em>",
"    is found worldwide and is usually contracted from swimming in freshwater lakes and rivers, geothermic heated bodies of water, or inadequately chlorinated pools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/127\">",
"     127",
"    </a>",
"    ]. Irrigation devices can also become contaminated with the bacteria present in the patient&rsquo;s nasal cavities, although it is not clear that this causes any clinically significant problems. Still, irrigation devices should be cleaned as directed and replaced regularly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5476779\">",
"    <span class=\"h2\">",
"     Alternative and complementary therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several alternative and complementary therapies are available for the treatment of allergic rhinitis and are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6953?source=see_link\">",
"     \"Complementary and alternative therapies for allergic rhinitis and conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with allergic rhinitis who are taking herbal therapies for other reasons should be aware of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      St. John's wort may decrease",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      levels, making these antihistamines less effective. (See",
"      <a class=\"local\" href=\"#H25107417\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with weed pollen allergies should be cautious about taking",
"      <em>",
"       Echinacea",
"      </em>",
"      <em>",
"       purpurea",
"      </em>",
"      , which has extensive homology with ragweed pollen and has been implicated in anaphylaxis in atopic patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/129\">",
"       129",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107530\">",
"    <span class=\"h1\">",
"     APPROACH TO SPECIFIC PATIENT GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of allergic rhinitis in a specific patient is influenced by the frequency and severity of symptoms, the age of the patient, and the presence of concurrent conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/1-10\">",
"     1-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107537\">",
"    <span class=\"h2\">",
"     Young children (&lt;2 years of age)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of allergic rhinitis requires repeated exposure to inhaled allergens and is therefore uncommon in children under two years of age. If a child under two years appears to have persistent nasal symptoms, other disorders should be considered initially, such as adenoidal hypertrophy or chronic sinusitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11194?source=see_link&amp;anchor=H35#H35\">",
"     \"The pediatric physical examination: HEENT\", section on 'Adenoidal hypertrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If after an evaluation for other causes, a young child is determined to have allergic rhinitis, treatment options include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"       Cromolyn sodium",
"      </a>",
"      nasal spray, one to two sprays three to four times daily, is attractive to some parents and clinicians because it has essentially no adverse effects. However, cromolyn is less effective than intranasal glucocorticoids (INGCs) and the dosing is inconvenient. Despite these limitations, it can be sufficient for controlling mild symptoms. (See",
"      <a class=\"local\" href=\"#H25107445\">",
"       'Cromolyn sodium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The second generation antihistamines",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      are currently available in liquid formulations. Cetirizine and fexofenadine are approved for children &ge;6 months of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children with severe symptoms not responsive to the above measures, an intranasal glucocorticoid (INGC) may be administered instead.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36080?source=see_link\">",
"     Mometasone",
"    </a>",
"    furoate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    furoate, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide are approved by the US Food and Drug Administration (FDA) for use in children &ge;2 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]. The dose for each of these agents in young children is one spray per nostril once daily.",
"   </p>",
"   <p>",
"    We avoid first generation antihistamines in young children because these agents can cause paradoxical agitation and may be dangerous in infants, as reviewed previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25107382\">",
"     'Oral antihistamines'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107544\">",
"    <span class=\"h2\">",
"     Older children and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children over two years of age, the approach to pharmacotherapy is essentially the same as that in adults, and depends upon the severity and persistence of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107551\">",
"    <span class=\"h3\">",
"     Mild or episodic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild or episodic symptoms, or episodic symptoms that are related to predictable allergen exposures (visiting a relative's house with a pet), can be managed with one of the following options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A second generation oral antihistamine, administered regularly or as needed (ideally two to five hours before an exposure).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       Cetirizine",
"      </a>",
"      (approved for children &ge;6 months),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      (both approved for children &ge;2 years) are similarly efficacious and are available in syrups.",
"     </li>",
"     <li>",
"      An intranasal antihistamine (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"       azelastine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"       olopatadine",
"      </a>",
"      ): The US FDA has approved the use of azelastine in children &gt;5 years of age, and intranasal olopatadine, for children over 12 years of age (its safety and efficacy have not been evaluated in younger children).",
"     </li>",
"     <li>",
"      An intranasal glucocorticoid (INGC) (more effective than antihistamines), administered regularly or as needed. For predictable exposures, we suggest initiating therapy two days before, continuing through, and for two days after the end of exposure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/14,132\">",
"       14,132",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36080?source=see_link\">",
"       Mometasone",
"      </a>",
"      furoate,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      furoate, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide are approved by the US Food and Drug Administration (FDA) for use in children &ge;2 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/130,131\">",
"       130,131",
"      </a>",
"      ]. In young children, the dose for each of these agents is one spray per nostril once daily, but if necessary, two sprays each nostril can be tried for a limited period (we limit to two weeks and reassess symptoms) in view of the age-limited dose approval and the concern for potential systemic side effects (eg, adrenal suppression) in children at the higher dosage.",
"     </li>",
"     <li>",
"      Intranasal cromolyn, administered regularly or as needed (ideally 30 minutes before an exposure). Taken in this manner, cromolyn is helpful for brief exposures (minutes to hours). For prolonged exposures, administration should ideally begin four to seven days in advance. As discussed previously, some parents and clinicians prefer to try cromolyn first in children because of its excellent safety profile. (See",
"      <a class=\"local\" href=\"#H25107445\">",
"       'Cromolyn sodium'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be explained to patients that each of these therapies is more effective when taken regularly, although as needed use may be sufficient for very mild symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107558\">",
"    <span class=\"h3\">",
"     Persistent symptoms and moderate to severe symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical intranasal glucocorticoids (INGCs) are the most effective pharmacologic intervention for allergic rhinitis and are, in our opinion, the best initial therapy for patients with persistent or moderate to severe symptoms. All of the currently available INGC preparations are equally effective, although the newer agents are more convenient and probably safer for long-term use than the older agents. The INGCs with low bioavailability and once daily dosing, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36080?source=see_link\">",
"     mometasone",
"    </a>",
"    furoate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    furoate, are preferred for use in children. Mometasone and fluticasone furoate are approved by the FDA for use in children &ge;2 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/130\">",
"     130",
"    </a>",
"    ]. Fluticasone propionate is approved for children &ge;4 years. (See",
"    <a class=\"local\" href=\"#H25107347\">",
"     'Intranasal glucocorticoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with moderate to severe symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in those who fail to respond adequately to initial therapy with INGCs, a second agent can be added. Options include topical nasal antihistamines, oral antihistamines, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    , and",
"    <span class=\"nowrap\">",
"     antihistamine/decongestant",
"    </span>",
"    combination products. There are few clinical trials directly comparing different combinations of these therapies, and the choice of additional agents should be based upon the patient's residual symptoms, preferences, and coexistent conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of INGCs and intranasal antihistamines may provide additional benefit over either therapy alone, especially for breakthrough symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/46,104\">",
"       46,104",
"      </a>",
"      ]. A nasal spray containing both an antihistamine and a glucocorticoid is available in the US. (See",
"      <a class=\"local\" href=\"#H236313\">",
"       'Combined with antihistamine sprays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Addition of a second generation oral antihistamine: The combination of INGCs and oral antihistamines has not shown clear advantage over INGCs alone in most studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/133,134\">",
"       133,134",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Addition of a second generation oral",
"      <span class=\"nowrap\">",
"       antihistamine/decongestant",
"      </span>",
"      combination: These provide better symptom relief than antihistamines alone, although the adverse effects of the decongestant component limit their use in some patients, as previously reviewed (",
"      <a class=\"graphic graphic_table graphicRef65742 \" href=\"mobipreview.htm?7/5/7260\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25107438\">",
"       'Oral antihistamine/decongestant combinations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107565\">",
"    <span class=\"h3\">",
"     With concomitant asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 40 percent of patients with allergic rhinitis are believed to have concomitant asthma. The leukotriene-modifying agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    , may be a particularly useful additive therapy for patients with either asthma or nasal polyposis. (See",
"    <a class=\"local\" href=\"#H25107466\">",
"     'Montelukast'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107572\">",
"    <span class=\"h3\">",
"     With concomitant allergic conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with allergic rhinitis and allergic conjunctivitis, we prefer a combination of intranasal glucocorticoids (INGCs) and topical ophthalmic antihistamine drops, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/60/16323?source=see_link\">",
"     epinastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/56/33664?source=see_link\">",
"     levocabastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/20/323?source=see_link\">",
"     emedastine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"     olopatadine",
"    </a>",
"    , rather than INGCs plus oral antihistamines. A small number of randomized trials have shown the combination of INGCs plus ophthalmic drops to be more effective and cause less ocular drying than the combination of INGCs and oral antihistamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/135,136\">",
"     135,136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some preparations of INGCs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36080?source=see_link\">",
"     mometasone",
"    </a>",
"    furoate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    furoate) have been shown to have a small but statistically significant effect on allergic eye symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/137-139\">",
"     137-139",
"    </a>",
"    ]. However, many patients require an additional agent for adequate relief.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"     Cromolyn sodium",
"    </a>",
"    is available in ophthalmic preparations and may also be useful as prophylactic therapy before allergen exposures.",
"   </p>",
"   <p>",
"    Further information about the management of allergic conjunctivitis is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107579\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of allergic rhinitis in pregnant women is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3914?source=see_link&amp;anchor=H10#H10\">",
"     \"Recognition and management of allergic disease during pregnancy\", section on 'Allergic rhinitis/conjunctivitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27574600\">",
"    <span class=\"h2\">",
"     Breastfeeding women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics strongly recommends breastfeeding because of the benefits to the neonate and has published a guide to the use of medications during lactation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/140\">",
"     140",
"    </a>",
"    ]. Another resource is LactMed, an on-line database of information on medications and lactation hosted by the National Library of Medicine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Food and Drug Administration has developed a drug classification system consisting of five pregnancy precaution categories, A, B, C, D, and X. No similar classification exists for lactation. Based upon pregnancy categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No rhinitis medication meets the requirements for pregnancy category A (ie, well controlled human studies show no risk for the developing child).",
"     </li>",
"     <li>",
"      There are several rhinitis drugs within category B (ie, either animal studies show no fetal risk and human studies are unavailable, or animal studies show a risk but human studies have not).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Breastfeeding women with very mild allergic rhinitis may not require any medication, although more severe symptoms may warrant treatment.",
"   </p>",
"   <p>",
"    General guidelines have been proposed (",
"    <a class=\"graphic graphic_table graphicRef58772 \" href=\"mobipreview.htm?8/11/8381\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/142\">",
"     142",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients should practice allergen avoidance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=see_link\">",
"       \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nasal saline can always be tried for any nonspecific relief it can provide. (See",
"      <a class=\"local\" href=\"#H25107516\">",
"       'Nasal saline irrigation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intermittent congestion (symptoms less than four days per week) may be treated judiciously with a topical decongestant spray. (See",
"      <a class=\"local\" href=\"#H25107494\">",
"       'Nasal decongestant sprays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild persistent symptoms (symptoms more than four",
"      <span class=\"nowrap\">",
"       days/week",
"      </span>",
"      and more than four",
"      <span class=\"nowrap\">",
"       weeks/year)",
"      </span>",
"      may be treated with intranasal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (category B) or cromolyn and supplemented by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      (both are category B).",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Moderate/severe",
"      </span>",
"      persistent symptoms may be treated with maintenance intranasal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunotherapy injections and supplemented as needed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107586\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intranasal glucocorticoids (INGCs) are the first-line agents for older adults with allergic rhinitis. Second generation antihistamines can be used safely in some elderly patients, although a few may experience adverse effects and slowed metabolism may warrant lower starting doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/143\">",
"     143",
"    </a>",
"    ]. Topical antihistamine sprays are also a good option. We avoid first generation antihistamines in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/60/37834/abstract/144\">",
"     144",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25107389\">",
"     'Adverse effects and safety'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107593\">",
"    <span class=\"h1\">",
"     REFRACTORY SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suspicion for chronic rhinosinusitis or rhinitis caused by other etiologies should be raised if a patient with presumed allergic rhinitis fails to improve significantly as a result of pharmacologic therapy and appropriate allergen avoidance. Evaluation for other conditions should be preformed prior to pursuing allergen immunotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=see_link&amp;anchor=H14#H14\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107607\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an",
"    <span class=\"nowrap\">",
"     allergist/immunologist",
"    </span>",
"    should be considered for the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with moderate to severe allergic rhinitis: referral should be considered because allergen immunotherapy has been shown to alter the progression of allergic disease and subsequent development of asthma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=see_link&amp;anchor=H14#H14\">",
"       \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Preventive effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with prolonged or severe symptoms of rhinitis or significant residual symptoms despite pharmacologic therapy and avoidance measures.",
"     </li>",
"     <li>",
"      Patients whose management might be enhanced by identification of allergic triggers.",
"     </li>",
"     <li>",
"      Patients with coexisting asthma or nasal polyposis (referral to a pulmonologist or otolaryngologist, respectively, are other options for such patients).",
"     </li>",
"     <li>",
"      Patients with significant complications of allergic rhinitis, such as recurrent otitis media or recurrent sinusitis.",
"     </li>",
"     <li>",
"      Patients with intolerable adverse effects from medications or side effects that interfere with",
"      <span class=\"nowrap\">",
"       school/work",
"      </span>",
"      productivity.",
"     </li>",
"     <li>",
"      Patients who are interested in immunotherapy as a treatment option.",
"     </li>",
"     <li>",
"      Patients who have required systemic glucocorticoids to control symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are able to discontinue antihistamines without experiencing intolerable symptoms should do so at least one week prior to their appointment, in case skin testing is indicated at the initial visit. INGCs and asthma medications do not interfere with skin testing and should NOT be discontinued. Patients with questions concerning which medications to continue or withhold should be instructed to contact the specialist's office prior to their appointment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/38/37474?source=see_link\">",
"       \"Patient information: Seasonal allergies in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=see_link\">",
"       \"Patient information: Giving your child over-the-counter medicines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/10/13475?source=see_link\">",
"       \"Patient information: Seasonal allergies in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=see_link\">",
"       \"Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/40/5764?source=see_link\">",
"       \"Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34856?source=see_link\">",
"       \"Allergic conjunctivitis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25107621\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most patients, allergic rhinitis is a persistent condition that requires ongoing therapy over a period of years. Management combines allergen avoidance and pharmacologic therapy, with allergen immunotherapy added for refractory or severe cases. (See",
"      <a class=\"local\" href=\"#H25107326\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=see_link&amp;anchor=H2#H2\">",
"       \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Topical intranasal glucocorticoids (INGCs) are presently the most effective single maintenance therapy for allergic rhinitis and cause few side effects at the recommended doses. INGCs are particularly effective in relieving nasal congestion. Specific agents include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33392?source=see_link\">",
"       flunisolide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      propionate,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36080?source=see_link\">",
"       mometasone",
"      </a>",
"      furoate, fluticasone furoate, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33488?source=see_link\">",
"       ciclesonide",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef55833 \" href=\"mobipreview.htm?16/18/16685\">",
"       table 1",
"      </a>",
"      ). Mometasone furoate, fluticasone furoate, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide are approved by the US Food and Drug Administration (FDA) for use in children &ge;2 years. Dry powder formulations became available in 2012 in the US. (See",
"      <a class=\"local\" href=\"#H25107347\">",
"       'Intranasal glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First generation sedating antihistamines are familiar to patients and available without a prescription, but they have several significant adverse effects, including sedation and impairment of cognitive function, paradoxical agitation in young children, and cholinergic side effects in older adults. Second generation agents, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/45/44757?source=see_link\">",
"       levocetirizine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12934?source=see_link\">",
"       desloratadine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      have few of these problems and are preferred when antihistamine therapy is desired. (See",
"      <a class=\"local\" href=\"#H25107382\">",
"       'Oral antihistamines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with",
"      <strong>",
"       mild or intermittent",
"      </strong>",
"      symptoms, we suggest intranasal glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). We start at the maximal recommended dose for age, and then taper to the lowest effective dose once symptoms are controlled. (See",
"      <a class=\"local\" href=\"#H25107347\">",
"       'Intranasal glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with mild symptoms may prefer other agents because of oral administration or desire to avoid glucocorticoids. Thus, the following are appropriate choices as well:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An intranasal antihistamine spray, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"       azelastine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"       olopatadine",
"      </a>",
"      , administered regularly or as needed. (See",
"      <a class=\"local\" href=\"#H25107431\">",
"       'Antihistamine nasal sprays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A second generation oral antihistamine, administered regularly or as needed. (See",
"      <a class=\"local\" href=\"#H25107403\">",
"       'Second and third generation antihistamines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intranasal cromolyn, administered regularly or as needed. This is often preferred by parents of young children because of its excellent safety profile, although it is less effective than other agents. (See",
"      <a class=\"local\" href=\"#H25107445\">",
"       'Cromolyn sodium'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients",
"      <strong>",
"       with persistent or moderate to severe",
"      </strong>",
"      symptoms, we recommend intranasal glucocorticoids (INGCs) as first-line therapy (",
"      <a class=\"graphic graphic_table graphicRef55833 \" href=\"mobipreview.htm?16/18/16685\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The newer agents, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      propionate,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36080?source=see_link\">",
"       mometasone",
"      </a>",
"      furoate, and fluticasone furoate, have minimal systemic bioavailability and are conveniently dosed once or twice daily. We start at the maximal recommended dose for age, and then taper to the lowest effective dose once symptoms are controlled. (See",
"      <a class=\"local\" href=\"#H25107347\">",
"       'Intranasal glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25107558\">",
"       'Persistent symptoms and moderate to severe symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If INGCs alone are not sufficient to control symptoms, we suggest adding a topical second generation antihistamine spray (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"       azelastine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"       olopatadine",
"      </a>",
"      ) in preference to other agents (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A nasal spray containing both azelastine and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      is available in the US. Other options include an oral",
"      <span class=\"nowrap\">",
"       antihistamine/decongestant",
"      </span>",
"      combination or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H236313\">",
"       'Combined with antihistamine sprays'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25107558\">",
"       'Persistent symptoms and moderate to severe symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with rhinitis symptoms that are refractory to INGCs and concomitant asthma or nasal polyposis, the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      to INGCs may be helpful. (See",
"      <a class=\"local\" href=\"#H25107466\">",
"       'Montelukast'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25107565\">",
"       'With concomitant asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with rhinitis refractory to INGCs and concomitant allergic conjunctivitis, we suggest the addition of an antihistamine eye drop, rather than the addition of an oral antihistamine (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, patients with severe symptoms may require all three agents to attain adequate relief. (See",
"      <a class=\"local\" href=\"#H25107572\">",
"       'With concomitant allergic conjunctivitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic sinusitis or mixed rhinitis should be suspected if a patient with presumed allergic rhinitis fails to improve significantly as a result of pharmacologic therapy and appropriate allergen avoidance. (See",
"      <a class=\"local\" href=\"#H25107593\">",
"       'Refractory symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/1\">",
"      Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/2\">",
"      Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/3\">",
"      van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/4\">",
"      Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 Suppl 86:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/5\">",
"      Bousquet J, van Cauwenberge P, A&iuml;t Khaled N, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy 2006; 61:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/6\">",
"      Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/7\">",
"      Angier E, Willington J, Scadding G, et al. Management of allergic and non-allergic rhinitis: a primary care summary of the BSACI guideline. Prim Care Respir J 2010; 19:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/8\">",
"      Siow JK, Alshaikh NA, Balakrishnan A, et al. Ministry of Health clinical practice guidelines: Management of Rhinosinusitis and Allergic Rhinitis. Singapore Med J 2010; 51:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/9\">",
"      Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008; 38:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/10\">",
"      Okubo K, Kurono Y, Fujieda S, et al. Japanese guideline for allergic rhinitis. Allergol Int 2011; 60:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/11\">",
"      Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/12\">",
"      van Bavel J, Findlay SR, Hampel FC Jr, et al. Intranasal fluticasone propionate is more effective than terfenadine tablets for seasonal allergic rhinitis. Arch Intern Med 1994; 154:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/13\">",
"      Welsh PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987; 62:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/14\">",
"      Kaszuba SM, Baroody FM, deTineo M, et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 2001; 161:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/15\">",
"      Rak S, Heinrich C, Jacobsen L, et al. A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001; 108:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/16\">",
"      Pullerits T, Praks L, Ristioja V, L&ouml;tvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/17\">",
"      Berger WE, Kaiser H, Gawchik SM, et al. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. Otolaryngol Head Neck Surg 2003; 129:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/18\">",
"      Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. Ann Allergy Asthma Immunol 1997; 79:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/19\">",
"      Patel P, Patel D, Kunjibettu S, et al. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. Ear Nose Throat J 2008; 87:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/20\">",
"      Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 2007; 28:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/21\">",
"      Couroux P, Kunjibettu S, Hall N, Wingertzahn MA. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2009; 102:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/22\">",
"      Borish L. Allergic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol 2003; 112:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/23\">",
"      Barnes ML, Menzies D, Fardon TC, et al. Combined mediator blockade or topical steroid for treating the unified allergic airway. Allergy 2007; 62:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/24\">",
"      LaForce C. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol 1999; 103:S388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/25\">",
"      Onrust SV, Lamb HM. Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 1998; 56:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/26\">",
"      Juniper EF, St&aring;hl E, Doty RL, et al. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol 2005; 115:S390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/27\">",
"      Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf 2007; 30:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/28\">",
"      Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/29\">",
"      Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 2007; 28:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/30\">",
"      Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003; 26:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/31\">",
"      Brogden RN, McTavish D. Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/32\">",
"      Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997; 19:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/33\">",
"      Rachelefsky GS. Pharmacologic management of allergic rhinitis. J Allergy Clin Immunol 1998; 101:S367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/34\">",
"      Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105:E22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/35\">",
"      Allen DB, Meltzer EO, Lemanske RF Jr, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002; 23:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/36\">",
"      Galant SP, Melamed IR, Nayak AS, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics 2003; 112:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/37\">",
"      Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids. Otolaryngol Head Neck Surg 2003; 129:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/38\">",
"      Kim KT, Rabinovitch N, Uryniak T, et al. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol 2004; 93:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/39\">",
"      Kim K, Weiswasser M, Ruediger N. Safety of once daily ciclesonide nasal spray in children 2 to 5 years of age with perennial allergic rhinitis. Pediatric Asthma Allergy Immunol 2007; 20:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/40\">",
"      Murphy K, Uryniak T, Simpson B, O'Dowd L. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol 2006; 96:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/41\">",
"      Passalacqua G, Albano M, Canonica GW, et al. Inhaled and nasal corticosteroids: safety aspects. Allergy 2000; 55:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/42\">",
"      Bui CM, Chen H, Shyr Y, Joos KM. Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J Allergy Clin Immunol 2005; 116:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/43\">",
"      Opatowsky I, Feldman RM, Gross R, Feldman ST. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology 1995; 102:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/44\">",
"      Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med 2008; 9:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/45\">",
"      Baroody FM, Brown D, Gavanescu L, et al. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2011; 127:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/46\">",
"      Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012; 129:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/47\">",
"      Church MK. H(1)-antihistamines and inflammation. Clin Exp Allergy 2001; 31:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/48\">",
"      Hasala H, Moilanen E, Janka-Junttila M, et al. First-generation antihistamines diphenhydramine and chlorpheniramine reverse cytokine-afforded eosinophil survival by enhancing apoptosis. Allergy Asthma Proc 2007; 28:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/49\">",
"      Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999; 36:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/50\">",
"      Gengo FM, Manning C. A review of the effects of antihistamines on mental processes related to automobile driving. J Allergy Clin Immunol 1990; 86:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/51\">",
"      Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004; 92:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/52\">",
"      Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010; 65:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/53\">",
"      O'Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94. Allergy 1995; 50:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/54\">",
"      Ray WA, Thapa PB, Shorr RI. Medications and the older driver. Clin Geriatr Med 1993; 9:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/55\">",
"      Cimbura G, Lucas DM, Bennett RC, et al. Incidence and toxicological aspects of drugs detected in 484 fatally injured drivers and pedestrians in Ontario. J Forensic Sci 1982; 27:855.",
"     </a>",
"    </li>",
"    <li>",
"     United States Department of Transportation: Digest of State Alcohol-Highway Related Legislation. 147th ed, 1996.",
"    </li>",
"    <li>",
"     Sen A, Akin A, Craft KJ, et al. First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. Federal Aviation Administration, Publication AM-07/12, US Department of Transportation, Washington, DC, 2007. www.faa.gov/library/reports/medical/oamtechreports/2000s/media/200712.pdf (Accessed on August 08, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/58\">",
"      Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000; 105:S622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/59\">",
"      Simons FE, Reggin JD, Roberts JR, Simons KJ. Benefit/risk ratio of the antihistamines (H1-receptor antagonists) terfenadine and chlorpheniramine in children. J Pediatr 1994; 124:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/60\">",
"      Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993; 71:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/61\">",
"      Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. MMWR Morb Mortal Wkly Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/62\">",
"      Busse PJ. Allergic respiratory disease in the elderly. Am J Med 2007; 120:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/63\">",
"      Kay GG, Plotkin KE, Quig MB. Sedating effects of AM/PM antihistamine dosing with evening chlorpheniramine and morning terfenadine. Am J Manag Care 1997; 3:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/64\">",
"      Starbuck VN, Kay GG, Platenberg RC, et al. Functional magnetic resonance imaging reflects changes in brain functioning with sedation. Hum Psychopharmacol 2000; 15:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/65\">",
"      Berkowitz RB, McCafferty F, Lutz C, et al. Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies. Clin Ther 2006; 28:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/66\">",
"      Berkowitz RB, McCafferty F, Lutz C, et al. Fexofenadine HCl 60 mg/ pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit. Allergy Asthma Proc 2004; 25:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/67\">",
"      Kakutani C, Ogino S, Ikeda H, Enomoto T. [Comparison of clinical efficacy and cost-quality of antihistamines in early treatment for Japanese cedar pollinosis]. Arerugi 2006; 55:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/68\">",
"      St&uuml;bner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Curr Med Res Opin 2004; 20:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/69\">",
"      Horak F, Zieglmayer PU, Zieglmayer R, et al. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol 2005; 60:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/70\">",
"      Day JH, Briscoe MP, Rafeiro E, et al. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 2004; 25:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/71\">",
"      Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998; 101:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/72\">",
"      Deruaz C, Leimgruber A, Berney M, et al. Levocetirizine better protects than desloratadine in a nasal provocation with allergen. J Allergy Clin Immunol 2004; 113:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/73\">",
"      Simons FE, Prenner BM, Finn A Jr, Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003; 111:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/74\">",
"      Layton D, Wilton L, Boshier A, et al. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf 2006; 29:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/75\">",
"      Gentile DA, Friday GA, Jr Skoner. Management of allergic rhinitis: Antihistamines and decongestants. Immunol Allergy Clin North Am 2000; 20:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/76\">",
"      Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/77\">",
"      Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000; 105:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/78\">",
"      Simons FE. Advances in H1-antihistamines. N Engl J Med 2004; 351:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/79\">",
"      Hansen GR. Loratadine in the high performance aerospace environment. Aviat Space Environ Med 1999; 70:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/80\">",
"      Meltzer EO. Performance effects of antihistamines. J Allergy Clin Immunol 1990; 86:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/81\">",
"      Vacchiano C, Moore J, Rice GM, Crawley G. Fexofenadine effects on cognitive performance in aviators at ground level and simulated altitude. Aviat Space Environ Med 2008; 79:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/82\">",
"      Newer antihistamines. Med Lett Drugs Ther 2001; 43:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/83\">",
"      Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002; 32:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/84\">",
"      Hindmarch I, Shamsi Z, Stanley N, Fairweather DB. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999; 48:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/85\">",
"      Ridout F, Shamsi Z, Meadows R, et al. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car. Clin Ther 2003; 25:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/86\">",
"      Ousler GW, Wilcox KA, Gupta G, Abelson MB. An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride. Ann Allergy Asthma Immunol 2004; 93:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/87\">",
"      Ratliff JC, Barber JA, Palmese LB, et al. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring) 2010; 18:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/88\">",
"      Yanai K, Rogala B, Chugh K, et al. Safety considerations in the management of allergic diseases: focus on antihistamines. Curr Med Res Opin 2012; 28:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/89\">",
"      Borrelli F, Izzo AA. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J 2009; 11:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/90\">",
"      Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 1996; 51:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/91\">",
"      Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistaminic drug loratadine. Int Arch Allergy Immunol 1995; 107:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/92\">",
"      Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003; 31:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/93\">",
"      Katta A, Dhananjeyan M, Bykowski C, et al. Verapamil, but not probenecid, co-administration can convert desloratadine to a sedating antihistamine in mice. Drug Metab Lett 2007; 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/94\">",
"      Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 2006; 62:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/95\">",
"      De Weck AL, Derer T, B&auml;hre M. Investigation of the anti-allergic activity of azelastine on the immediate and late-phase reactions to allergens and histamine using telethermography. Clin Exp Allergy 2000; 30:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/96\">",
"      Lee TA, Pickard AS. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy 2007; 27:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/97\">",
"      Berger W, Hampel F Jr, Bernstein J, et al. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 97:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/98\">",
"      Shah SR, Nayak A, Ratner P, et al. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. Clin Ther 2009; 31:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/99\">",
"      LaForce CF, Carr W, Tilles SA, et al. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. Allergy Asthma Proc 2010; 31:132.",
"     </a>",
"    </li>",
"    <li>",
"     Azelastine hydrochloride (generic drug). www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory (Accessed on August 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/101\">",
"      Y&aacute;&ntilde;ez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 89:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/102\">",
"      Carr WW, Ratner P, Munzel U, et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy Asthma Proc 2012; 33:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/103\">",
"      Kaliner MA, Storms W, Tilles S, et al. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc 2009; 30:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/104\">",
"      Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008; 100:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/105\">",
"      Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol 1995; 96:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/106\">",
"      Hatton RC, Winterstein AG, McKelvey RP, et al. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. Ann Pharmacother 2007; 41:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/107\">",
"      Horak F, Zieglmayer P, Zieglmayer R, et al. A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2009; 102:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/108\">",
"      Norris AA, Alton EW. Chloride transport and the action of sodium cromoglycate and nedocromil sodium in asthma. Clin Exp Allergy 1996; 26:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/109\">",
"      Pitsios C, Papadopoulos D, Kompoti E, et al. Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/110\">",
"      Chervinsky P, Philip G, Malice MP, et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 2004; 92:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/111\">",
"      Perry TT, Corren J, Philip G, et al. Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. Ann Allergy Asthma Immunol 2004; 93:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/112\">",
"      Patel P, Philip G, Yang W, et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol 2005; 95:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/113\">",
"      Ratner PH, Howland WC 3rd, Arastu R, et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 2003; 90:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/114\">",
"      Nathan RA. Do leukotriene receptor antagonists have a place in pharmacotherapy of allergic rhinitis? Ann Allergy Asthma Immunol 2003; 90:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/115\">",
"      Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/116\">",
"      Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007; 67:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/117\">",
"      Cingi C, Gunhan K, Gage-White L, Unlu H. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope 2010; 120:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/118\">",
"      Moinuddin R, deTineo M, Maleckar B, et al. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004; 92:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/119\">",
"      Lieberman PL, Settipane RA. Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis. Allergy Asthma Proc 2003; 24:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/120\">",
"      Cingi C, Ozlugedik S. Effects of montelukast on quality of life in patients with persistent allergic rhinitis. Otolaryngol Head Neck Surg 2010; 142:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/121\">",
"      Milgrom H, Biondi R, Georgitis JW, et al. Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children. Ann Allergy Asthma Immunol 1999; 83:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/122\">",
"      Wang YH, Yang CP, Ku MS, et al. Efficacy of nasal irrigation in the treatment of acute sinusitis in children. Int J Pediatr Otorhinolaryngol 2009; 73:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/123\">",
"      Garavello W, Somigliana E, Acaia B, et al. Nasal lavage in pregnant women with seasonal allergic rhinitis: a randomized study. Int Arch Allergy Immunol 2010; 151:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/124\">",
"      Li H, Sha Q, Zuo K, et al. Nasal saline irrigation facilitates control of allergic rhinitis by topical steroid in children. ORL J Otorhinolaryngol Relat Spec 2009; 71:50.",
"     </a>",
"    </li>",
"    <li>",
"     Louisiana Department of Health and Hospitals. file://new.dhh.louisiana.gov/index.cfm/newsroom/detail/2332 (Accessed on January 22, 2012).",
"    </li>",
"    <li>",
"     The US FDA issued a consumer warning regarding the risk of N. fowleri infection. file://www.fda.gov/ForConsumers/ConsumerUpdates/ucm316375.htm (Accessed on September 04, 2012).",
"    </li>",
"    <li>",
"     Information about Naegleria infection is available online from the United States Centers for disease control. file://www.cdc.gov/parasites/naegleria/faqs.html#how_infect.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/128\">",
"      Psaltis AJ, Foreman A, Wormald PJ, Schlosser RJ. Contamination of sinus irrigation devices: a review of the evidence and clinical relevance. Am J Rhinol Allergy 2012; 26:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/129\">",
"      Mullins RJ, Heddle R. Adverse reactions associated with echinacea: the Australian experience. Ann Allergy Asthma Immunol 2002; 88:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/130\">",
"      Cutler DL, Banfield C, Affrime MB. Safety of Mometasone Furoate Nasal Spray in Children with Allergic Rhinitis as Young as 2 Years of Age: A Randomized Controlled Trial. Pediatr Asthma Allergy Immunol 2006; 19:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/131\">",
"      Weinstein S, Qaqundah P, Georges G, Nayak A. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Ann Allergy Asthma Immunol 2009; 102:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/132\">",
"      Dykewicz MS, Kaiser HB, Nathan RA, et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn). Ann Allergy Asthma Immunol 2003; 91:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/133\">",
"      Stempel DA, Thomas M. Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus nonsedating antihistamines. Am J Manag Care 1998; 4:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/134\">",
"      Can D, Tana&ccedil; R, Demir E, et al. Is the usage of intranasal glucocorticosteroids alone in allergic rhinitis sufficient? Allergy Asthma Proc 2006; 27:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/135\">",
"      Lanier BQ, Abelson MB, Berger WE, et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin Ther 2002; 24:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/136\">",
"      Ousler GW 3rd, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 2007; 29:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/137\">",
"      Prenner BM, Lanier BQ, Bernstein DI, et al. Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2010; 125:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/138\">",
"      Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 119:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/139\">",
"      Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007; 28:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/140\">",
"      American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     LactMed is available on line at file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT (Accessed on December 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/142\">",
"      Incaudo GA, Takach P. The diagnosis and treatment of allergic rhinitis during pregnancy and lactation. Immunol Allergy Clin North Am 2006; 26:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/143\">",
"      Kaliner MA. H1-antihistamines in the elderly. Clin Allergy Immunol 2002; 17:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/60/37834/abstract/144\">",
"      Slavin RG. Treating rhinitis in the older population: special considerations. Allergy Asthma Clin Immunol 2009; 5:9.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7526 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-190.102.30.19-A54EBD57DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37834=[""].join("\n");
var outline_f36_60_37834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25107621\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25107326\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25107333\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25107340\">",
"      AVAILABLE MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107347\">",
"      Intranasal glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25107354\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3675056\">",
"      - Onset of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25107361\">",
"      - Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25107368\">",
"      - Safety in children and adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2446146\">",
"      - Possible drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25107375\">",
"      - Optimal use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3895306\">",
"      Dry powder formulations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11910521\">",
"      - Combined with decongestant sprays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H236313\">",
"      - Combined with antihistamine sprays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107382\">",
"      Oral antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24818398\">",
"      - First generation agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25107389\">",
"      Adverse effects and safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25107396\">",
"      Role in therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25107403\">",
"      - Second and third generation antihistamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25107410\">",
"      Role in therapy and efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25107417\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107431\">",
"      Antihistamine nasal sprays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107438\">",
"      Oral antihistamine/decongestant combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107445\">",
"      Cromolyn sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107466\">",
"      Montelukast",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2336638\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107480\">",
"      Ipratropium bromide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107487\">",
"      Therapies requiring caution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25107494\">",
"      - Nasal decongestant sprays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25107501\">",
"      - Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25107508\">",
"      ADJUNCTIVE AND OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107516\">",
"      Nasal saline irrigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5476779\">",
"      Alternative and complementary therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25107530\">",
"      APPROACH TO SPECIFIC PATIENT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107537\">",
"      Young children (&lt;2 years of age)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107544\">",
"      Older children and adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25107551\">",
"      - Mild or episodic symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25107558\">",
"      - Persistent symptoms and moderate to severe symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25107565\">",
"      - With concomitant asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25107572\">",
"      - With concomitant allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107579\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27574600\">",
"      Breastfeeding women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25107586\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25107593\">",
"      REFRACTORY SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25107607\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25107621\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/7526\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7526|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/18/16685\" title=\"table 1\">",
"      Glucocorticoid nasal sprays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/5/7260\" title=\"table 2\">",
"      Adverse effects antihis decong",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/33/43548\" title=\"table 3\">",
"      Nasal irrigation instruct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/11/8381\" title=\"table 4\">",
"      Allergic rhinitis treatments during breastfeeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34856?source=related_link\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12250?source=related_link\">",
"      Chronic nonallergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/50/6953?source=related_link\">",
"      Complementary and alternative therapies for allergic rhinitis and conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6775?source=related_link\">",
"      Pathogenesis of allergic rhinitis (rhinosinusitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=related_link\">",
"      Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/38/37474?source=related_link\">",
"      Patient information: Seasonal allergies in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/10/13475?source=related_link\">",
"      Patient information: Seasonal allergies in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/40/5764?source=related_link\">",
"      Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3914?source=related_link\">",
"      Recognition and management of allergic disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13146?source=related_link\">",
"      The common cold in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_60_37835="Patient agreement mifepristone";
var content_f36_60_37835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Components of patient agreement when administering Mifeprex",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The patient agrees to:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Read the medication",
"guide provided by the manufacturer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss the information",
"with her care provider and have all of her questions answered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Take Mifeprex and",
"misoprostol in the provider's office according to protocol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Call the provider with",
"questions, concerns, or if complications (eg, fever, pain, bleeding)",
"occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follow",
"the provider's instructions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Return to the provider for follow-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make emergency room",
"personnel or other providers aware of her procedure if she needs care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The patient confirms that she understands:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        She is no more than 7",
"weeks pregnant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The risks, benefits, and alternatives to the procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What signs/symptoms to",
"watch for and what to do if a complication occurs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        That the procedure",
"might fail and her options if failure occurs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk of birth defects",
"if the abortion fails and the pregnancy is continued",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The possible need for a",
"surgical procedure to treat complications or effect abortion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Per manufacturer (Danco Laboratories).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37835=[""].join("\n");
var outline_f36_60_37835=null;
var title_f36_60_37836="ACC AHA immediate manage ACS";
var content_f36_60_37836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for immediate management of patients with an acute coronary syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The initial evaluation of the patient with suspected acute coronary syndrome should include a search for noncoronary causes that could explain the development of symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. The history, physical examination, 12-lead ECG, and initial cardiac marker tests should be integrated to assign patients with chest pain into 1 of 4 categories: a noncardiac diagnosis, chronic stable angina, possible acute coronary syndrome (ACS), and definite ACS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Patients with definite or possible ACS, but whose initial 12-lead ECG and cardiac marker levels are normal, should be observed in a facility with cardiac monitoring (eg, chest pain unit), and a repeat ECG and cardiac marker measurement should be obtained 6 to 12 h after the onset of symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. In patients in whom ischemic heart disease is present, if the follow-up 12-lead ECG and cardiac marker measurements are normal, a stress test (exercise or pharmacological) to provoke ischemia may be performed in the emergency department, in a chest pain unit, or on an outpatient basis shortly after discharge. Low-risk patients with a negative stress test can be managed as outpatients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Patients with definite ACS and ongoing pain, positive cardiac markers, new ST-segment deviations, new deep T-wave inversions, hemodynamic abnormalities, or a positive stress test should be admitted to the hospital for further management.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Patients with possible ACS and negative cardiac markers who are unable to exercise or who have an abnormal resting ECG should undergo a pharmacological stress test.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6. Patients with definite ACS and ST-segment elevation should be evaluated for immediate reperfusion therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ACC/AHA classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         Class IIb:",
"        </strong>",
"        Usefulness/efficacy is less well established by evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Class III:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Braunwald E, Antman EM, Beasley JW, et al. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000; 36:970.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37836=[""].join("\n");
var outline_f36_60_37836=null;
var title_f36_60_37837="Dx hepatic mass lesions";
var content_f36_60_37837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of hepatic mass lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"7\" width=\"14%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hepatocellular carcinoma",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metastatic carcinoma",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hepatocellular adenoma",
"       </td>",
"       <td class=\"subtitle1\">",
"        Focal nodular hyperplasia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cavernous hemangioma",
"       </td>",
"       <td class=\"subtitle1\">",
"        Simple cyst",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Incidence/ 100,000",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        1-4800",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        8-20",
"       </td>",
"       <td>",
"        1",
"        <sup>",
"         &Delta;",
"        </sup>",
"        -4",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        3-4",
"       </td>",
"       <td>",
"        400-7500",
"       </td>",
"       <td>",
"        170",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Solitary",
"        </strong>",
"       </td>",
"       <td>",
"        20-40 percent",
"       </td>",
"       <td>",
"        5-10 percent",
"       </td>",
"       <td>",
"        90 percent",
"       </td>",
"       <td>",
"        90 percent",
"       </td>",
"       <td>",
"        90 percent",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Coexisting liver disease",
"        </strong>",
"       </td>",
"       <td>",
"        HBV, HCV, cirrhosis, hemochromatosis",
"       </td>",
"       <td>",
"        Uncommon in cirrhotic liver",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Pathogenesis",
"        </strong>",
"       </td>",
"       <td>",
"        HBV, HCV, alcohol, aflatoxin, cirrhosis",
"       </td>",
"       <td>",
"        Hematogenous, lymphatic or direct spread",
"       </td>",
"       <td>",
"        Estrogens, anabolic steroids",
"       </td>",
"       <td>",
"        Congenital, ? estrogens",
"       </td>",
"       <td>",
"        Congenital, estrogens",
"       </td>",
"       <td>",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Imaging",
"        </strong>",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        US, CT",
"       </td>",
"       <td>",
"        US, CT, CTAP",
"       </td>",
"       <td>",
"        US, CT, 99mTc",
"       </td>",
"       <td>",
"        US, CT, MRI, 99mTc",
"       </td>",
"       <td>",
"        Dynamic bolus CT, 99mTc-RBC-SPECT scan, MRI",
"       </td>",
"       <td>",
"        US, CT",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Alpha-fetoprotein",
"        </strong>",
"       </td>",
"       <td>",
"        &gt;300-500 ng/mL",
"       </td>",
"       <td>",
"        Nomal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Characteristic gross features",
"        </strong>",
"       </td>",
"       <td>",
"        Hemorrhage, necrosis; invasion/ obstruction",
"       </td>",
"       <td>",
"        Hemorrhage, necrosis; umbilicated",
"       </td>",
"       <td>",
"        Hemorrhage, necrosis",
"       </td>",
"       <td>",
"        Central scar",
"       </td>",
"       <td>",
"        Blood filled \"cyst\"",
"       </td>",
"       <td>",
"        Thin walled cyst with clear fluid",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Characteristic microscopic features",
"        </strong>",
"       </td>",
"       <td>",
"        \"Thick\" (&gt;3-4 cells) trabeculae",
"       </td>",
"       <td>",
"        Replacement of hepatocytes, by malignant cells no portal structures",
"       </td>",
"       <td>",
"        \"Neohepatocytes\", normal cord structure, no portal structures",
"       </td>",
"       <td>",
"        \"Focal cirrhosis\" with pseudoductiles",
"       </td>",
"       <td>",
"        Blood filled spaces lined by single layer of flat epithelium",
"       </td>",
"       <td>",
"        Simple cuboidal endothelium",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        FNAB or core biopsy",
"       </td>",
"       <td>",
"        FNAB or core biopsy",
"       </td>",
"       <td>",
"        Imaging, biopsy",
"       </td>",
"       <td>",
"        Imaging, biopsy",
"       </td>",
"       <td>",
"        Imaging",
"       </td>",
"       <td>",
"        Imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Treatment",
"        </strong>",
"       </td>",
"       <td>",
"        \"Curative resection\" or ethanol injection if solitary, &lt;5.0 cm; ? transplantation&plusmn; chemoembolization",
"       </td>",
"       <td>",
"        \"Curative resection\" if &lt;3.0 cm and 3 or fewer nodules especially if large; otherwise periodic imaging; malignant potential",
"       </td>",
"       <td>",
"        Discontinue estrogens/ androgens; resect if possible, especially if large; otherwise periodic imaging; malignant potential",
"       </td>",
"       <td>",
"        Discontinue estrogens; periodic imaging",
"       </td>",
"       <td>",
"        Surgical resection only if symptomatic or &gt;10.0 cm; discontinue estrogens; periodic imaging",
"       </td>",
"       <td>",
"        Usually no treatment percutaneous aspiration or surgical enucleation if symptomatic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     US: ultrasound; CT: computerized axial tomography; dynamic bolus CT: rapid sequential CT images taken at plane of the mass, with delayed images up to 20 minutes; CTAP: computerized axial tomography arterioportogram; MRI: fast spin echo magnetic resonance imaging; 99mTc: 99mTecrictium labelled sulfur colloid scan; RBC-SPECT: 99mTechnetium tagged red blood cell study utilizing single photon emission computerized tomography; FNAB: fine needle aspiration biopsy for cytology.",
"     <br/>",
"     * From autopsy series.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Varies with geographic origin.",
"     <br/>",
"     &Delta; Overall population.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Females on birth control pills.",
"     <br/>",
"     &sect; Most useful imaging technique with which to obtain a diagnosis.",
"     <br/>",
"     &yen; Definitive test required for confident diagnosis.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: LaBrecque DR, Cakir-Yedidag A. Management of Liver Neoplasms in Medical Management of Liver Disease, EL Krawitt (Ed), Marcel Dekker, Inc. 1999, p.310.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37837=[""].join("\n");
var outline_f36_60_37837=null;
var title_f36_60_37838="Darbepoetin alfa sub for rHuEPO";
var content_f36_60_37838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Graph showing patients who switched from rHuEPO to darbepoetin alfa in one randomized trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 285px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Overall, ninety-six percent of patients in one study were successfully switched from rHuEPO to less frequent dosing regimens using darbepoetin alfa. Results are from a large, multicenter, randomized trial in which 522 patients undergoing hemodialysis or peritoneal dialysis were switched from rHuEPO administered two to three times weekly or once weekly to darbepoetin alfa administered once weekly or once every two weeks, respectively. Hemoglobin levels were maintained between 9 and 13 g/dL, as well as within -1 to +1.5 g/dL of a patient's baseline levels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Vanrenterghem, Y, Barany, P, Mann, J, et al. J Am Soc Nephrol 1999; 10:270A.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37838=[""].join("\n");
var outline_f36_60_37838=null;
var title_f36_60_37839="Fulguration of vasal ends during vasectomy illustration";
var content_f36_60_37839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Fulguration of vasal ends during vasectomy illustration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The vas is divided and a segment removed. A hand held cautery can be used to fulgarate the lumen of each vasal end.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_60_37839=[""].join("\n");
var outline_f36_60_37839=null;
